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1. INTRODUCTION 
 
Cells continuously monitor changes in their extracellular environments and elicit 
appropriate adaptive responses. Nearly every aspect of cell life is controlled by signal 
transduction processes, by which extracellular perturbations are perceived, converted 
into intracellular signals, and conveyed to effectors whose activities are necessary to 
generate cellular responses. Many of these intracellular processes are controlled by 
signal transduction pathways that regulate protein phosphorylation. It has been 
estimated that more than a third of all proteins in a mammalian cell can be modified by 
phosphorylation and that up to 2% of the genes in a vertebrate genome encode either 
protein kinases or phosphatases (Manning et al., 2002). It has becoming apparent that 
phosphorylation is the most common type of protein modification, and the major 
mechanism for reversible regulation of protein activity and function. In particular, 
reversible tyrosine phosphorylation is one of the fundamental mechanisms for 
controlling cell proliferation, differentiation as well as development. Though the overall 
level of phosphotyrosine (ca. 0.5%) in proteins in normal vertebrate cells is very low 
compared to the levels of phosphoserine (ca. 90%) and phosphothreonine (ca 10%) 
(Hunter and Sefton, 1980; Hunter, 2000), after oncogenic transformation or growth 
factor stimulation, the level of tyrosine phosphorylation increases to 1-2 % of total 
protein phosphorylation in the cells (Zhang, 1998; Zhang, 2002). The extent of tyrosine 
phosphorylation is determined by the opposing actions of protein tyrosine kinases 
(PTKs) and protein tyrosine phosphatases (PTPs). Thus, PTKs and PTPs are important 
regulators of various cellular processes whose activities are normally tightly controlled. 
When dysregulated, both PTKs and PTPs can become potent oncoproteins causing 
cellular transformation.  
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1.1 Receptor Tyrosine Kinases (RTKs) 
 
One of the fundamental mechanisms by which cells of multicellular organisms 
communicate is the binding of ligands to cell surface transmembrane receptors that 
possess tyrosine kinase activity. After binding of ligands, the receptors become 
activated, the incoming signal is transmitted through the cell membrane and distributed 
to intracellular signal molecules. The surface receptors can be classified in a variety of 
different receptor families, such as cytokine receptors, G-protein-coupled receptors 
(GPCR), receptor serine/threonine kinase (RS/TK) or receptor tyrosine kinases (RTKs). 
Although each receptor family uses individual cellular signaling mechanisms, they do 
not simply form linear pathways but are part of a complex and interdependent cellular 
network (Hackel et al., 1999; Hubbard and Till, 2000; Hunter, 2000).  
Receptor tyrosine kinases form a major family of signal transducing surface 
receptors that use their intrinsic tyrosine kinase activity to phosphorylate other proteins 
(van der Geer et al., 1994). All RTKs possess a glycosylated extracellular ligand-
binding domain, a single hydrophobic transmembrane domain and a cytoplasmic region 
containing the catalytic domain. With the exception of the insulin receptor (IR) 
subfamily members that form heterotetramers, RTKs are single polypeptide chains in 
their inactivated states.  
The extracellular domains contain distinctive patterns of cysteine-rich regions or 
characteristic arrays of structural motifs, such as immunoglobulin (Ig)-like structures 
(van der Geer et al., 1994; Hunter, 2000). Based on these structural properties of their 
extracellular domains, the RTKs can be classified into subfamilies (Figure 1). The 
ligand-binding domain is the most distinctive feature in RTKs and reflects the 
individual requirements for the binding of a specific ligand.  
The transmembrane domain consists of a stretch of hydrophobic amino acids. 
Although the transmembrane domains function primarily as passive lipid anchors, they 
can also influence receptor function. For example, the oncogenic form of receptor 
HER2 from the epidermal growth factor receptor (EGFR) family is constitutively 
activated due to a point mutation in its transmembrane domain (Bargmann et al., 1986). 
Mutations in the transmembrane region of the fibroblast growth factor receptor (FGFR) 
are associated with clinical disease (Klint and Claesson-Welsh, 1999; Powers et al., 
2000; Ornitz and Marie, 2002).  
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Figure 1: The receptor tyrosine kinases subfamilies. 
The figure shows the division of the receptor tyrosine kinase family into 19 subfamilies. The 
classification is based on the structural differences of the extracellular domains. (Adopted from 
Wallasch, 1996.) 
 
The intracellular domain can be subdivided into a juxtamembrane domain 
followed by a tyrosine kinase catalytic domain and a carboxyl-terminal regulatory tail 
(Ullrich and Schlessinger, 1990). The catalytic domain, which distinguishes RTKs from 
other receptors, consists of 250-300 residues and is related to that of cytoplasmic 
protein tyrosine kinases as well as serine/threonine kinases. Three separate roles can be 
ascribed to the catalytic domain: first, binding of the adenosine triphosphate (ATP); 
second, binding and orientation of the protein substrate; and third, transfer of the γ-
phosphate from ATP to the acceptor hydroxyl residue (tyrosine, serine or threonine) of 
the protein substrate (Hunter, 1998). In some subfamilies, the kinase domain is divided 
into two halves by a kinase insert, which participates in the recruitment of cytoplasmic 
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molecules to receptor-based signaling complexes. Within the carboxyl-terminal 
sequence there are autophosphorylation sites that serve as binding sites for substrates 
and effectors (Ullrich and Schlessinger, 1990).  
Ligand binding to the extracellular portion of these receptors results in receptor 
dimerization, which facilitates trans-autophosphorylation of specific tyrosine residues 
in the cytoplasmic portion. These phosphotyrosine residues enhance receptor catalytic 
activity and/or provide docking sites for downstream signaling proteins. Because of the 
critical roles played by RTKs in cellular signaling processes, their catalytic activity is 
normally under tight control by intrinsic regulatory mechanisms as well as by protein 
tyrosine phosphatases.  
 
1.1.2 Epidermal Growth Factor Receptor Signaling  
 
The epidermal growth factor receptor (EGFR) family consists of four closely 
related receptors: EGFR (also known as ErbB1), HER2 (or ErbB2/neu), HER3 (ErbB3) 
and HER4 (ErbB4). An interesting feature of HER3 is the exchange of several amino 
acids, which are conserved in all other protein tyrosine kinases (Guy et al., 1994). As a 
consequence, HER3 has no intrinsic kinase activity. However, it is transphosphorylated 
by HER2 and thus participates in signal transduction of the EGFR family (Wallasch et 
al., 1995). For all EGFR family members, except for the orphan receptor HER2, a 
number of different ligands have been described. Seven epidermal growth factor (EGF)-
like mammalian gene products are known to directly activate the EGFR: EGF, 
transforming growth factor alpha (TGF-α), heparin-binding EGF (HB-EGF), heregulin 
(also known as the neu differentiation factor, NDF), amphiregulin, betacellulin and 
epiregulin (Yarden and Sliwkowski, 2001). Each of these molecules is synthesized as a 
transmembrane precursor and subjected to proteolytic cleavage of its ectodomain to 
produce the soluble form of the growth factor. The integrated biological responses to 
EGFR signaling are pleiotropic, including mitogenesis, apoptosis, cell mobility, 
differentiation, as well as tumor progression such as invasion and metastasis.  
Binding of EGF to its receptor at the cell surface results in activation of the 
intrinsic tyrosine kinase of the receptor and tyrosine phosphorylation of the C-terminus 
of the EGFR. The amino acid sequences containing phosphorylated tyrosine residues 
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serve as binding sites for signal transduction molecules that contain Src homology 2 
(SH2) and phosphotyrosine-binding (PTB) domains. Some of these proteins possess 
catalytic activity, whereas others serve as adaptors that couple receptors and 
downstream enzymes involved in signal transduction. Therefore, interactions of the 
receptor with these signal molecules are the key initial steps of signaling pathways 
activated by growth factors. For example, binding of Shc and Grb2 (growth-factor-
receptor-bound protein 2) adaptor proteins to phosphorylated EGFR is essential for 
activation of Ras GTPase and mitogen-activated protein kinase (MAPK). 
The SH2 domain of Grb2 binds to the activated EGFR (Lowenstein et al., 1992), 
while its SH3 domains constitutively bind to son-of-sevenless (SOS), the Ras 
guanidine-nucleotide-exchange factor (Li et al., 1993; Rozakis-Adcock et al., 1993). 
Binding of Grb2 to the EGFR recruits the Grb2-SOS complex to the membrane and to 
the membrane-anchored Ras, thus linking EGFR to the Ras/MAPK signaling cascade. 
Grb2 can bind to EGFR directly through its main binding site on EGFR, pY-1068, or 
indirectly through three phosphotyrosines of Shc (Lowenstein et al., 1992; Batzer et al., 
1994; Okabayashi et al., 1994). Shc binds to pY-1148 and pY-1173 of the EGFR 
through its PTB and SH2 domains, respectively, and is phosphorylated efficiently by 
the EGFR kinase (Soler et al., 1994b; Batzer et al., 1995). Membrane translocation and 
phosphorylation of Shc are sufficient to recruit the Grb2-SOS complex to Ras (Soler et 
al., 1994a). Other signal molecules directly involved in EGFR signaling include 
phospholipase Cγ (PLCγ)  and its downstream calcium- and protein kinase C (PKC)-
mediated cascades; phosphatidylinositol-3-OH kinase (PI3K) and its downstream 
effector Akt (or protein kinase B, PKB); ubiquitin ligase Cbl; adaptor proteins Gabl 
(Grb2-associated binder-1), Grb7, Nck, Crk; as well as the protein tyrosine phosphatase 
and adaptor protein SHP2 (Hackel et al., 1999; Zwick et al., 1999; Prenzel et al., 2000).  
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1.1.3 Fibroblast Growth Factor Receptor Signaling  
 
The fibroblast growth factors (FGFs) belong to a family of heparin-binding 
polypeptides with more than 20 members (Ornitz and Itoh, 2001; Moroni et al., 2002). 
FGFs are potent mitogens for a variety of different cell types in tissue culture and in 
vivo, and are implicated in differentiation of endothelial and neuronal cells (Klint and 
Claesson-Welsh, 1999). The binding of FGFs to heparin or heparin-like 
glycoaminoglycan (HLGAG) may serve two physiologically relevant goals: the 
protection of the FGFs from degradation and the creation of a local reservoir of growth 
factors. The local reservoir allows for a strict spatial regulation of FGF signaling. 
Moreover, the association of FGFs with heparin is required for effective activation of 
the FGF receptor (FGFR), where heparin increases the affinity and half-life of the FGF-
FGFR complex (Ornitz and Itoh, 2001; Ornitz and Marie, 2002).  
The FGFR family has four members: FGFR1 (also known as Flg), FGFR2 
(Bek), FGFR3, and FGFR4, which share between 55% and 72% homology at the 
protein level. The FGFRs play important roles in embryonic development, angiogenesis, 
as well as wound healing (Powers et al., 2000). One distinct feature of FGFRs is that 
they contain three extracellular Ig-like domains (IgI, IgII and IgIII), with an acidic box 
(eight consecutive acidic residues) inserted between the first and second Ig-like 
domains. Alternative mRNA splicing of the fgfr1-3 genes leads to variants with two or 
three Ig-like domains, or specifies the sequence of the carboxyl-terminal half of the 
third Ig-like domain that resulting in either IIIa, IIIb or IIIc isoforms of FGFR. The fgfr4 
gene is unique in that there is only one possible form of its IgIII domain. The IIIa splice 
variant codes for a truncated, secreted protein unable to independently transduce 
extracellular signals. However, it may sequester released FGFs and inhibit FGF 
signaling. Expression of IIIb and IIIc isoforms is differentially regulated in a tissue-
specific manner and determines the ligand-receptor binding specificity. The expression 
of FGFR2 isoforms of IgIIIb and IgIIIc is restricted to cells of epithelial and 
mesenchymal lineages, respectively. Since FGF-7 (also known as keratinocyte growth 
factor, KGF) is known to bind FGFR2/IIIb but not FGFR2/IIIc. Thus, this may explain 
the selectivity of FGF-7 for keratinocytes over fibroblasts as due to the expression of 
the different FGFR splice variants (Powers et al., 2000; Ornitz and Itoh, 2001).  
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A single transmembrane stretch connects the FGFR extracellular part with its 
intracellular juxtamembrane (JM) domain. The JM domains of FGFR1 and FGFR2 
contain one phosphorylatable tyrosine residue that may serve as docking site for 
downstream signaling molecules, while the FGFR3 and FGFR4 lack tyrosine residues 
in this region. The tyrosine kinase domain of FGFRs is split in two parts by insertion of 
about 15 amino acids, which comprises two tyrosine residues in FGFR1 and FGFR2, 
one in FGFR3 and none in FGFR4. The mitogenic potential of the FGFR4 appears to be 
lower than the other FGFRs, which in part is due to the lack of tyrosine residues in the 
kinase insert. The C-terminal tails of the FGFRs contain a number of conserved tyrosine 
residues that play critical roles in mediating the FGFR signaling (Klint and Claesson-
Welsh, 1999). For example, pY-653 and pY-654 are important for kinase activity; pY-
766 is the binding site of PLCγ. Unlike the EGFR, FGFR recruits the Grb2/SOS 
complex only indirectly through the docking protein FRS2 (FGFR substrate 2, also 
known as SNT) (Rabin et al., 1993; Kouhara et al., 1997). FRS2 associates directly with 
Grb2 or indirectly through SHP2, thereby linking the FGFR to the MAPK cascade 
(Kouhara et al., 1997; Hadari et al., 1998).  
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1.2 Protein Tyrosine Phosphatases (PTPs) 
 
The precise and rapid propagation of signals demands both strict and flexible 
regulatory processes. Protein phosphorylation is one of the major posttranslational 
modification mechanisms that cells utilize to control various cellular regulatory 
processes. Addition or removal of a phosphoryl moiety from a protein can generate a 
recognition motif for protein-protein interactions, control protein stability, and most 
importantly, modulate enzyme activity. In vivo, protein phosphorylation is reversible 
and dynamic; the phosphorylation states are governed by the opposing activities of 
protein kinases and protein phosphatases. Based on substrate specificity, the family of 
phosphatases can be grouped into two subfamilies: the protein serine/threonine 
phosphatases (PPs) and the protein tyrosine phosphatases (PTPs). Amino acid sequence 
comparison of the catalytic domains has shown no sequence similarity between the two 
groups (Charbonneau et al., 1988). Moreover PPs and PTPs use different chemical 
reaction mechanisms to catalyze the hydrolysis of phosphate monoesters suggesting a 
separate evolution of both families.  
The PTPs include both the tyrosine-specific phosphatases that hydrolyze 
phosphotyrosine (pY)-containing proteins, and dual-specific phosphatases that target 
proteins containing pY, as well as phosphoserine (pS) and phosphothreonine (pT) as 
substrates. The PTPs are characterized by the presence of the active site signature motif 
(H/V)C(X)5R(S/T) in the conserved catalytic domain (Zhang, 2002), and are 
traditionally further divided into receptor-like and cytoplasmic PTPs (Figure 2). The 
receptor-like PTPs generally have an extracellular domain, a single transmembrane 
region and one or two cytoplasmic catalytic domains (Tonks and Neel, 2001; Zhang, 
2002). The extracellular domains of the receptor-like PTPs show high variability, 
presumably due to different functions and physiological ligands. The cytoplasmic PTPs 
contain a single catalytic domain and various amino- or carboxyl-terminal extensions, 
including SH2 domains, that have targeting or regulatory functions. All PTPs are 
characterized by their sensitivity to vanadate, ability to hydrolyze p-nitrophenyl 
phosphate, insensitivity to okadaic acid, and lack of metal ion requirement for catalysis 
(Tonks and Neel, 2001; Zhang, 2002).  
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Figure 2:The family of protein tyrosine phosphatases. 
The protein tyrosine phosphatases (PTPs) are divided into receptor like and cytoplasmic PTPs. 
The receptor-like PTPs have an extracellular domain, a single transmembrane region and one or 
two cytoplasmic PTP domains. The cytoplasmic PTPs contain a single catalytic domain and 
additional amino- or carboxyl-terminal domains. (Adopted from Stein-Gerlach, 1998a.) 
 
The content of tyrosine phosphorylated proteins within a cell is the result of the 
balanced interplay between tyrosine kinase and phosphatase activity (Tonks and 
Charbonneau, 1989; Tonks and Neel, 2001; Tiganis, 2002). Whereas activation of 
RTKs generates tyrosine phosphorylation of proteins, PTPs dephosphorylate proteins 
and could therefore lead to termination of signals. For example, studies of PTP1B 
knockout mice show that this phosphatase is a major negative regulator of insulin 
receptor (IR) signaling in muscle and liver (Elchebly et al., 1999; Klaman et al., 2000). 
In addition to IR, PTP1B might also negatively regulate insulin-like growth factor-1 
receptor (IGF-IR) and EGFR signaling (Kenner et al., 1996; Flint et al., 1997; Lee et 
al., 1998). The receptor-like PTP LAR has also been suggested as a negative regulator 
of multiple RTKs, as reduction of LAR protein levels by an antisense approach 
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increased autophosphorylation of the insulin, EGF and hepatocyte growth factor (HGF) 
receptors (Kulas et al., 1996).  
 
 
1.2.1 Phosphotyrosine Phosphatase SHP2 
 
Protein tyrosine kinase and phosphatase do not simply oppose each other's 
action; rather, they may work in concert to maintain a fine balance of effector activation 
needed for the regulation of cell growth and differentiation, as the PTP SHP2 
demonstrated. SHP2, also known as SH-PTP2, SH-PTP3, PTP2C, PTP1D, and Syp, 
was identified independently by several groups as a cytosolic SH2 domain-containing 
PTP (Adachi et al., 1992; Freeman et al., 1992; Ahmad et al., 1993; Feng et al., 1993; 
Lechleider et al., 1993a; Vogel et al., 1993). It is ubiquitously expressed and contains 
two tandem SH2 domains at its N-terminus and one tyrosine phosphatase domain at the 
C-terminus.  
SHP2 has been implicated in diverse signaling pathways including those 
initiated by platelet-derived growth factor (PDGF), EGF, IGF-1, insulin and cytokines 
(Feng et al., 1993; Kazlauskas et al., 1993; Kuhne et al., 1993; Vogel et al., 1993; 
Manes et al., 1999). Within a single signaling pathway, SHP2 may act at multiple sites 
to participate in signal transduction. SHP2 directly binds to activated RTKs and 
becomes rapidly tyrosine phosphorylated. At the same time, it can interact with 
downstream signaling intermediates such as Grb2, p85 subunit of PI3 kinase, IRS-1, 
and Gab1 and 2 (Stein-Gerlach et al., 1998; Feng, 1999; Qu, 2000).  
The function of SHP-2 is assumed to be dephosphorylation of associated 
signaling molecules and to result in diminished local signals. However, the ultimate 
effect of SHP2 in most signaling pathways is to enhance the signals relayed from RTKs 
(Tang et al., 1995; Bennett et al., 1996; Hadari et al., 1998; O'Reilly and Neel, 1998; 
Shi et al., 1998). The enzymatic activity is required for its function since introduction of 
a catalytically inert SHP2 markedly inhibited activation of MAP kinase in response to 
insulin, EGF, PDGF, and FGF (Noguchi et al., 1994; Yamauchi et al., 1995; Bennett et 
al., 1996; Maegawa et al., 1999; Manes et al., 1999; Inagaki et al., 2000). Although the 
precise biochemical basis for such a positive regulation by SHP2 in the MAP kinase 
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pathway remains unclear, SHP2 appears to act in association with the Grb2-SOS 
complex (Li et al., 1994; Hadari et al., 1998).  
On the other hand, SHP-2 does play a negative role in certain intracellular 
signaling processes. It inhibits signaling pathways initiated by the cytokines interferon-
α and -γ , leukemia inhibitory factor, ciliary neurotrophic factor, and IL-6 (Kim et al., 
1998; Qu and Feng, 1998; Burdon et al., 1999; You et al., 1999; Ohtani et al., 2000). 
However, signaling via the erythropoietin receptor, a member of the cytokine receptor 
family, was found to be enhanced by SHP2 (Tauchi et al., 1995; Tauchi et al., 1996). 
Thus, SHP2 may have dual functions both in cytokine and growth factor signal 
transduction.  
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1.3 G-protein Coupled Receptor Signaling and EGFR Transactivation  
 
G-protein-coupled receptors (GPCRs) constitute the largest family of cell-
surface molecules involved in signal transmission. They play key physiological roles in 
secretion from endocrine and exocrine glands, exocytosis, chemotaxis, photo- and 
chemoreception, neurotransmission, as well as embryogenesis, angiogenesis, tissue 
regeneration, and control of normal and aberrant cell growth. These receptors are 
activated by a wide variety of ligands, including peptide and non-peptide 
neurotransmitters, hormones, growth factors, odorant molecules as well as light. GPCRs 
owe their name to their extensively studied interaction with heterotrimeric G-proteins 
(composed of α, β and γ subunits). In response to receptor activation the G-proteins 
undergo conformational changes that lead to the exchange of GDP for GTP bound to 
the α-subunit. Consequently, the Gα and Gβγ subunits stimulate effector molecules, 
thereby activating or inhibiting the production of second messengers, promoting 
increases in intracellular Ca2+ concentration and opening or closing of ion channels 
(Figure 3) (Gutkind, 2000; Marinissen and Gutkind, 2001; Pierce et al., 2002).  
Many potent mitogens such as thrombin, lysophosphatidic acid (LPA), 
bombesin, vasopressin, bradykinin, substance K, acetylcholine receptor agonists and 
angiotensin II stimulate cell proliferation by acting on their cognate GPCRs. The nature 
of the intracellular signaling pathways mediating these proliferative effects is still 
poorly understood. Whereas conventional second messenger-generating systems, such 
as adenylyl cyclases, ion channels and phospholipases, were the focus of the early 
research efforts addressing this issue, an emerging body of information indicates that 
additional effector pathways participate in proliferative signaling by GPCRs. In 
particular, GPCRs have been shown to activate members of the MAPK family, which 
are key components of intracellular signaling pathways that control cell proliferation.  
It is well established that various stimuli which are unrelated to EGF-like 
ligands, can also activate the EGFR. These stimuli include GPCR agonists such as 
endothelin, thrombin, lysophosphatidic acid, angiotensin II, as well as cytokines, 
chemokines and cell adhesion elements (Pawson, 1994; Daub et al., 1996; Daub et al., 
1997; Carpenter, 1999; Carpenter, 2000; Gschwind et al., 2001). Furthermore, EGFR 
signaling may also be induced by environmental stress factors, such as ultraviolet and 
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gamma-radiation, hydrogen peroxide and heavy metal ions (Gschwind et al., 2001). 
This so-called transactivation of the EGFR by these seemingly unrelated stimuli might 
occur through a mechanism common to at least a part of the agonists. In this context, 
stimulation of cells via GPCR or ionizing radiation results in the activation of a 
metalloprotease that cleaves a precursor of the EGF-like family of ligands and thereby 
produces a soluble growth factor which in turn, activates the EGFR (Figure 3) (Dent et 
al., 1999; Prenzel et al., 1999). Activation of the EGFR by GPCR-agonists results in the 
RTK tyrosine phosphorylation, association with signal adaptors, such as Shc or Grb2 
and activation of the MAP kinase pathway. In addition to its role in GPCR-activated 
mitogenic signaling, the EGFR also serves as signal transducer of LPA-induced stress 
fiber formation and in the modulation of potassium channel activity (Tsai et al., 1997; 
Gohla et al., 1998). In GPCR-mediated EGFR transactivation, the intrinsic receptor 
kinase activity is necessary for downstream signaling (Daub et al., 1996; Daub et al., 
1997; Prenzel et al., 1999). In contrast, upon stimulation with growth hormone the 
EGFR is phosphorylated directly by the cytosolic tyrosine kinase Jak2 at tyrosine 1068, 
the major Grb2 binding site, and allows downstream signaling even by a kinase 
deficient EGFR mutant (Batzer et al., 1994; Batzer et al., 1995; Yamauchi et al., 1997).  
 
 
 
 
Figure 3: Multiple pathways link GPCRs to MAP kinase.  
GPCR-induced metalloprotease-mediated proteolytic cleavage of EGF-like growth factor precursors leads 
to transactivation of the EGFR and activation of MAPK. The metalloprotease is presented as a pair of 
scissors. In response to receptor activation the G-proteins stimulate effector molecules, such as PKC and 
PLC, thereby activating the Ras/MAPK cascade. (Modified from Marinissen and Gutkind, 2001.)  
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1.4 Adaptor and Docking Proteins 
 
A common feature in intracellular signaling pathways is the assembly of multi-
protein complexes involving extensive protein-protein interactions. Typical examples 
are the interactions between RTKs and their downstream effectors. Upon activation and 
autophosphorylation of the RTKs, phosphotyrosine residues at their carboxyl-terminal 
tail serve as binding sites for downstream signal transducing molecules. These 
associations are usually directed by protein interaction domains, such as Src homology 
2 (SH2), Src homology 3 (SH3), phosphotyrosine binding (PTB) and pleckstrin 
homology (PH) domains, among others (Figure 4). The SH2 domain interacts with 
proteins that contain a phosphotyrosine embedded in a specific sequence, in general 
residues at position +1 through +3 relative to the phosphotyrosine are recognized 
(Songyang et al., 1993). The SH3 domain interacts with target proteins in a 
phosphorylation-independent, sequence-specific fashion, binding to short sequences 
containing a central PXXP sequence (Pawson, 1994; Songyang, 1999). The PTB 
domain, first identified in Shc and IRS-1, consists of about 150 residues and recognizes 
the consensus NPXpY motif. The PH domain acts as a phospholipid-dependent 
membrane-anchoring domain. 
Docking proteins are one group of proteins containing N-terminal interaction 
domains and multiple C-terminal tyrosine phosphorylation sites that function as 
phosphorylation-dependent docking sites for other SH2 as well as PTB domain-
containing proteins (Figure 4). Often these proteins have a means of membrane 
attachment, such as a PH domain for IRS and myristylation for FRS2 (Kouhara et al., 
1997; White, 1998). A number of such docking proteins have been identified, including 
Shc, insulin receptor substrates (IRS) 1-4, FRS2 and Gab1-2 (Grb2-associated binder) 
(Hunter, 2000; Schlessinger, 2000; Guy et al., 2002).  
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Figure 4: Protein modules and docking proteins that participate in signaling via 
receptor tyrosine kinases  
(A) Protein modules implicated in the control of intracellular signaling pathways. Activated 
RTKs form a complex with SH2 and PTB domains of signaling proteins. SH2 domains bind to 
phosphotyrosine sites in activated receptors while PTB domains bind to tyrosine phosphorylated 
and nonphosphorylated regions in RTKs. PH domains bind to different phosphoinositides 
leading to membrane association. SH3 and WW domains bind to proline-rich sequences in 
target proteins. PDZ domains bind to hydrophobic residues at the C-termini of target proteins. 
FYVE domains bind specifically to PdtIns(3)P. While adaptor proteins such as Grb2 or Nck 
contain only SH2 and SH3 domains, other signaling proteins contain additional enzymatic 
activities such as protein kinases (Src, PKB), PTP (SHP2) phospholipase C (PLCγ), Ras-GAP 
or Rho-GRF (Vav). (B) Docking proteins that function as platforms for recruitment of signaling 
proteins. All docking proteins contain a membrane-targeting region in their N-termini as well as 
multiple tyrosine phosphorylation sites that function as binding sites for SH2 or PTB domains 
of a variety of signaling proteins. (Adopted from Schlessinger, 2000) 
 
The ability of docking proteins to recruit diverse signaling molecules may help 
to expand the repertoire of signaling pathways activated by a given receptor. 
Mammalian Shc has one C-terminal SH2 domain and one N-terminal PTB domain. 
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Although both the SH2 and PTB domains recognize phosphotyrosine motifs on 
activated receptors, they are structurally distinct and recognize phosphopeptides in quite 
different fashions. The Shc PTB and SH2 domains flank a central region with two 
principal sites of tyrosine phosphorylation, both in Y-X-N sequences. Once 
phosphorylated, Shc can recruit multiple Grb2 molecules and potentially other SH2-
domain proteins (Pawson et al., 2001). Thus, Shc functions, in part, as an auxiliary 
docking subunit of activated RTKs, which can extend or amplify the binding potential 
of a receptor. Moreover, Shc becomes tyrosine phosphorylated upon activation of a 
variety of RTKs, demonstrating that a single docking protein can integrate signals from 
various receptors by serving as a common substrate to integrate multiple inputs.  
Adaptor proteins, such as Grb2, Nck and Crk, comprise a single SH2 domain 
and multiple SH3 domains but lack intrinsic catalytic function. They can couple a 
phosphotyrosine signal, recognized by the SH2 domain, to downstream targets with 
proline-rich motifs that bind to the SH3 domains (Pawson et al., 2001). Thus, the Grb2 
SH2 domain binds to specific pY-X-N motifs on activated RTKs or cytoplasmic 
docking proteins, while its SH3 domains associate with SOS, the Ras GDP-GTP 
exchange factor.  
The interaction domain-containing proteins include not only adaptors or docking 
proteins, but also enzymes, such as p85 subunit of PI3K, PLCγ, tyrosine kinases Src and 
Syk. The cytoplasmic protein tyrosine phosphatase SHP2 and the related SHP1 are 
unique among tyrosine phosphatases as they have two tandem SH2 domains. Besides 
serving to target SHP2 to various tyrosine-phosphorylated proteins, these SH2 domains 
also regulate the activity of SHP2 (Stein-Gerlach et al., 1995; Feng, 1999). Moreover, 
SHP2 is also able to serve as a docking protein (Li et al., 1994). 
 
 
 
1.4.1 Regulation of Docking Proteins through Serine/Threonine Phosphorylation  
 
The importance of tyrosine phosphorylation for generating protein binding sites 
and mediating protein complex formation has been realized early on (Pawson and Scott, 
1997; Pawson and Nash, 2000). However, the same concept for serine/threonine 
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phosphorylation started to draw attention only recently (Yaffe and Cantley, 1999; Yaffe 
and Elia, 2001; Yaffe, 2002).  
One of the best-studied docking proteins is IRS-1. Upon activation of the insulin 
receptor, IRS-1 provides phosphotyrosine residues as docking sites for downstream 
effector proteins and subsequently triggers the PI3K and MAPK pathways (Le Roith 
and Zick, 2001). In addition, IRS-1 also becomes phosphorylated on serine/threonine 
residues. These modifications may either positively or negatively modulate IRS-1 
signaling (Zick, 2001). Phosphorylation of IRS-1 on serine residues by PKB upon 
insulin stimulation protects it from rapid dephosphorylation by PTPs, thus implicating 
PKB-mediated phosphorylation as a positive regulatory module (Paz et al., 1999). In 
contrary, serine/threonine phosphorylation of IRS-1 by protein kinase Cζ (PKCζ) or c-
Jun N-terminal kinase (JNK) has been shown to act as a negative-feedback control 
mechanism that uncouples IRS-1 from its upstream regulator or downstream effector 
and terminates signal transduction (Paz et al., 1997; Aguirre et al., 2000; Liu et al., 
2001; Aguirre et al., 2002).  
Similar effects were observed for the docking protein Gab1, which becomes 
tyrosine phosphorylated in cells stimulated with growth factors, cytokines, and ligands 
for GPCRs (Gu and Neel, 2003). The major Gab1-binding proteins detected in cells 
treated with extracellular stimuli include the p85 subunit of PI3K and the tyrosine 
phosphatase SHP2. In addition to tyrosine phosphorylation, Gab1 is phosphorylated by 
the MAP kinase family member ERK2 (extracellular-regulated kinase) on 
serine/threonine residues (Roshan et al., 1999). Interestingly, EGF and HGF mediated 
ERK activation result in divergent effects on Gab1/PI3K signaling. HGF-stimulated 
ERK activation increases the Gab1/PI3K association, whereas EGF-stimulated ERK 
activation results in a decrease in the tyrosine phosphorylation of Gab1 and a decreased 
association with the PI3K. As SHP2 is shown to dephosphorylate Gab1, EGF-
stimulated ERK might act through the regulation of SHP2 (Yu et al., 2001; Yu et al., 
2002).  
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1.5 Mitogen-Activated Protein Kinase Signaling Pathway 
 
The MAP kinase cascade is one of the best-characterized signaling pathways. 
Initiated by a wide variety of extracellular stimuli including growth factors, mitogens 
and cytokines, as well as environmental stress factors, through a series of protein-
protein interactions and phosphorylation, a protein kinase cascade consisting of at least 
three kinases, MEKK (MAP kinase kinase kinase), MKK (MAP kinase kinase), and 
MAPK (MAP kinase), is activated. A sequential phosphorylation mechanism by which 
one kinase phosphorylates and activates a downstream kinase ultimately results in 
MAPK activation. Once activated, the MAPKs, which are serine/threonine kinases, 
phosphorylate different cytosolic, membrane-bound and nuclear substrates including 
transcription factors. Thereby MAPKs can regulate transcription of particular sets of 
genes. (Lewis et al., 1998; Whitmarsh and Davis, 1999; Chen et al., 2001; Zhan et al., 
2001).  
The family of MAPKs can be divided into three subfamilies: extracellular-
regulated kinase (ERK), c-Jun N-terminal kinase (JNK)/stress-activated protein kinase 
(SAPK) and p38 kinase. The members of the ERK subfamily are key downstream 
components of RTK mediated signal transduction pathways which control fundamental 
cellular processes such as cell cycle, proliferation, differentiation, survival and 
apoptosis. More than 50 different proteins have been reported to be substrates of ERK 
(Whitmarsh and Davis, 1999; Sharrocks et al., 2000; Chen et al., 2001). Besides 
transcription factors, ERK phosphorylates signal proteins that function upstream such as 
Syk, SOS, Raf, MEK and Gab1, as well as signal proteins that function downstream 
such as the ribosomal S6 kinase p90Rsk.  
As all MAP kinases phosphorylate serine and threonine residues within the 
minimal consensus sequence PXS/TP (Songyang et al., 1996), it is important that the 
substrate proteins provide further specificity determinants. A comparison of different 
MAP kinase substrates and interaction partners reveals several different arrangements of 
specificity-determining domains, which have been termed MAP kinase-recognition 
modules (Figure 5). Besides sequences surrounding the phosphoacceptor motifs, 
docking domains and FxF motifs may be present in these modules. The requirement for 
multiple determinants might reflect that each of the different components of the module 
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provides a unique function. For example, the docking site might serve to recruit MAP 
kinases to a substrate and once bound, the FxF motif might then act to stabilize this 
binding. Alternatively, the two motifs could act together to recruit the kinase. The 
presence of both the docking domain and FxF motif is likely to enhance the specificity 
of kinase selectivity and to improve the fidelity and efficiency of phosphorylation by 
directing the kinase to the phosphoacceptor motifs (Sharrocks et al., 2000).  
 
 
 
 
 
 
Figure 5: MAP kinase-recognition modules.  
The docking domains, FxF motifs and the local context of the phosphoacceptor motifs have 
been identified as three determinants that constitute MAP kinase-recognition modules. The 
different arrangements of these determinants found are shown in (A)–(E). S/TP indicates the 
domain containing the phosphoacceptor motifs. Abbreviations: MEF2A, myocyte-specific-
enhancer-binding factor 2A; Rsk1, ribosomal S6 kinase. (Adopted from Sharrocks, 2000.) 
 
Studies demonstrate that specific targeting of MAP kinases to substrates via 
docking domains is found in all categories of its substrates, including transcription 
factors, protein kinases, protein phosphatases and other signaling molecules (Jacobs et 
al., 1999; Sharrocks et al., 2000; Tanoue et al., 2000; Fantz et al., 2001). Furthermore, 
docking sites for MAPK kinase MEK1 and other upstream kinases have been identified 
(Bardwell and Thorner, 1996; Xu et al., 1999). Analysis of the docking domain in the 
phosphatase PTP-SL lead to identification of critical residues designed kinase 
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interaction motif (KIM, L-X-X-K/R-K/R-X1-5-L/I-X-L) (Pulido et al., 1998; Zuniga et 
al., 1999). MAPK docking domains not directly related to substrate phosphorylation 
have also been described. For example, JIP-1 binds specifically to JNK MAP kinases 
via its docking domain and acts as a scaffold protein that nucleates the formation of a 
single complex containing multiple components of the JNK cascade (Whitmarsh and 
Davis, 1999; Davis, 2000; Enslen and Davis, 2001).  
While multiple motifs on substrates cooperate to determine their specificity 
towards upstream kinases, multiple determinants must exist on the kinases themselves 
to recognize such motifs. All MAPKs possess a conserved common docking (CD) 
domain located in the near the C-terminal region outside the catalytic domain, that is 
commonly used for recognition of both their activators, regulators as well as substrates 
(Tanoue et al., 2000).  
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1.6 Fibroblast Growth Factor Receptor Substrate 2 (FRS2) 
 
The FGF receptor substrate 2 (FRS2) was identified as a major downstream 
mediator of FGFR signaling (Kouhara et al., 1997). FRS2 is also known as SNT (suc-
associated neurotrophic factor target) and is rapidly tyrosine phosphorylated upon 
stimulation of nerve growth factor (NGF) and FGF (Rabin et al., 1993). FRS2 
comprises an amino-terminal myristylation site followed by a PTB domain, and 
multiple tyrosine phosphorylation sites in its carboxyl-terminal region. Two isoforms of 
FRS2 coded by two different genes have been identified: FRS2α/SNT1 with 508 amino 
acids and FRS2β/SNT2 with 492 residues, which share over 70% identity at the protein 
level. The FRS2α is the most studied form and little is known about the β-form. If not 
indicated, the FRS2α is referred to as FRS2 in this study.  
As a membrane anchored docking protein, FRS2 interacts with the 
juxtamembrane domain of FGF receptor 1 (Xu et al., 1998; Ong et al., 2000). This 
interaction allows for FGF-induced, receptor-mediated FRS2 tyrosine phosphorylation, 
which in turn creates docking sites for the adaptor protein Grb2 and the tyrosine 
phosphatase SHP2 (Kouhara et al., 1997; Ong et al., 1997; Hadari et al., 1998). 
Tyrosine phoshorylated FRS2 binds to Grb2 in association with the Ras activator SOS. 
This FRS2-Grb2-SOS ternary complex then activates Ras/MAP kinase signaling 
cascade. FRS2 also indirectly recruits Grb2 via complex formation with SHP2. In NGF 
signaling, FRS2 functions in a similar way. However, while the FRS2 PTB domain 
constitutively associates with a juxtamembrane region of FGFR1 lacking both tyrosine 
and asparagine residues, it recognises a canonical tyrosine phosphorylated NPXpY 
motif on the NGF receptor TrkA that also serves as binding site for Shc (Figure 6) (Xu 
et al., 1998; Meakin et al., 1999). In the rat pheochromocytoma PC12 cells, 
overexpression of FRS2 enhances and mediates sustained MAPK activity. Since 
neuronal differentiation correlates with sustained MAPK activation, FRS2 is believed to 
play an essential role in differentiation (Traverse et al., 1992; Traverse et al., 1994; 
Marshall, 1995; Kouhara et al., 1997; Xu and Goldfarb, 2001).  
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Figure 6: FRS2 in Trk and FGFR signaling. 
Schematic representation of FRS2 in Trk receptor (A) and FGF receptor (B) signaling. The right 
and left halves represent the disposition of the proteins in unstimulated and stimulated cells, 
respectively. While FRS2 only binds to the activated Trk receptor, it constitutively associates 
with the FGF receptor. Activation of the receptors leads to phosphorylation of FRS2 on 
strategically located tyrosine residues that become targets for the SH2 domains on Grb2 and 
SHP2. FRS2 binds to Grb2 directly or indirectly via SHP2, resulting in activation of the 
Ras/MAPK pathway. (Modified from Guy, 2002.) 
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In addition to the Ras/MAPK cascade, FRS2 also plays a pivotal role in FGF-
induced recruitment and activation of PI3K and its downstream effector protein 
PKB/Akt, a mediator of a cell survival pathway (Ong et al., 2001). Tyrosine 
phosphorylated FRS2 binds to the SH2 domain of Grb2, which interacts primarily via 
its N-terminal SH3 domain with the nucleotide exchange factor SOS, and via its C-
terminal SH3 domain with a proline-rich region in Gab1. Within this complex, Gab1 
becomes tyrosine phosphorylated resulting in the recruitment and activation of PI3K.  
Recently, involvement of FRS2 in attenuation of FGFR signaling was reported 
(Wong et al., 2002). The product of Cbl protooncogene functions as an ubiquitin ligase 
that ubiquitinates and promotes the degradation of a variety of cell signaling proteins. 
FRS2-Grb2-Cbl form a ternary complex resulting in the ubiquitination and degradation 
of FGFR and FRS2 in response to FGF stimulation. These observations highlight the 
importance of FRS2 in the assembly of both positive (i.e., SOS, PI3K) and negative 
(i.e., Cbl) signaling proteins to mediate a balanced FGF signal transduction (Wong et 
al., 2002). 
Targeted disruption of the FRS2α gene causes severe impairment in mouse 
development resulting in embryonal lethality at embryonic day E7.0-E7.5, establishing 
that FRS2 mediates multiple FGFR-dependent signaling pathways critical for 
mammalian embryonic development (Hadari et al., 2001). FRS2 also functions as a 
critical mediator of FGF signaling in Xenopus early embryogenesis through its 
association with the FGFR and the Src family kinase Laloo (Hama et al., 2001; 
Kusakabe et al., 2001; Akagi et al., 2002). The mechanism of the FRS2/Laloo 
interaction, however, is controversial. While Kusakabe et al. suggest that the FRS2 N-
terminal region lacking the PXXP motif and the SH4 domain of Laloo are sufficient for 
the association, Hama et al. show that both the SH3 and SH4 domains are necessary in a 
yeast two-hybrid system (Hama et al., 2001; Kusakabe et al., 2001). It is suggested that 
the FGFR and Laloo functionally cooperate to induce tyrosine phosphorylation of 
FRS2, since Laloo mediated FRS2 tyrosine phosphorylation is independent of the 
kinase activity of FGFR but requires the intracellular domain of the receptor (Kusakabe 
et al., 2001). Conversely, the Laloo kinase activity is dependent on the tyrosine 
phosphorylation of FRS2 (Hama et al., 2001). However, injection of high dose wild 
type xFRS2 mRNA alone caused embryonic death. Overexpression of xFRS2 in the 
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marginal zone appeared also to have toxic effect on the embryo (Kusakabe et al., 2001). 
All these results indicate an important role of FRS2 in early mesoderm development.  
There is evidence of FRS2 being involved in signaling induced by other growth 
factors, such as brain-derived neurotrophic factor (BDNF), glial cell-derived 
neurotrophic factor (GDNF), IGF-I, as well as insulin (Easton et al., 1999; Delahaye et 
al., 2000; Kimpinski and Mearow, 2001; Kurokawa et al., 2001; Melillo et al., 2001). 
FRS2 becomes tyrosine phosphorylated by the activated receptors TrkB, Ret, IGF-IR 
and IR. In case of TrkB and Ret, FRS2 associates with the receptors through the known 
Shc binding sites. Recently, it has been reported that FRS2 also participates in vascular 
endothelial growth factor (VEGF) signaling through the VEGFR2 (or kinase insert 
domain-containing receptor, KDR) in a similar manner as in FGFR signaling. FRS2 
constitutively associates with the VEGFR2 and undergoes tyrosine phosphorylation 
upon activation of the receptor (Stoletov et al., 2002).  
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1.7 Objective 
 
FRS2/SNT was identified as a specific intermediate of FGFR and NGFR 
signaling pathways in rodent cells (Rabin et al., 1993; Kouhara et al., 1997). The goal 
of this study was to investigate the function of the human homologue in cellular signal 
transduction.  
Being a downstream signaling molecule of receptor tyrosine kinases (RTKs) that 
play important role in cellular and oncogenic signaling, the expression pattern of FRS2 
in tumor cells as well as normal cells would be examined. This might give a hint about a 
possible involvement of FRS2 in oncogenesis.  
As a membrane-anchored docking protein comprising a phosphotyrosine-
binding (PTB) domain, FRS2 is very likely to target to more RTKs and function as a 
general mediator in various cellular signaling pathways. This work addresses this issue 
by testing different ligands for their effects on FRS2.  
FRS2 contains multiple tyrosine phosphorylation sites that serve as docking sites 
for other phosphotyrosine-binding proteins. Identification of further interaction partners 
of FRS2 by appropriate association experiments would help to study the differential role 
of FRS2 in signal transduction as well as its underlying regulation mechanism.  
FRS2 possesses multiple potential serine and threonine phosphorylation sites. 
This raised the question whether FRS2 becomes phosphorylated on these residues, and 
what potential function this modification could have. These subjects will be investigated 
by phosphoamino acid analysis and by interfering the function of different signal 
transduction molecules as well as by examination of truncation mutants.  
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2. MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Chemicals 
Acrylamide Serva, Heidelberg, Germany 
Agarose BRL, Eggenstein, Germany 
Ampicillin Roche Diagnostics, Mannheim, Germany 
Aprotinin Roche Diagnostics, Mannheim, Germany 
APS (ammoniumperoxydisulfate) Sigma, Taufkirchen, Germany 
ATP (adenosinetriphosphate) Amersham Biotech, Freiburg, Germany 
β-mercaptoethanole Sigma, Taufkirchen, Germany 
Bisacrylamide Roth, Karlsruhe, Germany 
Bromophenolblue Sigma, Taufkirchen, Germany 
BSA (bovine serum albumine) Sigma, Taufkirchen, Germany 
Bisbenzimide Roche Diagnostics, Mannheim, Germany 
Comassie G250 Serva, Heidelberg, Germany 
DAPI (4',6-diamidino-2-phenylindole) Sigma, Taufkirchen, Germany 
Desoxynucleotides  Roche Diagnostics, Mannheim, Germany 
Didesoxynucleotides  Amersham Biotech, Freiburg, Germany 
Dimethyldichlorsilan Sigma, Taufkirchen, Germany 
DTT (dithiothreitol) Sigma, Taufkirchen, Germany 
Ethidiumbromid Sigma, Taufkirchen, Germany 
Formamide Merck, Darmstadt, Germany 
Formaldehyde Merck, Darmstadt, Germany 
Freund's adjuvant Sigma, Taufkirchen, Germany 
Geneticin (G418) Gibco, Eggenstein, Germany 
Gelatine Merck, Darmstadt, Germany 
Glucose Sigma, Taufkirchen, Germany 
Gluthatione Sigma, Taufkirchen, Germany 
HEPES (4-(2-hydroxylethyl)- Serva, Heidelberg, Germany 
1-piperazin-ethansulfonicacid) 
tRNA Sigma, Taufkirchen, Germany 
IPTG Biomol, Hamburg, Germany 
(isopropyl-β-thiogalactopyranoside) 
Lipofectamine® Gibco, Eggenstein, Germany 
Lithium acetate Sigma, Taufkirchen, Germany 
MBP (myelin basic protein) Sigma, Taufkirchen, Germany 
MOPS Serva, Heidelberg, Germany 
(3-(N-morpholino)-propanesulfonic acid) 
Phenol Roth, Karlsruhe, Germany 
PMSF (phenylmethylsulfonylfluorid) Sigma, Taufkirchen, Germany 
Polbren (hexadimethrinbromide) Sigma, Taufkirchen, Germany 
Polyethylenglycol 4000 Sigma, Taufkirchen, Germany 
Ponceau S Sigma, Taufkirchen, Germany 
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Sodium azide Sigma, Taufkirchen, Germany 
Sodium fluoride Sigma, Taufkirchen, Germany 
Sodium Orthovanadate Sigma, Taufkirchen, Germany 
SDS (sodium dodecyl sulfate) Roth, Karlsruhe, Germany 
TEMED (N,N,N'N'-Tetraethyl- Serva, Heidelberg, Germany 
methylene diamine) 
Triton X-100 Serva, Heidelberg, Germany 
 
 
 
2.1.2 Restriction, Modification Enzymes and Polymerases  
 
Alkaline phosphatase Roche Diagnostics, Mannheim, Germany 
Lysozyme Roche Diagnostics, Mannheim, Germany 
Restriction enzymes New England Biolabs, Schwalbach, Germany 
 MBI Fermentas, St. Leon-Rot, Germany 
RNase A Sigma, Taufkirchen, Germany 
Reverse transciptase Roche Diagnostics, Mannheim, Germany 
RNaseH Roche Diagnostics, Mannheim, Germany 
T4-DNA-ligase MBI Fermentas, St. Leon-Rot, Germany 
T7-DNA-polymerase Amersham Biotech, Freiburg, Germany 
DNA-polymerase TaKaRa Biomedicals, Japan 
 
 
 
2.1.3 Kinase Inhibitors 
 
Inhibitor  Kinase   Source      
 
AG1295  PDGFR  Calbiochem, Schwalbach, Germany 
AG1478  EGFR   Calbiochem, Schwalbach, Germany 
GÖ6976  PKC   Calbiochem, Schwalbach, Germany 
H-89   PKA   Calbiochem, Schwalbach, Germany 
KN-93   CaMK II  Calbiochem, Schwalbach, Germany 
ML-7   MLCK  Calbiochem, Schwalbach, Germany 
PKG inhibitor  PKG   Calbiochem, Schwalbach, Germany 
PP1   Src   Calbiochem, Schwalbach, Germany 
Roscovitine  Cdc2   Calbiochem, Schwalbach, Germany 
SB202190  p38 kinase  Calbiochem, Schwalbach, Germany 
SB600125  JNK   Calbiochem, Schwalbach, Germany 
Staurosporine  PKC, PKA, PKG,  Calbiochem, Schwalbach, Germany 
MLCK, CaMK-II 
SU5402  FGFR   Calbiochem, Schwalbach, Germany 
U-0126  MEK1   Calbiochem, Schwalbach, Germany 
U73122  PLC γ   Calbiochem, Schwalbach, Germany 
Wortmannin  PI-3K   Calbiochem, Schwalbach, Germany 
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2.1.4 Ligands 
 
EGF (mouse) Toyoba, Japan 
FGF (acid, human) Peprotech, USA 
Insulin (human) Lilly, Giessen, Germany 
IGF-I (human) Sigma, Taufkirchen, Germany 
NGF-β (human) Sigma, Taufkirchen, Germany 
PDGF B/B (human) Roche Diagnostics, Mannheim, Germany 
Carbachol (carbamylcholine chloride) Sigma, Taufkirchen, Germany 
LPA (lysophosphatidic acid) Sigma, Taufkirchen, Germany 
Thrombin Sigma, Taufkirchen, Germany 
 
 
 
2.1.5 Radiochemicals 
 
[α-32P]-dATP, [γ-32P]-ATP >5000 Ci/mmol 
[α-35S]-dATP, L-[35S]-Methionine >1000 Ci/mmol 
[32P]-Phosphate 10mCi/ml 
 
All radiochemicals were purchased from Amersham Biotech (Freiburg, Germany) or 
NEN (Cologne, Germany) and used before the first half life. 
 
 
 
2.1.6 Commertial Kits and Diverse Materials 
 
QIAEX II gel extraction kit Qiagen, Hilden, Germany 
QIAquick PCR purification kit Qiagen, Hilden, Germany 
QIAGEN plasmid maxi kit Qiagen, Hilden, Germany 
Random primed DNA labeling kit Amersham Biotech, Freiburg, Germany 
Micro BCA protein assay kit Pierce, USA 
ECL kit Amersham Biotech, Freiburg, Germany 
 PerkinElmer Life Science, Boston, USA  
 
Nitrocellulose membrane Schleicher & Schuell, Germany 
Polyvinylidene difluoride  Millipore, USA 
(PVDF) membrane 
Hyperfilm Amersham Biotech, Freiburg, Germany 
CNBr-activated sepharose 4B Amersham Biotech, Freiburg, Germany 
Protein A-sepharose Amersham Biotech, Freiburg, Germany 
Protein G-sepharose Amersham Biotech, Freiburg, Germany 
Glutathione Sepharose 4B Amersham Biotech, Freiburg, Germany 
Tissue cultur plates Nunclon, Danemark 
 Flacon, U.K. 
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2.1.7 Media and Buffers 
 
2.1.7.1 Bacterial Media 
 
LB-medium 1.0 % tryptone 
 0.5 % yeast extract 
 1.0 % NaCl 
  pH 7.2 
 
2 x TY-medium 1.6 % tryptone 
 1.0 % yeast extract 
 0.5 % NaCl 
  pH 7.2 
 
The following concentrations of the antibiotics were used if required: 
Ampicillin 100 µg/ml 
Kanamycin 100 µg/ml 
Chloramphenicol 30 µg/ml 
 
1.5 % agar was added to the media for production of agar plates. 
 
2.1.7.2 Cell Culture Media 
 
All the media for the cell culture were purchased from Gibco (Eggenstein, Germany). 
The fetal calf serum (FCS) was purchased from Sigma (Taufkirchen, Germany). 
 
Dulbecco's Modified Eagle Medium (DMEM) with 4.5 mg/ml glucose, 5 or 10% FCS, 
2 mM glutamin, 1 mM sodium pyruvat. 
 
Dulbecco's Modified Eagle Medium (DMEM) with 1.0 mg/ml glucose, 10% FCS, 2 
mM glutamin, 1 mM sodium pyruvat.  
 
RPMI 1640 with 10%FCS, 2 mM glutamin, 1 mM sodium pyruvat.  
 
Leibovitz's L-15 with 10%FCS, 2 mM glutamin, 1 mM sodium pyruvat.  
 
Methionine free media for radioactive labeling of cells: 
MEM (Eagle) with Earle's salts, 2 mM glutamin, 40 µCi/ml L-[35S]-methionine.  
 
Phosphate free media for radioactive labeling of cells:  
MEM (Eagle) with Earle's salts, 2 mM glutamin, 200 µCi/ml [32P]-phosphate.  
 
Media for storage of frozen cells: 
90 % FCS, 10 % DMSO.  
 
Coating medium for tissue culture plate (for PC12 cells):  
0.01% collagen type I, 30% ethanol in 1xPBS.  
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2.1.8 Stock Solutions and Frequently Used Buffers 
 
Denhardt (100x) 2.0 % polyvinylpyrollidone 
 2.0 % ficoll 
 2.0 % bovine serum albumine (BSA) 
 
DNA sample buffer (6x) 2.5 ‰ bromophenolblue 
 2.5 ‰ xylenecyanol 
 30.0 % glycerine 
 100.0 mM EDTA pH 8.0 
 
HNTG (4x) 200.0 mM HEPES-NaOH pH 7.5 
 600.0 mM NaCl 
 40.0 % glycerine 
 0.4 % Triton X-100 
 
Laemmli buffer (2x) 187.5 mM Tris-HCl pH 6.8 
 6.0 % sodium dodecyl sulfate (SDS) 
 30.0 % glycerine 
 0.01 % bromophenolblue 
 5.0 % β-mercaptoethanol 
 
MOPS (10x) 200.0 mM 3-(N-morpholino)-propanesulfonic  
  acid (MOPS) 
 80.0 mM sodium acetate 
 10.0 mM EDTA pH 8.0 
 pH 7.0  (NaOH) 
 
NET (10x) 500.0 mM Tris-HCl pH 8.0 
 50.0 mM EDTA pH 8.0 
 1500.0  mM NaCl 
 0.5 % Triton X-100 
 
PBS 13.7 mM NaCl 
 2.7 mM KCl 
 80.9 mM Na2HPO4 
 1.5 mM KH2PO4 
 pH 7.4  (HCl) 
 
RNA sample buffer (2x) 48.0 % formamide 
 17.0 % formaldehyde 
 11.0 % glycerine 
 0.1 % bromophenolblue 
 
SSC (20x) 3.0 M NaCl 
 30.0 mM sodiumacetate 
 
SD-transblot 50.0 mM Tris-HCl pH 8.5 
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 40.0 mM glycine 
 20.0 mM methanol 
 0.04 ‰ SDS 
 
TAE (10x) 400.0 mM sodium acetate 
 10.0 mM EDTA pH 8.0 
 
TBE (10x) 890.0 mM Tris-HCl pH 8.0 
 890.0 mM boric acid 
 20.0 mM EDTA pH 8.0 
 
TE (10/0.1) 10.0 mM Tris-HCl pH 7.5 
 1.0 mM EDTA pH 8.0 
 
Tris-glycine-SDS (10x) 248.0 mM Tris-HCl pH 7.5 
 1918.0 mM glycine 
 1.0 % SDS 
 
 
 
2.1.9 Bacteria Strains and Cell Lines 
 
2.1.9.1 Bacteria Strains 
 
Strain    Genotype    Reference  
E. coli XL-1 Blue  F'proAB lacIqZ∆M15 Tn10 /  Stratagene 
    endA1 supE44 thi-1 recA1  
    gyrA96 relA1 lac  
 
2.1.9.2 Cell Lines 
 
Cell line Origin  Reference   
 
HEK293  Human embryionic kidney fibroblasts ATCC CTL 1573 
 
Cos-7 immortalised green monkey   ATCC CRL-1651 
 kidney fibroblasts 
Bosc Helper free retrovirus producing  W. S. Pear 
 cells based on HEK 293 cells 
Phoenix A Helper free retrovirus producing  G.P. Nolan 
 cells based on HEK 293 cells 
Ovcar-3 Human ovarian adenocarcinoma  ATCC HTB-161 
A-431 Human epidermoid carcinoma  ATCC CRL-1555 
U-1242 Human glioblastoma   SUGEN, USA 
Dal Human mammary carcinoma   G. Natali 
MDA-MB-231 Human mammary adenocarcinoma ATCC HTB-26 
MDA-MB-361 Human mammary adenocarcinoma ATCC HTB-27 
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MCF-10A Human mammary gland epithelia ATCC CRL-10317 
Daudi Human Burkitt's lymphoma   ATCC CCL-213 
IM-9 Human B lymphoblast   ATCC CCL-159 
KG-1 Human acute myelogenous leukemia ATCC CCL-246 
HEL Human erythroleukemia   ATCC TIB-180 
NCI-H460 Human large cell lung carcinoma  ATCC HTB-177 
NCI-H661 Human lung carcinoma   ATCC HTB-183 
NT-2 Human teratocarcinoma   Stratagene 
NIH/3T3 Mouse embryo fibroblst   ATCC CRL-1658 
PC-12 Rat pheochromocytoma   ATCC CRL-1721 
RIN-5AH-T2B Rat insulinoma   Billestrup, 1985 
Rat-1 Rat fibroblasts, immortalised   R. Friedrich 
B-29 Mouse mammary carcinoma   ATCC CRL-6325 
L-8A Mouse mammary carcinoma   ATCC CRL-6363 
MM2SCT Mouse mammary carcinoma   ATCC CRL-6375 
MM5MTC Mouse mammary carcinoma   ATCC CRL-6378 
MM5.1 Mouse mammary carcinoma   ATCC CRL-6380 
MM5/C1 Mouse mammary carcinoma   ATCC CRL-6444 
MM5MT Mouse mammary carcinoma   ATCC CRL-6590 
 
 
 
2.1.10 Antibodies 
 
2.1.10.1 Commercial Antibodies 
 
Antibody  Description    Reference   
 
PY(4G10)  Mouse monoclonal anti-  Upstate Biotechnology, 
   phosphotyrosine antibody  USA 
 
Flag   Rabbit polyclonal anti-Flag  Santa Cruz Biotech, USA 
Flag   Mouse monoclonal anti-Flag  Sigma, Germany 
 
EGFR   Rabbit polyclonal anti-EGFR Santa Cruz Biotech, 
 (amino acid 1006-1116)  USA 
EGFR   Sheep polyclonal anti-EGFR  Upstate Biotechnology, 
   (GST-fusion protein of   USA 
   extracellular domain) 
ERK1   Rabbit polyclonal anti-ERK1 Santa Cruz Biotech, 
   (C-terminal domain of rat ERK2) USA 
ERK2   Rabbit polyclonal anti-ERK2 Santa Cruz Biotech, 
   (C-terminal domain of rat ERK2) USA 
SHP2   Monoclonal anti-SHP2   Tranduction Laboratory,  
        USA 
Grb2   Monoclonal anti-Grb2  Upstate Biotechnology, 
        USA 
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Caveolin-1  Rabbit polyclonal anti-caveolin-1 Santa Cruz Biotech, USA 
 
The following HRP-conjugated secondary antibodies were used in immunoblot 
(Western blot) and were purchased from BioRad (Munich, Germany). 
 
Antibody   Dilution  
Goat anti-mouse  1 : 50'000 
Goat anti-rabbit  1 : 50'000 
Rabbit anti-sheep  1 : 20'000 
Protein A   1 : 20'000 
 
2.1.10.2 Home-Made Antibodies 
 
Antibody  Description     Reference  
 
FRS2-NT  Rabbit polyclonal anti-FRS2-NT,  This work 
   GST-FRS2-NT as antigen 
 
FRS2-CT  Rabbit polyclonal anti-FRS2-CT,  This work 
   GST-FRS2-CT as antigen 
 
FRS2-WT  Rabbit polyclonal anti-FRS2-WT,  This work 
   GST-FRS2-WT (full-length) as antigen 
 
SHP2    Rabbit polyclonal anti-SHP2-CT   R. Lammers, 
   Peptide as antigen    This department. 
 
Gab1   Rabbit polyclonal anti-Gab1-NT  A. Lankenau, 
   GST-Gab1 fusion protein as antigen  This department. 
 
 
 
2.1.11 Commercial Purified Proteins 
 
Protein  Description    Reference   
 
p13suc1   Recombinant yeast p13suc1 GST  Upstate Biotechnology,  
fusion protein agarose conjugated USA 
ERK2, active  Recombinant mouse ERK2 GST  Upstate Biotechnology,  
fusion protein, phosphorylated USA 
ERK2, unactive Recombinant mouse ERK2 GST  Upstate Biotechnology,  
fusion protein, unphosphorylated USA 
MEK1, acitvated Recombinant human MEK1 GST  Upstate Biotechnology,  
fusion protein, phosphorylated USA 
MEK1, unacitvated Recombinant human MEK1 GST  Upstate Biotechnology,  
fusion protein, unphosphorylated USA 
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2.1.12 Plasmids and Oligonucleotides 
 
2.1.12.1 Original Plasmids 
 
Plasmid  Description    Reference   
 
pGEX5X-1/  Expression vector of GST fusion- Amersham Biotechnology,  
pGEX5X-3/  proteins, Ampr   Freigurg, Germany 
pGEX-2T        
 
pRK5 Expression vector, Ampr,   Genentech,  
   CMV promotor, SV40 poly A, San Francisco, USA 
   high copy plasmid 
 
pcDNA3  Expression vector, Ampr, Neor,  Invitrogen, Netherlands 
   CMV promotor, BGH poly A, 
   high copy plasmid  
 
pEGFP-N3  Expression vector, Kanr, Neor,  Clontech, Palo Alto, USA 
   CMV promotor, SV40 poly A, 
 
pLXSN  Retroviral expression vector, Ampr, Miller & Rosman, 1989 
 Neor, ori of PBR322, 5'-LTR and  
  3' LTR of MoMuLV, SV40 promoter 
 
2.1.12.2 Plasmids with Inserts 
Plasmid   Insert     Reference  
 
pRK5-FRS2   Full-length cDNA of human   This work 
    FRS2 (amino acids 1-508) 
 
pRK5-FRS2-Flag  Full-length cDNA of human   This work 
    FRS2 (amino acids 1-508),  
carboxyl terminal Flag-tag 
 
pcDNA3-FRS2-Flag  Full-length cDNA of human   This work 
    FRS2 (amino acids 1-508),  
carboxyl terminal Flag-tag 
 
pGEX-5X-3-FRS2-WT Full-length cDNA of human   This work 
    FRS2 (amino acids 1-508) 
 
pGEX-5X-1-FRS2-PTB cDNA of human FRS2  This work 
    (amino acids 1-163) 
 
pGEX-5X-3-FRS2  cDNA of human FRS2  This work 
-Myr/∆PTB   (amino acids 1-9 + 153-508) 
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pGEX-5X-1-FRS2-∆PTB cDNA of human FRS2  This work 
    (amino acids 156-508) 
 
pGEX-2T-FRS2-NT  cDNA of human FRS2  This work 
    (amino acids 1-240) 
 
pGEX-5X-1-FRS2-CT cDNA of human FRS2  This work 
    (amino acids 326-508) 
 
pGEX-2T-CR   cDNA of human FRS2  This work 
    (amino acids 238-345) 
 
pGEX-5X-3-∆CR  cDNA of human FRS2  This work 
    (amino acids ∆240-351) 
 
pcDNA3-FRS2-G2A  cDNA of human FRS2, G2A  This work 
    myristylation site mutant 
 
pEGFP-N3-FRS2-WT Full-length cDNA of human   This work 
    FRS2, C-terminal GFP 
 
pEGFP-N3-FRS2-∆C1 cDNA of human FRS2,   This work 
    (amino acids 1-428), 
 
pEGFP-N3-FRS2-∆C2 cDNA of human FRS2,   This work 
    (amino acids 1-345) 
 
pEGFP-N3-FRS2-∆C3 cDNA of human FRS2,   This work 
    (amino acids 1-185) 
 
pcDNA3-HA-ERK2  cDNA of mouse ERK2,  H. Daub, 
amino terminal HA-tag This department 
 
pRK5-SHP2   cDNA of human SHP2  W. Vogel  
         This department 
 
pRK5-SHP2-C459A  cDNA of human SHP2,  W. Vogel 
C459A mutant, inactive  This department 
 
pGEX-5X-2-α-Heregulin cDNA of human heregulin  C. Wallasch 
         This department 
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2.1.13 Oligonucleotides (selection) 
 
For cDNA cloning of full-length FRS2: 
 
GCG AAT TCC ATG GGT AGC TGT TGT AGC TGT C 
 Sense starting at nucleotide 1, EcoRI 
 
GCG GAA TTC TCT GAA GAA GCC ATG GGT AGC TGT TGT AGC TG 
Sense starting at nucleotide 1, including Kozak consensus sequence, EcoRI 
 
CCG ACT GAC CTC GAG TCA CAT GGG CAG ATC AGT ACT ATT GT 
 Antisense ending at nucleotide 1527, XhoI 
 
CCG ACT GAC CTC GAG TCA CTT GTC GTC ATC GTC TTT GTA GTC 
CAT GGG CAG ATC AGT ACT ATT 
 Antisense ending at nt 1527 including Flag-tag sequence 
 
 
For generation of truncation and deletion mutants: 
 
For CT mutant: 
GCG AAT TCT CCA CCA GTA CCT CAG ATA CCC  
 Sense starting at nt 979, EcoRI 
 
For PTB mutant: 
CCG ACT GAC CTC GAG CGG ATG GGA TGA AGC ATC TCC 
 Antisense ending at nt 489, XhoI 
 
For ∆PTB mutant: 
CGA CCC GGG GAT GCT TCA TCC CAT CCG 
Sense starting at nt 472, smaI 
 
CCA CCC GGG ACA GCT ACA ACA GCT ACC 
Antisense starting at nt 4, smaI 
 
For ∆CR mutant:  
CCG GAT CCA TCT TTG CCT CCT GTT TGG 
Sense starting at nt 1057, BamHI 
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2.2 Methods 
 
2.2.1 Preparation, Analysis and Enzymatic Treatment of DNA 
 
2.2.1.1 Plasmidpreparation for Analytical Purpose 
Small amounts of DNA (2- 10 µg) from 2- 3 ml bacteria culture were prepared for 
analytical purposes according to the alkaline lysis method. 
 
2.2.1.2 Plasmidpreparation for Preparative Purpose 
A pure quality of plasmid DNA was needed for transfection into mammalian cells. The 
plasmid purification kit of QIAGEN was used to purify plasmids for this purpose 
according to the manufacturers protocols. 
 
2.2.1.3 Restriction Digestions of DNA-Fragments 
1.5 units/µg of restriction enzyme were incubated with DNA in 30 µl of the 
recommended incubation buffer at 37 °C for 2 hours.  
 
2.2.1.4 Dephosphorylation of 5'-Ends of DNA-Fragments 
Dephosphorylation of the 5'-ends prevented the religation of plasmids with sticky ends. 
1 - 3 µg of cut plasmids was incubated in 10 - 20 µl of 1x phosphatase buffer (50 mM 
Tris-HCl pH 8.0, 0.1 mM EDTA pH 8.5 ) with 1 unit calf intestine phosphatase at 37°C 
for 60 min. 
 
2.2.1.5 Gel Electrophoresis of DNA-Fragments 
Double stranded DNA-molecules between 0.5 and 10 kb were separated in 0.5- 2 % 
horizontal agarose gels. The running buffer was 1 x TAE. The DNA-sample was mixed 
with 1/6 volume of 6 x DNA loading buffer. The electrophoresis was performed 
between 50-100 volts for 1 - 2 hours. After the separation the gel was stained for 10 min 
in 1 x TAE/ethidiumbromide (2mg/ml) and destained for 10 min in 1 x TAE buffer. 
 
2.2.1.6 Isolation of DNA-Fragments from Agarose Gels 
DNA-Fragments were isolated from agarose gels with the QIAquick gel extraction kit 
of QIAGEN according to the manufacturers instructions. The principle of the kit is the 
adsorption of DNA fragments (100 bp - 10 kb) to silica-gel membranes in the presence 
of high concentration of chaotropic salts, which modify the structure of water. The 
elution is performed under basic conditions and low salt concentrations. 
 
2.2.1.7 Ligation of DNA-Fragments into Plasmid Vectors 
The T4-DNA-ligase was used to synthesize the phosphodiester-bonds between the 5'-
phosphate and the 3'-hydroxy-group of polynucleotides. 20 - 200 ng of cut vector were 
incubated with a 2 - 5 fold molar excess of the insert fragment in 10 µl 1x T4-DNA-
ligase buffer (66 mM Tris-HCl pH 7.5, 5 mM MgCl2, 5 mM DTT, 1 mM ATP) and 1 
unit T4-DNA-ligase overnight at 16 °C. The whole ligation reaction was used for 
transformation of bacteria as described. 
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2.2.1.8 Chemical Transformation of Bacteria 
Competent E. coli bacteria were prepared according to the method of Chung and Miller 
(Chung and Miller, 1993). A bacteria preculture was grown overnight. After 12 hours, 
inoculated in 250 ml LB and grown until the mid-log phase (OD600 = 0.3 - 0.5). The 
bacteria were harvested, resuspended in 12 ml cold TSB-buffer (2 x TY media, 12.5% 
PEG 6000, 0.125 mM MgSO4, 0.125 mM MgCl2, 0.06 % DMSO) and incubated on ice 
for 30 min. Aliquots were stored at - 80 °C. For the transformation, 20 µl 5 x KCM (500 
mM KCl, 150 mM CaCl2, 250 mM MgCl2) and 10 µl of the ligation mix were added to 
70 µl ddH2O . The competent bacteria were thawed on ice and 100 µl were added to the 
sample. The reaction was incubated on ice for 20 min and then transferred to room 
temperature for another 10 min. After addition of 400 µl LB-media the bacteria were 
incubated at 37 °C for 60 min in a shaking incubator and subsequently plated out on 
agar plates containing the appropriated resistance drug. The transformation efficiency 
was greater than 5 x 106 clones/µg DNA. 
 
2.2.1.9 Sequencing of Plasmids 
For the verification of DNA sequences a modified protocol of the chain termination 
reaction according to Sanger was used (Sanger et al., 1977). 2 µg of DNA were 
denatured in 20 µl TE(10/0.1) by the addition of 2 µl 2 M NaOH/2 mM EDTA at room 
temperature for 5 min. The sample was ethanol precipitated and the pellet resuspended 
in 14 µl 1 x annealing mix (40 mM Tris-HCl pH 7.5, 50 mM NaCl, 15 mM MgCl2, 0.7 
µM specific primer). The primer was allowed to anneal for 5 min at 37 °C and at room 
temperature for another 5 min. The template was labeled by addition of 6 µl T7 DNA 
pol mix (50 mM DTT, 1 µM dTTP/dCTP/dGTP, 0.25 mCi/ml [α-35S]-dATP, 1 unit T7 
DNA polymerase) for 2 min at room temperature. 2.5 µl of this mixture were aliquoted 
to each of the 4 termination mixtures (80 µM dNTP (all nucleotides except X and 8 µM 
ddXTP) and incubated at 42 °C for 5 minutes. 2 µl formamide dye (deionized 
formamide, 1 mg/ml xylene cyanol, 1 mg/ml bromophenol blue, 10 mM EDTA pH 8.0) 
were added and the reaction was incubated at 90 °C for 10 min. The fragments were 
resolved on a denaturing 6 % acrylamide/7.6 M urea gel. 
 
 
 
2.2.2 Analysis of RNA 
 
The ubiquity of contaminating RNases and the concomitant difficulties in ensuring that 
an RNA preparation remains reasonably undegraded requires specific precautions. All 
the solutions were prepared with MilliporeTM-water and the glassware was baked at 
200 °C for two hours. Gloves were used for all the procedures. The gloves were 
changed frequently. If necessary, the deionized water was treated with 
diethylpyrocarbonate (DEPC) to inhibit RNase activity. 
 
2.2.2.1 Preparation of Total RNA  
Total RNA from cell cultures were isolated with the RNeasy mini kit of QIAGEN 
according the manufacturers instructions. The cells were lysed in a denaturing 
guanidinium isothiocyanate containing buffer and homogenized with a QIAshredder 
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column. The RNA was then purified in spin columns containing special silica-gel 
membranes. 
 
2.2.2.2 Preparation of Poly (A)+-RNA 
The monolayer cells were washed once with 1 x PBS and 3.5 ml guanidine solution (4 
M guanidine solution, 20 mM sodium acetate, 0.5 % Sarkosyl and 0.1 mM DTT) for 108 
cells were added to the dish to lyse the cells immediately. The viscous lysate was 
recovered by scraping the dish with a rubber policeman and removed with a 6-ml 
syringe with a 20-G needle. 1.5 ml 5.7 M CsCl were place in a ultracentrifuge tube and 
3.5 ml of cell lysate were laid on top of the CsCl solution to create a step gradient. The 
sample was centrifuged for at 150'000 g 24 hours. The supernatant was removed 
carefully with a Pasteur pipette and the pellet was allowed to air dry for 5 to 10 min and 
then resuspended in 100 µl H2O at room temperature. 0.5 g oligo (dT9) cellulose 
powder was added to 1 ml of 0.1 M NaOH and the slurry was poured into a silanized 
Pasteur pipette that was plugged with silanized glass wool. The column was equilibrated 
with 15 ml loading buffer (0.5 M LiCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 
0.1 % sodium dodecyl sulfate). The total RNA was heated to 70 °C for 10 min and LiCl 
was added to 0.5 M final concentration. The RNA solution was passed twice over the 
oligo (dT) column. The column was washed with 1 ml poly (A) loading buffer and with 
2 ml middle wash buffer (0.5 M LiCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.1 % 
sodium dodecyl sulfate). The poly (A)+–RNA was eluted with 2 ml elution buffer (2 
mM EDTA pH 8.0, 0.1 % sodium dodecyl sulfate). The eluted RNA was precipitated by 
adjusting the salt concentration to 0.3 M sodium acetate and addition of 2.5 volume 
ethanol. The sample was incubated on dry ice/ethanol for 30 min and resuspended in 30 
µl TE-buffer. 
 
2.2.2.3 Gel Electrophoresis of RNA 
1.8 g agarose was dissolved in 130 ml H2O and cooled to about 60 °C. Immediately 
before the gel was poured, 15 ml 10 x MOPS (200 mM 3-(N-morpholino)-
propanesulfonic acid) and 4.56 ml formaldehyd were added. 5 - 10 µg total RNA were 
diluted in 11.25 µl H2O and 38.75 µl sample buffer (20 mM MOPS, 5.7 % 
formaldehyde, 40 % formamide) were added. The samples were incubated at 55 °C for 
15 min 5 µl loading buffer (40% formamide, 20 % glycerine, 2 mM EDTA pH 8.0, 
0.1% bromophenol dye) was added and the samples were loaded onto the gel. The gel 
was run at 5 V/cm (running buffer 1 x MOPS) until the bromophenol dye has migrated 
two-thirds the length of the gel. The gel was stained with 1 x MOPS/10 µl EtBr for 20 
min. A picture of the gel was taken on a UV transilluminator with a ruler laid alongside 
the gel, so that band positions could later be identified on the membrane. The gel was 
than destained 3 times for 10 min with 1 x MOPS. 
 
2.2.2.4 Transfer of RNA onto Nitrocellulose Membrane 
The RNA was transferred from the gel to a nitrocellulose membrane by upward 
capillary transfer (Thomas, 1980). Two glass dishes were filled with 20 x SSC (3 M 
NaCl, 0.3 M sodium citrate) and a glass plate, that forms the support for the gel was 
placed between the dishes. Three pieces of Whatman 3MM paper were presoaked in 2 x 
SSC (0.3 M NaCl, 0.03 M sodium citrate) and placed on the glass plate so that the ends 
submerge into both 20 x SSC buffer tanks. Three pieces of Whatman 3MM paper were 
cut to the same size as the gel, presoaked in 2 x SSC and placed into the middle of other 
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filter papers. The gel was placed upside down on the filter paper. A nitrocellulose 
membrane was wetted in 2 x SSC and placed on the surface of the gel. Air bubbles 
under the membrane were squeezed out. The membrane was covered with three layers 
of Whatman 3MM paper, which were presoaked in 2 x SSC. Whatman 3MM paper and 
paper towels were stacked on top to a height of 5 - 6 cm. A weight was added and the 
blot was left overnight. After blotting the membrane was placed between two sheets of 
Whatmann 3MM filter paper and baked in a vacuum oven at 80 °C for 2 hours. 
 
2.2.2.5 Labeling of DNA Fragments with [α-32P]-dATP 
DNA probes were labeled with the "MegaprimeTM DNA labeling system" from 
Amersham pharamcia biotech. 25 ng of template DNA were placed in a 
microcentrifugation tube and 5 µl of random nonamer primers and H2O were added to 
50 µl. The samples were denatured at 100 °C for 5 min. After cooling to room 
temperature 5 µl reaction buffer, 4 µl unlabelled dCTP, dGTP, dTTP 2 µl DNA 
polymerase I Klenow (2 u/µl) were added. The reaction was incubated at 37 °C for 10 
min. The labeled DNA fragment was purified with a QIAnucleotide removal kit from 
QIAGEN according to the manufacturers instructions. 
 
2.2.2.6 Hybridization of RNA-blots with Radioactive Probes 
The membrane was blocked in prehybridization solution (50 % formamide, 5 x SSC, 
5 x Denhard, 0,1 % SDS) containing 20 µg/ml denatured and sheared DNA for at 42 °C 
1 hours. The prehybridization solution was changed once after 6 hours. The membrane 
was the incubated in hybridization solution (50 % formamide, 5 x SSC, 0.2 % SDS, 5 x 
Denhardt, pH 7.5 - 7.8) containing the denatured and labeled probed for 12 hours. After 
washing the membrane twice in 2 x SSC, 0.1 % SDS at 42 °C for 20 min and once with 
0.2 x SSC, 0.1 % SDS for at 42 °C 15 min, autoradiography using intensifying screens 
was performed at - 80 °C for 12 - 60 hours. If the membrane was to be reprobed, the 
probe was removed by placing the membrane in boiling water containing 10 mM Tris 
pH 8.0, 0.1 % SDS. After 5 min the solution was slowly cooled down to room 
temperature by switching off the heat.  
 
 
 
2.2.3 Amplification of RNA- and DNA-Fragments 
 
2.2.3.1 Conversion of mRNA into Doubled-stranded cDNA 
Purified mRNA can be used to produce cDNA with the help of the enzyme reverse 
transcriptase, which plays a crucial role in the replication of retroviruses. 2 µg poly 
(A)+-RNA were incubated with 1 µg random hexamer primer in a reaction volume of 
13.5 µl and heated at 68 °C for 2 min. The first strand was synthesized by addition of 
0.5 µl RNase inhibitor (40 units/ml), 1 µl AMV reverse transcriptase (25 units/µl), 1 µl 
10 mM dNTPs (endconcentration 500 µM) and a 5 x buffer to the endconcentration of 
30 mM Tris-HCl, pH 8.0, 10 mM MgCl2, 5 mM DTT, 100 mM KCl. The reaction 
(volume 20 µl) was incubate on ice for 5 min and at 42 °C for 60 min. The second 
strand synthesis was then performed by addition of 2 µl 10 mM dNTPs 
(endconcentration 500 µM), 1.2 µl RNaseH (1unit/µl), 1.3 µl DNA-Polymerase I (5 
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units/µl) and a 5 x buffer to the endconcentration of 30 mM Tris-HCl, pH 8.0, 10 mM 
MgCl2, 5 mM DTT, 100 mM KCl. The reaction (volume 60 µl) was incubated at 15 °C 
for 60 min and at 22 °C for another 60 min. After addition of 90 µl H2O to a final 
volume of 150 µl, the reaction was phenol/chloroform extracted and precipitated by the 
addition of 1/10 volumes 3 M sodiumacetate pH 9.0 and 3 volumes ethanol and 
incubation in a ethanol/dry ice bath for 15 min. The pellet was washed with ice-cold 
70% ethanol and resuspended in 20 µl H2O. 
 
2.2.3.2 PCR-Amplification of DNA and cDNA-Fragments 
The method of the polymerase chain reaction (PCR) techniques allows the exponential 
amplification of a specified DNA sequence in vitro.. In a repeating cycle, doubled 
stranded DNA is separated by heat denaturation, the primers anneal to their binding 
sites that flank the target region and a polymerase can synthesize new strands of DNA, 
complementary to the template (Mullis et al., 1986; Mullis and Faloona, 1987). Each 
PCR reaction was performed in a total reaction volume of 50 µl containing 0.1 µg 
template DNA, 1x TaKaRa PCR buffer, 2.5 µM MgCl2, 0.5 µM of each primer, 200 µM 
dNTP and 0.1 – 0.75 units TaKaRaTaq.  
The following cycle was used in a Techne thermo cycler: 
 
94°C  3 min  
25x [94°C, 30 sec—>T°C, 60 sec —> 72°C, 60sec] 
 72°C, 10 min 
 4 °C 
 
The annealing temperature T was calculated as T= 2 ((A+T) + 2 (G+C)) -5, where the 
A, T, G and C correspond to the number of each respective eoxyribonuclotides in the 
oligonucleotide). An elongation time of 60 sec was used for the synthesis of a fragment 
of one kilobase. 
The amplification was verified by running an analytical agarose gel with an aliquot of 
the reaction. 
 
 
2.2.3.3 Purification of PCR Products 
The PCR-products were purified with the QIAquick PCR purification kit of QIAGEN 
according to the manufacturers instructions. The principle of the kit is the adsorption of 
DNA fragments (100 bp- 10 kb) to silica-gel membranes in the presence of high 
concentration of chaotropic salts, which modify the structure of water. The elution is 
performed under basic conditions and low salt concentrations. 
 
2.2.3.4 Subcloning of PCR Fragments 
PCR-products were subcloned by using primers with recognition sites for restriction 
enzymes. After restriction digest and gel purification the fragments were ligated into the 
required plasmids. 
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2.2.4 Rabbit Polyclonal Antibodies 
 
2.2.4.1 Production of Antibodies 
GST-fusion proteins were used as antigens for production of rabbit polyclonal 
antibodies. 0.5 mg of antigen was mixed with the same volume of complete Freund's 
adjuvant and injected subcutaneously into a rabbit. For booster immunization, 0.5 mg of 
antigen were mixed with the same volume of incomplete Freund's adjuvant and injected 
four, eight and ten weeks after the priming immunization. Prior to the priming 
immunization and each booster immunization, the animal was bled and the titer of the 
serum was tested in immunoprecipitations and immunoblotting as described. The 
preimmune bleed was used as a control to ensure that the antibody activity detected in 
later bleeds was due to the immunization. 
 
 
2.2.4.2 Purification of Antibodies 
Polyclonal antibodies were immunopurified on an antigen column to isolate specific 
antibodies from a mixed pool. CNBr-activated sepharose 4B beads were swollen for 15 
min in 1 mM HCl which preserves the activity of the reactive groups and washed on a 
sintered filter (porosity G3) with the same solution. The gel is then washed with 
coupling buffer (0.1 M NaHCO3 pH 8.3, 0.5 M NaCl) and immediately transferred to 
solution of the ligand (GST-fusion protein used as antigen). About 5-10 mg protein 
were used per milliliter gel. The mixture was rotated end-over-end for 2 hours at room 
temperature. The beads were then pelleted and resuspended in 1 M ethanolamine pH 8.0 
to block the residual active groups by adding an excess of small primary amino groups. 
After washing the beads three times with coupling buffer, they were transferred to a 
column. The column was first washed with 10 bed-volumes of 10 mM Tris-HCl pH 7.5, 
followed by 10 bed-volumes of 100 mM glycine-HCl pH 2.5 and 10 bed-volumes of 10 
mM Tris-HCl pH 8.8. Then 10 bed-volumes of 100 mM triethylamine pH 11.5 were 
added and the column was equilibrated with 10 mM Tris-HCl pH 7.5 until the pH was 
stable. The polyclonal serum was centrifuged at 5'000 rpm for 5 min to remove any 
debris, diluted 1:10 in 10 mM Tris-HCl pH 7.5 and passed three times through the 
column. The column was then washed three times with 20 bed-volumes of 10 mM Tris-
HCl pH 7.5 followed by 20 bed-volumes of 500 mM NaCl, 10 mM Tris-HCl pH 7.5. 
The antibodies that were bound by acid-sensitive interactions were eluted by passing 10 
bed-volumes of 100 mM glycine-HCl pH 2.5 through the column and collected in 1 
bed-volume 1 M Tris-HCl pH 8.0. The column was washed with 10 mM Tris-HCl pH 
8.8 until the pH was stable and the remaining antibodies bound by base-sensitive 
interactions were eluted by passing 10 bed-volumes of 100 mM triethylamine pH 11.5 
through the column and collected in 1 bed-volume 1 M Tris-HCl pH 8.0. If the column 
was to be reused it was washed with 10 mM Tris-HCl pH 7.5 and stored at 4°C. The 
antibody fractions were combined and dialyzed against PBS containing 0.02 % sodium 
azide. 
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2.2.5 Techniques of Mammalian Cell Culture 
 
2.2.5.1 General Cell Culture Techniques 
All used mammalian cell lines were cultured in incubators (Heraeus, B5060 Ek/CO2) at 
5-7 % CO2, 37°C and a saturated water vapor atmosphere. All cell culture work was 
performed aseptic in a sterile hood (Heraeus, Laminair). The cells were passaged 
regularly and the media was changed every other day. In addition, the culture were 
checked routinely for infection with mycoplasma. The cells were frozen in a media 
containing 90 % FCS and 10 % DMSO for long term storage in liquid nitrogen. A 
Neubauer counting chamber was used for counting the cells. 
 
2.2.5.2 Test of Contamination with Mycoplasma 
The contamination of cell cultures with mycoplasma influences the expression of cell 
surface proteins, the transduction of extracellular signals, the metabolism and other 
processes. Because of these influences on the experimental results the cultures were 
regularly checked for infection with mycoplasma. Subconfluent cells on 6 cm plates 
were fixed with methanol, washed twice with PBS and incubated with the DNA-
staining reagent bisbenzimid (0.1 mg/ml in PBS) at 37 °C for 15 min. The cultures were 
then examined in a fluorescence microscope for the presence of mycoplasma. 
 
2.2.5.3 Transfection of Mammalian Cells by Lipofectamine 
Lipofectamine® is a polycationic transfection reagent. It binds DNA and its lipophilic 
property allows the transfer of DNA across the cell membrane into cells. Cos-7 cells 
were seeded at a density of 180'000 (80'000) cells/well in 6-well plates (12-well plate) 
24 hours before transfection. Two solutions were prepared for the transfection: For 
solution A, 10 µl Lipofectamine® were diluted in 90 µl DMEM without serum (4 µl 
Lipofectamine® and 36 µl DMEM without serum)  and 1.5 µg (0.8 µg) of plasmid DNA 
were diluted in 100 µl (40 µl) DMEM without serum for solution B. Both solutions 
were carefully mixed and incubated  at room temperature for 45 min. The cells were 
washed once with 2 ml (1 ml) DMEM without serum during this incubation time. 800 
µl (320 µl) of DMEM without serum were added to the transfection mixtures. The 
reaction was carefully mixed and added onto the cells, from which the media was 
removed before. After an incubation of 4 hours in the incubator 1000 µl (400 µl) 
DMEM with 20% FCS were added to the cells. The cells were incubated for another 12-
20 hour. For starvation, the media was replaced with DMEM without serum overnight. 
 
2.2.5.4 Transfection of Mammalian Cells by Calcium Phosphate-DNA 
Precipitation 
A solution of calcium chloride, plasmid DNA and N-N-bis(2-hydroxyethyl)-2-amino-
ethanesulfonic acid (BES) buffer is added to the a plate of cells. During a overnight 
incubation under an atmosphere of 3 % CO2 a calcium phosphate-DNA precipitate 
forms. This precipitate adheres to the cell surface and is taken up by the cells. 0.5 x 106 
cells/10 cm tissue culture plate were seeded in 5 ml complete medium the day before 
transfection. 10 µg plasmid DNA were diluted in 360 µl H2O, 20 µl CaCl2 and 200 µl 
2xBBS (50 mM N-N-bis(2-hydroxyethyl)-2-amino-ethanesulfonic acid (BES), 280 mM 
NaCl, 1,5 mM Na2HPO4, pH 6.95) were added. The solution was vortexed and 
incubated at room temperature for 15 min. The calcium phosphate-DNA solution was 
added dropwise onto the medium-containing plate. The cells were then incubated at 3 % 
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CO2 atmosphere for 12 - 24 hours. For starvation, the media was replaced with DMEM 
without serum for 24 hours.  
 
2.2.5.5 Control of Transfection Efficiency 
An expression plasmid of the β-galactosidase was transfected into the cells as described. 
48 hours after transfection, the cells were washed once with PBS and fixed with 3% 
paraformaldehyd solution at room temperature for 10 min. The cells were washed twice 
with PBS and permeabilized with 0.2 % Triton X-100 in PBS for 10 min. After four 
wash steps with PBS, the transfected cells were stained with X-gal solution (2 mg/ml in 
DMSO) at 37°C for 60 min. 
 
2.2.5.6 Retroviral Genetransfer into cells 
Ecotrophic virus containing supernatant released from transfected BOSC 23 cells was 
used to infect NIH3T3 fibroblasts. After sterile filtration through 0.45 µm filter, the 
supernatant was added to subconfluent cells (105cells/6-cm dish) for 4 hours in the 
presence of polybrene (4 µg/ml). If necessary different dilutions or several infections 
were performed sequentially. After infection the media was changed and the cells were 
directly used for experiments or grown for at least 14 days in medium containing 
antibiotics for selection of stable cell line. 
 
 
 
2.2.6 Metabolic Radiolabeling of Proteins 
 
2.2.6.1 Radiolabeling with 35S-Methionine 
To label proteins radioactively with [35S]-methionine, the cells were washed once with 
PBS and starved in DMEM without methionine and FCS for 24 hours. After the first 5 
hours, 40 µCi/ml [35S]-L-methionine were added to the media. 
 
2.2.6.2 Radiolabeling with 32P-Orthophosphate 
To label proteins with [32P]-phosphate, the cells were washed once with PBS and 
starved for 18 hours in DMEM without FCS. The cells were washed again with PBS, 
the media replaced with phosphate free DMEM and after 1 hour 150 µCi/ml [32P]-
orthophosphate were added for another 5 hours. 
 
 
 
2.2.7 Purification of GST-Fusion Proteins 
 
Eucaryotic proteins can be expressed in bacteria as glutathione-S-transferase (GST) 
fusion proteins. In many cases these fusion proteins are soluble and can be affinity 
purified with glutathion-sepharose after lysis of the bacteria. The purified fusion 
proteins can be used in precipitation experiments or for antibody production.  
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2.2.7.1 Expression of GST-Fusion Proteins 
3 ml LB-media containing the required antibiotics were inoculated with 2-3 freshly 
transformed bacteria colonies at 37 °C overnight. The next morning 10 ml of this 
preculture were transferred into 1000 ml LB-media containing antibiotics and further 
incubated until the OD600 was between 0.4 - 0.5. The expression of the fusion proteins 
was induced by addition of isopropyl-β-thiogalactopyranoside (IPTG) to a final 
concentration of 1 mM IPTG, the bacteria were further grown for 3 hours and collected 
by centrifugation.  
 
2.2.7.2 Purification of GST-Fusion Proteins 
Bacteria from a 1000 ml liquid culture were collected by centrifugation at 6000 rpm for 
5 min. The pellet was washed once with ice-cold PBS and resuspended in 10 volumes 
of ice-cold lysis PBS containing 0.5 mM EDTA, pH 8.0, 1 mM benzamidine, 150 ml 
aprotinin, 300 ml PMSF and 0.5 mM DDT. After disrupting the cell walls using a probe 
sonicator with a 2 mm-diameter probe, Triton X-100 was added to a final concentration 
of 1 % and the probe was incubated on ice for 10 min. The insoluble debris was 
removed by centrifugation at 10'000 g. The supernatant was incubated with 0.5 ml of a 
50 % slurry of glutathion-agarose beads at 4 °C for 12 hours. The beads were washed 
three times with 50 ml ice-cold PBS, loaded onto a column and the fusion proteins were 
eluted with a buffer containing 50 mM Tris-HCl pH 8.0 and 5 mM reduced glutathion. 
The first three bed-volumes were collected and analyzed by SDS-PAGE. After the 
estimation of the concentration of the fusion protein with a BSA-standard, aliquots were 
frozen in 20 % glycerol at - 20 °C. 
 
 
 
2.2.8 Precipitation and Detection of Proteins 
 
2.2.8.1 Stimulation and Lysis of Cells 
Different signal transduction pathways were investigated upon stimulation of cell with 
different growth factors. Before stimulation, the cells were starved in DMEM without 
serum for 18-24 hours. Cellular proteins were brought into solution with the detergent 
Triton X-100. This detergent lysis the cell membrane and leaves the nucleus and other 
intracellular compartments intact. Membrane and cytoskeletal fragments are pelleted by 
centrifugation and the supernatant is used for subsequent experiments. The cells were 
washed once with ice cold PBS and lysed on ice in an appropriate volume lysis buffer 
(50 mM HEPES pH 7.5, 150 mM NaCl, 10 % glycerin, 5 mM EDTA pH 8.0, 1% Triton 
X-100), to which 10.0 µg/ml aprotinin, 1.0 mM PMSF, 100.0 mM sodiumfluorid, 10.0 
mM p-nitrophenylphosphat 20.0 mM sodiumpyrophosphate, 2.0 mM sodium-
orthovanadate pH 10.0 were freshly added. Alternatively, RIPA (Radio Immuno 
Protection Assay) buffer eas used in stead (1% NP-40, 1% sodium deoxycholate, 0.1% 
SDS, 0.15 M NaCl, 0.01 M sodium phosphate pH7.2, 2 mM EDTA, 50 mM sodium 
fluoride, and 0.2 mM sodium vanadate along with 100 U/ml aprotinin added freshly) 
was used. The volume was adjusted to the size of the cell culture plate. After 10 min the 
cell lysate was collected in an Eppendorff-tube and the insoluble fragments were 
pelleted by centrifugation (13'000 rpm, 4 °C, 10 min). The supernatant was collected in 
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an new Eppendorff-tube and used either for immunoprecipitation as described or as 
whole cell lysate.  
 
2.2.8.2 Pierce BCA Protein Estimation Assay 
The Micro BCA Protein Assay Kit from Pierce was used to determine the protein 
concentration of the crude cell lysates. The kit is based on the Biuret reaction, in which 
proteins react with Cu2+ in an alkaline medium to produce Cu1+. The Cu1+ ions then 
react with bicinchonic acid (BCA) yielding a water-soluble, purple complex exhibiting 
a strong absorbance at 562 nm. The kit is not sensible to detergents (e.g. Triton X-100), 
which are used to lyse cells. The assay was performed in microtiter plates according to 
the manufacturer recommendation. A bovine serum albumin concentration series (100 - 
2000 µg protein/ml) was used as standard. 
 
2.2.8.3 Immunoprecipitation of Proteins 
In immunoprecipitations antibodies, which were coupled to protein A-sepharose, were 
used for the enrichment of proteins from total cell lysate. Protein A is a membrane 
protein of the bacteria Staphylococcus aureus, which binds specifically to the Fc-
domain of certains immunoglobulins (Chenais et al., 1977). For the 
immunoprecipitation, the cell lysate was diluted with an equal volume of HNTG-buffer 
(50 mM HEPES pH 7.5, 150 mM NaCl, 10 % glycerin, 5 mM EDTA pH 8.0, 0.1 % 
Triton X-100), 30 µl 50 % protein A-sepharose and 1-5 µg monoclonal antibody or 2-10 
µl polyclonal antibody were added. The samples were rotated at 4 °C for at least 4 hours 
end-over-end. The protein A-sepharose beads were pelleted by centrifugation (13'000 
rpm) and washed three times with HNTG-buffer. After addition of 50 µl 2 x Laemmli-
buffer, the beads were boiled at 100 °C for 5 min to denature the proteins.  
 
2.2.8.4 In vitro Binding Assay with GST-Fusion Proteins 
5 µg GST-fusion protein were incubated with 40 µl glutathion-sepharose in 600 µl 
HNTG-buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10 % glycerin, 5 mM EDTA pH 
8.0, 0.1 % Triton X-100) and rotated end-over-end at 4 °C for 1 hour. The sepharose 
beads were pelleted by centrifugation (13'000 rpm) and washed once with HNTG-
buffer. An equal volume of cell lysate and HNTG-buffer were added to the beads and 
the samples were processed as described in 2.2.11.3. 
 
2.2.8.5 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) of Proteins 
The SDS-polyacrylamide-gel electrophoresis allows the separation of proteins 
according to their molecular weight (Laemmli, 1970). The detergent sodium-dodecyl-
sulfate binds and denatures proteins. The binding of the dodecyl-sulfate, results in a 
negative, total charge of the protein independent of the specific amino acid composition, 
but correlated to its molecular weight. The negative charge determines the migration of 
the protein through the gel. 7.5, 10 or 15 % SDS-polyacrylamide gels or gradient gels 
with a continuous polyacrylamide gradient from 7.5 to 12.5 % were used, dependent on 
the molecular weight of the proteins. The stacking gels contained 4 % polyacrylamide. 
The SDS-gel electrophoresis was performed as described in Current Protocol in 
Molecular Biology (Ausubel F. M., 1988). After electrophoresis, the gels were either 
stained as described in 2.6.7 the proteins were blotted onto nitrocellulose as described in 
2.6.8. The following proteins were used as molecular weight markers: 
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 Protein Molecular Weight (kDa) 
 Myosin  200 
 β-galactosidase  116 
 Phosphorylase b  97 
 Bovine serum albumin  66 
 Ovalbumin  45 
 Carboanhydrase  29 
 Trypsin-inhibitor  21 
 Lysozyme  14 
 
2.2.8.6 Staining and Fixation of Polyacrylamide Gels 
The gels were stained for 5 min in Coomassie-solution (1 % Coomassie G250, 10 % 
acetic acid, 40 % methanol) and destained with 40 % methanol, 10 % acetic acid. The 
destained gels were placed on 3 MM Whatmann-paper and dried at 80°C under vacuum. 
If the proteins were radioactively labeled, the gels were exposed to films. 
 
2.2.8.7 Transfer of Proteins onto Nitrocellulose Membrane 
For immunodetection, the proteins were blotted onto nitrocellulose membranes. The 
transfer was performed with transblot-SD-buffer (50.0 mM Tris-HCl pH 7.5, 40.0 mM 
glycine, 20 % methanol, 3.75 x 10-5 % SDS) at 0.8 mA/cm2 nitrocellulose membrane in 
a semidry blot aperture for 2 hours. After the transfer, the proteins were stained with 
Ponceau S (2 g/liter in 2 % TCA), the bands of the molecular weight standard were 
marked and the membrane was destained and blocked with 1 x NET-gelatine (50.0 mM 
Tris-HCl pH 8.0, 5 mM EDTA pH 8.0, 150 mM NaCl, 0.5 % Triton X-100 0.25 % 
gelatine). 
 
2.2.8.8 Immunoblotting of Proteins (Western blot analysis) 
Proteins, that are immobilized on nitrocellulose membranes can be detected with 
antibodies. In a first step the immobilised protein (antigen) is recognized by a specific 
monoclonal or polyclonal antibody (primary antibody). In a second step the primary 
antibody is recognized by a species specific secondary antibody, to which a horse radish 
peroxidase is coupled. In alkaline medium luminol (a diacylhydrazide) is oxidized by 
horse radish peroxidase and hydrogen peroxide. Immediately following oxidation, the 
luminol is in an excited state which then decays to ground state via a light emitting 
pathway, which can be detected by exposure to a film. The nitrocellulose membrane 
was incubated for one hour with three changes of 1 x NET-gelatine (50.0 mM Tris-HCl 
pH 8.0, 5 mM EDTA pH 8.0, 150 mM NaCl, 0.5 % Triton X-100. 0.25 % gelatine) to 
block unspecific binding sites of antibodies. The membrane was incubated with the 
primary antibody (1:500 - 1:10000 dilution in 1 x NET-gelatin) at room temperature for 
3 hours or at 4°C overnight. After removal of the primary antibody, the membrane was 
washed 3 times for 20 min with 1 x NET-gelatine at room temperature and incubated 
with the secondary antibody for one hour. The membrane was washed 3 times for 20 
minutes with 1 x NET-gelatine before detection with a ECL-kit from NEN. The 
membrane was incubated in a 1:1 mixture of both ECL-reagents for one minute. 
Afterwards, the membrane was wrapped with plastic film, and the air bubbles between 
the membrane and the plastic film were removed by gently smoothing with a tissue 
paper. The membrane was exposed to the film for different time periods. When the 
membrane should be reprobed with another antibody, the bound antibodies were 
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removed by stripping in 62.5 mM Tris pH 6.8, 100 mM β-mercaptoethanol, 2% (w/v) 
SDS at 50 °C for 1 hour. 
 
 
 
2.2.9 In vitro Kinase Assay  
 
2.2.9.1 In vitro Kinase Assay with Precipitated FRS2 
Ovcar-3 cells were serum starved overnight and stimulation with 25 ng/ml EGF or 
aFGF. The lysates were subjected to immunoprecipitations with pre-immunserum or 
anti-FRS2 antibody as described in 2.2.8.3. After wash the immunoprecipitates 3 times 
with 0.75 ml HNTG-buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerin, 5 
mM EDTA pH 8.0, 0.1% Triton X-100) and once equilibrated with 0.4 ml equilibration 
buffer (20 mM HEPES/NaOH pH 7.5, 1 mM DTT, 10 mM MgCl2, 0.2 mM 
orthovanadate), 30 µl reaction buffer (20 mM HEPES/NaOH pH 7.5, 1 mM DTT, 10 
mM MgCl2, 200 µM orthovanadate, 5 µM p-nitrophenylphosphate, 0.5 mg/ml myelin 
basic protein (MBP), 50 µM ATP) and 1 µCi [γ-32P]-ATP were added to each 
precipitates. The samples were incubated in a shaker at room temperature for 10 min 
and the kinase reaction was stopped by addition of 20 µl 3 x Laemmli buffer. After 
SDS-PAGE, the gel was dried and detected by autoradiography.  
 
2.2.9.2 In vitro Kinase Assay with Precipitated ERK2 MAP Kinase  
The transiently expressed hemaglutinin-tagged MAP kinase HA-ERK2 was 
immunoprecipitated from cell lysat. The precipitates were washed 3 times with 0.75 ml 
HNTG-buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerin, 5 mM EDTA pH 
8.0, 0.1% Triton X-100) and once equilibrated with 0.4 ml equilibration buffer (20 mM 
HEPES/NaOH pH 7.5, 1 mM DTT, 10 mM MgCl2, 0.2 mM orthovanadate). 30 µl 
reaction buffer (20 mM HEPES/NaOH pH 7.5, 1 mM DTT, 10 mM MgCl2, 200 µM 
orthovanadate, 5 µM p-nitrophenylphosphate, 0.5 mg/ml myelin basic protein (MBP), 
50 µM ATP) and 1 µCi [γ-32P]-ATP were added to the precipitates. The samples were 
incubated in a shaker at room temperature for 10 min and the kinase reaction was 
stopped by addition of 20 µl 3 x Laemmli buffer. The probes were resolved by gradient 
(7-12.5%) SDS-PAGE. The gel was dried and detected by autoradiography.  
 
2.2.9.3 In Vitro Kinase Assay with Purified ERK2 and MEK1 
For each reaction, 1µg (7.5 pmol) of inactive ERK2 (unphosphorylated), 100ng (1.5 
pmol) of active ERK2 (phosphorylated), 0.2µg (3 pmol)of inactive MEK1, and 125ng 
(1.75 pmol) active MEK1 were used according to the manufacture recommendation. 
Each of the purified ERK2 and MEK1 proteins was incubated with 2µg of purified 
GST-FRS2 fusion proteins in presence of 1 µCi [γ-32P]-ATP in assay buffer (20 mM 
HEPES pH 7.5, 25 mM β-mercaptoethanol, 5 mM EGTA, 1 mM sodium ortovanadate, 
1 mM DTT, 15 mM MgCl2, 100µM ATP) for 30 min at 30°C. The activity of the 
purified kinases were controlled using myelin basic protein (MBP) as substrate for 
ERK2, and for MEK1 a two-step kinase assay were performed using unphosphorylated 
ERK2 as the first and MBP as second substrates. The reaction was stopped by addition 
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of Laemmli buffer, and the probes were solved by gradient (7-12.5%) SDS-PAGE. The 
gel was dried and followed by exposure of autoradiography.  
 
 
 
2.2.9.4 In-Gel Kinase Assay 
The lysates from stimulated and untreated cells were subjected to immunoprecipitation 
with anti-FRS2 antibody. The immunoprecipitates were then resolved by SDS-PAGE 
where 0.5 mg/ml myelin basic protein (MBP) was embedded as substrate. The gel was 
then fixed (20% isopropanol, 50 mM Tris pH 8.0) for 1 hour at room temperature, 
washed three times (50 mM tris pH8.0, 1 mM dithiothreitol), denatured (6 M 
guanidiniumhydrochloride, 20 mM dithiothreitol, 2 mM EDTA, 50 mM Tris pH 8.0) for 
1 hour at room temperature, and renatured (50 mM Tris pH 8.0, 0.04% Tween 40, 1mM 
dithiothreitol, 2 mM EDTA) for 16 hours at 4°C. After 1 hour washing (40 mM HEPES 
pH 8.0, 1 mM dithiothreitol, 10 mM MgCl2, 0.1 mM EGTA) at room temperature, the 
gel was incubated in kinase buffer (40 mM HEPES pH 8.0, 5 µCi/ml [γ-32P]-ATP, 40 
µM ATP, 10 mM MgCl2, 0.1 mM EGTA) for 1 hour at room temperature. Finally, the 
gel was washed extensively in 5% trichloroacetic acid and 1% sodium pyrophosphate, 
followed by drying and autoradiography  
 
 
 
2.2.10 Phosphoamino Acid Analysis 
 
[32P]-labeled phosphoamino acids can be identified by partial hydrolysis of the protein 
in HCl followed by two-dimensional thin layer electrophoresis. Cells were labeled with 
[32P]-ortho-phosphate. After precipitation of the protein of interest, it was transferred to 
a polyvinyldifluorid membrane using the same technique as for immunoblotting 
(2.2.11.8). The band of interest was located by autoradiography and excised of the 
membrane with a clean razor bladder. The piece of membrane was submerged in 6 M 
HCl and incubated at 110 °C for 60 min. The liquid hydrolysate was transfered to a 
fresh tube and dried in a Speedvac evaporator. The sample was resuspended in 10 µl 
H2O and spotted onto a cellulose thin-layer chromatography plate which was then 
carefully wetted with the respective electrophoresis buffer. A first dimension 
electrophoresis was performed at pH 1.9 (580 mM formic acid, 1360 mM glacial acetic 
acid) and 1.5 kV for 20 min, followed by a second dimension electrophoresis at pH 3.5 
(870 mM glacial acetic acid, 0.5 % (v/v) pyridine, 0.5 mM EDTA) and 1.3 kV for 16 
min. After the first run the plate was dried at 60 °C for 15 min rotated 90 ° 
counterclockwise for the second run. The plates were dried and exposed at - 80 °Cusing 
an intensifying screen.  
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2.2.11 Detergent-free Purification of Caveolin-rich Membrane Fractions 
 
According to the method described by Song et al. (Song et al., 1996). After two washes 
with ice-cold phosphate-buffered saline, Ovcar-3 cells (two confluent 150-mm dishes) 
were scraped into 2 ml of 500 mM sodium carbonate, pH 11.0. Homogenization was 
carried out sequentially in the following order using a loose-fitting Dounce 
homogenizer (10 strokes), a Polytron tissue grinder (three 10-s bursts), and a sonicator 
(three 20-s bursts). The homogenate was then adjusted to 45% sucrose by the addition 
of 2 ml of 90% sucrose prepared in MBS (25 mM Mes, pH 6.5, 0.15 M NaCl) and 
placed at the bottom of an ultracentrifuge tube. A 5-35% discontinuous sucrose gradient 
was formed above (4 ml of 5% sucrose/4ml of 35% sucrose; both in MBS containing 
250 mM sodium carbonate) and centrifuged at 32,000 rpm for 20-22 h in an SW40T 
rotor (Beckman Instruments, Palo Alto, CA). From the top of each gradient, 1-ml 
gradient fractions were collected to yield a total of 13 fractions. Gradient fractions were 
separated by SDS-PAGE. A light-scattering band confined to the 5-35% sucrose 
interface was observed that contained caveolin but excluded most other cellular 
proteins. 
 
 
 
2.2.12 Immunofluorescence 
 
Immunofluorescence allows for an examination of the subcellular localization of 
proteins. Cells are first fixed, then permeabilised with a mild detergent to allow the 
antibody access to subcellular compartments within the cell. Unspecific binding sites 
are blocked with PBG, and then the cells are immersed in a solution that contains 
antibody recognising the desired protein (the primary antibody). The sample is washed a 
second time and incubated with a second antibody that recognises the primary antibody 
(the secondary antibody). This antibody is coupled to a fluorophore. The emitted light 
of the fluorophore betrays the subcellular localization of the target protein when 
examined by fluorescence microscopy while exposing the sample to light at the 
excitation wavelength of the fluorophore. 
Adherent cell cultures were seeded on sterile, uncoated glass cover slips in a small cell 
culture well. At 50% confluency, the cells were washed with PBS and fixed in 4 % 
paraformaldehyde for 20 min at room temperature. Rinsed twice with PBS, the cells 
were permeabelized with 0.2 % Triton X-100 for ten minutes. After washing twice with 
PBS, the aldehyde groups were quenched with 100 mM glycin, 0.1 % NaBH4 for 20 
min. The cells were extensively washed with PBS and blocked for 60 min with 5 % 
BSA (bovine serum albumin), 2% NGS (normal goat serum), 0.1 % fish gelatine. The 
cells were incubated with the primary antibody (1:100 - 1:1'000) for 12 hours at 4 °C, or 
2 hours at room temperature. The cells were washed again several times in PBS to 
remove residual unbound antibody and subsequently incubated with Cy3-konjugated 
secondary antibody (Molecular Probes, Leiden, Netherlands) for 2 hours at RT. All 
stages following application of the secondary antibody were performed in the dark. 
Cells were finally incubated with DAPI in PBS for 10 minutes at RT, the cells washed 
once more and mounted upside down onto a glass slide in Permafluor (Molecular 
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Probes, Leiden, Netherlands). Samples were visualised and photographed with a Zeiss 
Axiovert X-100 Digital Confocal Microscope.  
 
 
 
2.2.13 Computational Analysis of Sequences 
 
Program  URL     Reference   
BLAST   www.ncbi.nlm.nih.gov/BLAST (Altschul et al., 1990) 
Prosite   www.expasy.org/prosite   (Sibbald et al., 1991) 
Scansite   www.scansite.mit.edu  (Yaffe et al., 2001) 
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3. RESULTS 
 
3.1 Phosphoprotein p90 Associates with SHP2  
 
SHP2 is a ubiquitously expressed cytoplasmic tyrosine phosphatase and is 
involved in diverse signaling pathways initiated by growth factors (Adachi et al., 1992; 
Freeman et al., 1992; Ahmad et al., 1993; Feng et al., 1993; Lechleider et al., 1993a; 
Vogel et al., 1993). Via its tandem SH2 domains, SHP2 targets not only to activated 
RTKs, but also to tyrosyl-phosphorylated signaling intermediates, such as IRS-1, Gab1, 
Gab2, gp130 and SIRPs (Holgado-Madruga et al., 1996; Kharitonenkov et al., 1997; 
Symes et al., 1997; Gu et al., 1998).  
In an attempt to identify interaction partners of SHP2, rat pheochromocytoma 
PC12 cells were stimulated with EGF, FGF, NGF and interleukin-6 (IL-6). SHP2 
immunoprecipitates were analyzed for the presence of phosphotyrosine proteins (Figure 
7). SHP2 of 68 kDa became tyrosine phosphorylated upon stimulation with any of the 
four ligands and coprecipitated several other proteins. The 170 kDa phosphoprotein in 
EGF or NGF stimulated cells was likely the receptor tyrosine kinase (RTK) of the 
respective ligand, since SHP2 is known to interact physically with a variety of ligand-
activated RTKs (Feng et al., 1993; Kazlauskas et al., 1993; Lechleider et al., 1993b; 
Vogel et al., 1993). The tyrosine phosphorylated bands of 116 and 97 kDa are possibly 
the adaptor proteins Gab1 and Gab2, respectively (Holgado-Madruga et al., 1996; Gu et 
al., 1998). A phosphoprotein of 90 kDa coprecipitated with SHP2 upon FGF or NGF 
stimulation but not upon treatment with EGF or IL-6. This 90 kDa band resembled the 
protein SNT (suc1-associated neurotrophic target), which was reported as a 78-90 kDa 
polypeptide that is rapidly tyrosine phosphorylated only in response to neurotrophic 
factor stimulation in PC12 cells (Rabin et al., 1993). Meanwhile, it was proposed that 
SNT might be identical to the protein designated FRS2 (FGF receptor substrate 2), 
which becomes phosphorylated on tyrosine residues and binds to Grb2 in response to 
FGF stimulation (Kouhara et al., 1997). Thus, the observation of this SHP2-binding 
protein p90 raised the question whether this protein is FRS2/SNT. 
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Figure 7: Phosphoprotein p90 associates with SHP2. 
PC12 cells were serum starved overnight and stimulated with the indicated ligands for 5 min at 
37°C or left untreated. The cell lysates were subjected to immunoprecipitation with anti-SHP2 
antibody. The immunoprecipitates were resolved by SDS-PAGE followed by immunoblotting 
with anti-phosphotyrosine antibody (PY). Lane 1, untreated; lane 2, 50 ng/ml EGF; lane 3, 50 
ng/ml FGF; lane 4, 50 ng/ml NGF; lane 5, 50 ng/ml interleukin-6 (IL-6). Molecular weights are 
indicated on the left in kilodaltons. 
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3.2 Molecular Cloning and Expression of Human FRS2  
 
At the beginning of this study, only the murine FRS2 amino acid sequence was 
published (Kouhara et al., 1997). As the focus of this study was the function of 
FRS2/SNT in human cells, a BLAST search (TBLASTN) was performed in order to 
identify the corresponding human DNA sequences. Specific oligonucleotide primers 
were designed according to the genomic DNA sequence obtained (GenBank access 
number U91327), and used for PCR amplification of human placenta cDNA. The full-
length cDNA of human FRS2 was then cloned into expression plasmids pcDNA3 or 
pRK5. The sequence was checked by DNA sequencing and found to be identical with 
the sequence of human FRS2α/SNT-1 published later (GenBank access number 
AF036718). The open reading frame (ORF) of 1527 bp encodes a protein of 508 amino 
acids with a predicted molecular weight of 56 kDa. The amino acid sequences of murine 
and human FRS2 share 95% identity. FRS2 contains a consensus myristylation 
sequence (MGXXXS/T) (Resh, 1994) at the amino-terminus of the molecule 
(MGSCCS), as well as a stretch of 130 amino acid (residues 11-140) with 29% 
sequence identity to the phosphotyrosine-binding (PTB) domain of IRS-1 (O'Neill et al., 
1994). In addition, FRS2 harbours four binding sites for Grb2 (pYXNX), Tyr196, Tyr306, 
Tyr349, Tyr392, and two for SHP2, Tyr436 and Tyr471 (see Figure 9). 
FRS2 cDNA was subcloned into a pcDNA3 expression plasmid, coding for the 
protein with a fused Flag-epitope at the C-terminus. Protein expression by this construct 
was checked in human embryo kidney (HEK) 293 cells by transient transfection. The 
cells were stimulated with sodium pervanadate or left untreated. The cell lysates were 
subjected to immunoprecipitations with anti-Flag antibody (Figure 8). Immunoblot with 
anti-phosphotyrosine and anti-Flag antibodies revealed that human FRS2 migrated at 
92-95 kDa and was tyrosine phosphorylated in pervanadate treated cells. This is in 
agreement with earlier report on murine FRS2 (Kouhara et al., 1997). 
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Figure 8: Expression of epitope-tagged FRS2 in HEK293 cells. 
HEK293 cells were transfected with either pcDNA3-FRS2-Flag or the empty vector. The 
transfectants were serum starved overnight and stimulated with 100 nM sodium pervanadate 
(PoV) for 5 min at 37°C. Cell lysates were subjected to immunoprecipitations with anti-Flag 
antibody. The immunoprecipitates were resolved by SDS-PAGE followed by immunoblotting 
with anti-phosphotyrosine (PY) or anti-Flag antibodies. Molecular weights are indicated on the 
left in kilodaltons. 
 
 
 
 
3.3 Production of Specific Anti-FRS2 Antibodies  
 
3.3.1 Production of Anti-FRS2 Polyclonal Antibodies  
 
Highly specific antibodies were necessary for biochemical characterization of 
endogenous FRS2. Thus, rabbit polyclonal anti-FRS2 antibodies were produced. Full-
length FRS2 as well as two fragments encoding N-terminus and C-terminus were 
subcloned into pGEX vectors in frame with the vector encoded GST peptide: FRS2-WT 
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(aa 1-508), FRS2-NT (aa 1-240) and FRS2-CT (aa 326-508) (Figure 9). The GST-FRS2 
fusion proteins were expressed in Escherichia coli, purified with glutathione sepharose 
and used as antigens for the immunization of rabbits.  
 
 
 
 
 
 
Figure 9: Schematic presentation of GST-FRS2 fusion proteins. 
Schematic presentation of all GST-FRS2 fusion proteins used in this study. The myristylation 
site is shown as grey box, PTB domain as black box. The phosphotyrosine sites that serve as 
binding sites for Grb2 and SHP2 are also indicated. 
 
 
 
3.3.2 Specificity Determination and Purification of the Antibodies 
 
The specificity of the obtained antibodies were first checked in 
immunoprecipitation. BHK21 cells were transiently transfected with pRK-FRS2-WT or 
the empty vector and stimulated with sodium pervanadate or left untreated. Cell lysates 
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were subjected to immunoprecipitation with either pre-immunserum or anti-FRS2 
antibodies and analysed by immunoblot for tyrosine phosphorylation. As shown in 
Figure 10, the anti-FRS2-CT antibody specifically recognizes the tyrosine 
phosphorylated FRS2 in both endogenous and overexpressed form when compared to 
the pre-immunserum. Results from other tests demonstrated that all three antibodies are 
able to precipitate endogenous FRS2, however, the anti-FRS2-NT and anti-FRS2-CT 
antibodies showed higher affinity toward the protein than the anti-FRS2-WT antibody 
(data not shown). Therefore the anti-FRS2-CT antibody was chosen for most of the 
subsequent experiments.  
 
 
 
 
 
Figure 10: Test of anti-FRS2 antibody. 
BHK21 cells were transiently transfected with pRK-FRS2 or the empty vector, stimulated with 
100nM sodium pervanadate (PoV) for 5 min at 37°C. The cell lysates were subjected to 
immunoprecipitation with either pre-immunserum or anti-FRS2 antibody followed by 
immunoblot with anti-PY antibody. Molecular weights are indicated on the left in kilodaltons. 
 
Since the antibodies in form of antisera failed to detect the endogenous FRS2 in 
immunoblot (data not shown), affinity purification was carried out with antigen 
columns containing GST-FRS2 fusion proteins coupled to CNBr-activated sepharose 
beads. The purified antibodies demonstrated the desired detection capability in 
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immunoblot (data not shown) and were used for all subsequent immunoblot analysis 
(see below). 
 
 
 
 
 
Figure 11: Immunofluoresence microscopy of FRS2. 
(A) NIH3T3 cells were incubated with pre-immunserum or (B) purified anti-FRS2 antibody. 
(C) NIH3T3 cells were transiently transfected with pRK-FRS2 and incubated with purified anti-
FRS2 antibody. Cell nuclei were stained with DAPI. 
 
The antibodies were also tested for immunofluoresence microscopy (Figure 11). 
The images obtained from NIH3T3 cells incubated pre-immunserum or purified anti-
FRS2-CT antibody displayed similar staining pattern (Figure 11A, B). These unspecific 
cross-reactions indicate that the purified antibody is not sufficient to detect endogenous 
FRS2. However, the antibody is capable of immunoflouresence detection when FRS2 is 
overexpressed in NIH3T3 cells. In accordance with the earlier report (Kouhara et al., 
1997), the protein is clearly localized to the plasma membrane of the transfected cells 
(Figure 11C). 
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3.4 p90/FRS2 Complexes with SHP2 and Grb2 upon TrkA Activation  
 
FRS2 was identified as a tyrosyl phosphoprotein that coprecipitates with the 
adaptor protein Grb2 in FGFR signaling (Wang et al., 1996; Kouhara et al., 1997), 
while SNT was first detected as a p13suc1-binding tyrosine phosphorylated protein 
downstream of the NGF receptor TrkA (Rabin et al., 1993). To test whether FRS2 
shares the suc1-binding properties of SNT, the expression plasmid pRK-FRS2-WT was 
transiently transfected into HEK293 cells followed by precipitation with p13suc1-
conjugated agarose beads which were reported to bind SNT (Rabin et al., 1993; Wang 
et al., 1996). As shown in Figure 12A, a tyrosine phosphorylated protein specifically 
precipitated with p13suc1 from pervanadate treated, FRS2-transfected cells. The 
apparent molecular weight of 92-95 kDa indicated that SNT and FRS2 are likely 
identical. 
To verify whether FRS2 also associates with Grb2 upon activation of TrkA, 
expression vectors for FRS2 along with wild-type or kinase-inactive TrkA were 
cotransfected transiently into HEK293 cells. As expected, the activated TrkA was able 
to phosphorylate FRS2 on tyrosine residues (Figure 12B, upper panel). Reblot with a 
specific anti-Grb2 antibody revealed an association of tyrosine phosphorylated FRS2 
and Grb2 (Figure 12B, middle panel). This result indicates that in addition to FGF-
induced signaling, FRS2 transmits signal from the NGF-activated TrkA by recruiting 
the adaptor protein Grb2. Thus, this is a further evidence indicating that FRS2 and SNT 
are the same protein. 
As described before, the initial observation in this study was the association of a 
tyrosyl phosphoprotein p90 with SHP2 upon NGF and FGF stimulation (Figure 7). 
When the membrane was reprobed with anti-SHP2 antibody, the tyrosine phosphatase 
was readily detected along with tyrosine phosphorylated FRS2 (Figure 12B, bottom 
panel). Thus, the tyrosyl phosphoprotein p90 was FRS2. Together, these data establish 
that, upon activation of TrkA, FRS2 becomes tyrosine phosphorylated and is able to 
associate with the adaptor protein Grb2 as well as the tyrosine phosphatase SHP2. The 
interaction between FRS2 and SHP2 was confirmed later by others also in FGFR 
signaling pathway, where FRS2 was indirectly linked to Grb2 through SHP2 (Hadari et 
al., 1998; Meakin et al., 1999).  
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A minor tyrosine phosphorylated protein of 116 kDa that coprecipitated with 
FRS2, which was also observed in Figures 8 and 10, possibly corresponds to the 
docking protein Gab1. The relatively weak 116 kDa band from cells without 
exogenously expressed FRS2 was possibly Gab1 that coprecipitated along with the 
endogenous FRS2. However, immunoblot with a polyclonal antibody against Gab1 was 
not able to confirm this hypothesis (data not shown). This is possibly owing to the low 
efficiency of the available antibody, as an indirect association of FRS2 and Gab1 
through Grb2 was reported later (Ong et al., 2001).  
 
 
 
 
 
Figure 12: FRS2/SNT associates with Grb2 and SHP2 upon TrkA activation.  
(A) HEK293 cells were transfected with either pRK5-FRS2 or the empty vector. The 
transfectants were serum starved overnight and stimulated with 100 nM sodium pervanadate 
(PoV) for 5 min at 37°C. Cell lysates were subjected precipitation with p13Suc1 agarose 
conjugate. The precipitates were resolved by SDS-PAGE and transferred to nitrocellulose 
membrane followed by immunoblot with anti-PY antibody. (B) HEK 293 cells were 
cotransfected with pRK-FRS2 or the empty vector along with wild type (WT) or kinase inactive 
(KM) TrkA. The cell lysates were subjected to immunoprecipitation with anti-FRS2 antibody 
and followed by immunoblotting with the indicated antibodies. Molecular weights are indicated 
on the left in kilodaltons. 
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3.5 FRS2 is Ubiquitously Expressed and Associates with Multiple 
Proteins  
 
3.5.1 Northern Blot Analysis of FRS2 in Mammary Carcinoma Cell Lines 
 
 
 
 
 
Figure 13: Northern blot analysis of FRS2 mRNA. 
(A) Northern blot analysis of mRNA from 7 mouse mammary carcinoma cell lines with a PCR 
fragment of mouse FRS2 amplified from L-8A cDNA as probe. Rehybridazition of the 
membrane with a β-actin specific probe served as loading control. (B) Northern blot analysis of 
mRNA from 18 human mammary carcinoma cell lines with full-length human FRS2 cDNA as 
probe.  
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The tissue distribution of mouse FRS2 mRNA has been reported to be most 
abundant in brain, kidney, lung, ovary and testis (Kouhara et al., 1997). In order to 
select a cell model, expression of endogenous FRS2 at the RNA level was examined. 
The mRNA from 7 mouse and 18 human mammary carcinoma cell lines was isolated 
and subjected to Northern blot analysis using PCR fragments of either murine or human 
FRS2 as probe. In 6 out of 7 mouse mammary carcinoma cell lines, FRS2 mRNA of 7 
kb was detected at comparable levels (Figure 13A). In MM5MT cells (lane 7) FRS2 
mRNA was not detectable.  
In the human mammary carcinoma cell lines (Figure 13B), the FRS2 mRNA 
expression level was low in 11 out of 18 cell lines, whilst it was moderately expressed 
in 5 cell lines, i.e. HBL-100, MCF-7, T-47D, ZR-75-1 and ZR-75-30 (lane 1, 4, 6, 16, 
17), and was highly expressed in 2 cell lines, DAL and MDA-MB-361 (lane 5 and 13). 
Comparable amounts of mRNA were loaded on the gel as visualized under UV-light 
after gel electrophoresis (data not shown).  
In summary, transcription of the FRS2 gene was detected in the vast majority of 
the mammary carcinoma cell lines. Thus, FRS2 may be involved in growth regulation 
of these cells and variations of its expression levels may reflect differences in the 
transformation status of the individual tumor lines. 
 
 
3.5.2 Detection of Tyrosine Phosphorylated Endogenous FRS2 
 
In order to obtain an overview of the endogenously expressed FRS2, a total of 
24 cell lines were analysed (listed in Material). The cells are of different tissue origins, 
including fibroblast, mammary carcinoma, ovarian adenocarcinoma, epidermoid 
carcinoma, glioblastoma, lung carcinoma, as well as hematopoietic cells. The cells were 
grown to 70-80% confluence, serum starved overnight and treated with sodium 
pervanadate for 5 min at 37°C or left untreated. Cell lysates were subjected to 
immunoprecipitation with both anti-FRS2-NT and CT antibodies. The immuno-
precipitates were resolved by SDS-PAGE followed by immunoblotting with anti-PY 
antibody. The representative blots of human epidermoid carcinoma A-431, human 
ovarian adenocarcinoma Ovcar-3 and human teratocarcinoma NT-2 cells are shown in 
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Figure 14, where endogenous FRS2 migrated as a tyrosine phosphorylated fuzzy band 
of 92-95 kDa. Together with data from other cell lines (not shown), these results 
confirmed that FRS2 is ubiquitously expressed. The variations of the expression levels 
are cell line-dependent rather than tissue-specific. 
 
 
3.5.3 Screening for Potential FRS2 Interaction Partners  
 
In search of FRS2 interaction partners, several strategies were applied. The yeast 
2-hybrid system, which is a sensitive method for protein-protein interaction studies, 
could not be employed. This was due to an auto-activation reaction where the bait 
(FRS2) protein/DNA-binding domain bound directly to the activation domain encoded 
by the pray vector thereby leading to transcription of the reporter gene. Thus, 
biochemical methods utilizing the specific anti-FRS2 antibodies as well as the GST-
FRS2 fusion proteins were applied. 
 
 
3.5.3.1 Coimmunoprecipitation with Endogenous FRS2  
 
The expression analysis described in the previous section also revealed that 
FRS2 coprecipitated with several phosphoproteins (Figure 14). The pattern of 
association phosphoproteins varies in different cell lines, suggesting that FRS2 interacts 
with different partners depending on the cellular context. There are common interaction 
partners of FRS2, such as p68 and p116/118 that possibly represent SHP2 and Gab1, 
respectively. Moreover, depending on the antibodies used in immunoprecipitations, the 
pattern of FRS2-associated proteins differs within the same cell line. For example, in 
Ovcar-3 cells, two bands of 156 and 120 kDa are detected in the immunocomplex with 
the anti-FRS2-CT antibody that are not coprecipitated with the anti-FRS2-NT antibody. 
These variations may be due to the different epitopes recognized by each antibodies, or 
competition of interacting proteins and the antibodies for binding sites on FRS2.  
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Figure 14: FRS2 is ubiquitously expressed in a variety of cell lines. 
A-431 (A), Ovcar-3 (B), and NT-2 (C) cells were serum starved overnight and stimulated with 
100 nM sodium pervanadate (PoV) for 5 min at 37°C. After lysis, the cell lysates were 
subjected to immunoprecipitations with anti-FRS2 antibodies. The immunoprecipitates were 
resolved by SDS-PAGE followed by immunoblotting with anti-phosphotyrosine (PY) antibody.  
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(D) NT-2 cells were serum starved overnight in methionine free medium supplied with 20 
µCi/ml [35S]-methionine, and stimulated with 100 nM sodium pervanadate for 5 min at 37°C, or 
left untreated. The lysates were subjected to immunoprecipitation with pre-immunserum (Pre), 
anti-FRS2-CT (αCT) or anti-FRS2-NT antibody (αNT). The immunoprecipitates were resolved 
by SDS-PAGE (7 %-12.5 %) followed by autoradiography. Molecular weights are indicated on 
the left in kilodaltons. 
 
 
In order to study non-phosphoproteins in association with endogenous FRS2 that 
are not detectable on anti-PY immunoblots, A-431, NT-2, Ovcar-3, U-1242, PC12, 
MM5MTC, MM5.1 and MM5/C1 cells were metabolically labelled with 35S-methionine 
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overnight, and either stimulated with sodium pervanadate or left untreated. The cell 
lysates were subjected to a two-step immunoprecipitation: first pre-clear with pre-
immunserum then precipitation with anti-FRS2 antibodies. The precipitates were 
separated by SDS-PAGE followed by autoradiography. A representative result from 
human teratocarcinoma NT-2 cells is shown in Figure 14D. The autoradiography 
displayed a number of proteins in constitutive association with FRS2 independent of 
stimulation. The pattern of binding proteins again differ dependent on the antibody 
used. More bands are observed in the immunocomplex with the anti-FRS2-CT antibody 
including p230, p190, p148, p136 and p68, whereas p110 and p102 are only detected in 
the anti-FRS2-NT antibody immunoprecipitates. This suggests that different regions of 
FRS2 have different interaction partners. Additionally, in agreement with the results 
from the immunoblots, patterns of FRS2-associated proteins vary from cell line to cell 
line (data not shown).  
 
 
3.5.3.2 In Vitro Binding Assay with GST-FRS2 Fusion Proteins 
 
In further search of FRS2 interaction partners, in vitro binding assays with GST-
FRS2 fusion proteins as affinity reagents were performed with lysates of several cell 
lines. The cells were either metabolically labelled with 35S-methionine overnight or 
serum starved overnight without radioactivity, before stimulation either with sodium 
pervanadate or left untreated. The lysates were pre-cleared with glutathione sepharose 
prior to incubation with glutathione sepharose bound GST or GST-FRS2 fusion proteins 
as affinity reagents. The precipitates were analysed by SDS-PAGE followed by 
autoradiography or anti-PY immunoblot. The autoradiographs from 35S-methionine 
labelled cells did not show any significant difference between treated and untreated cells 
(data not shown). In contrast, the immunoblot revealed several tyrosine phosphorylated 
proteins coprecipitated with different GST-FRS2 fusion proteins. The results from 
Ovcar-3 cells are presented in Figure 15. Since the fusion proteins represented different 
parts of FRS2, they bound to diverse proteins. GST-FRS2-NT associated p170 and 
GST-FRS2-CT associated p42 might correspond to EGFR and ERK2, respectively 
(Figure 15).  
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Figure 15: In vitro binding assay with GST-FRS2 fusion proteins. 
Ovcar-3 cells were serum starved overnight and stimulated with 100 nM sodium pervanadate 
for 5 min at 37°C or left untreated. The cell lysates were pre-cleaned with glutathione sepharose 
alone before incubated with 1µg GST or GST-FRS2 fusion proteins bound to glutathione 
sepharose. Precipitates were resolved by SDS-PAGE followed by immunoblotting with anti-PY 
antibody. Molecular weights are indicated on the left in kilodaltons. 
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3.5.4 FRS2 Is Localized within Caveolae  
 
Caveolae are vesicular invaginations of the plasma membrane. Functionally, 
caveolae were first implicated in cellular transport processes and more recently in signal 
transduction related events. The chief structural proteins of caveolae are the caveolins. 
Caveolins form a scaffold onto which many classes of signaling molecules can 
assemble to generate preassembled signaling complexes (Okamoto et al., 1998; Couet et 
al., 2001; Deurs et al., 2003). These caveolin-interacting proteins include G-protein α 
subunits, Ras, Src family tyrosine kinases, EGFR, PDGFR, TrkA, insulin receptor, 
MAP kinases, PKA, and PKC isoforms (Kim and Kim, 1997; Liu et al., 1997; 
Engelman et al., 1998a; Engelman et al., 1999; Smart et al., 1999; Deurs et al., 2003). 
In addition to concentrating these signal transducers within a distinct region of the 
plasma membrane, caveolin binding may functionally regulate the activation state of 
caveolae-associated signaling molecules (Okamoto et al., 1998; Couet et al., 2001; 
Razani and Lisanti, 2001; Anderson and Jacobson, 2002).  
 
 
 
 
 
 
Figure 15: Caveolae localization of FRS2. 
Ovcar-3 cells were used to prepare caveolin-enriched membrane fractions by detergent-free 
density-gradient ultra centrifugations as described in Methods. The fractions were resolved by 
SDS-PAGE followed by immunoblot with anti-FRS2 and anti-caveolin-1 (Cav-1) antibodies. 
Molecular weights are indicated on the left in kilodaltons. 
 
FRS2 is anchored to cell membrane through its N-terminal myristylation and 
interacts directly with FGFR and TrkA. Thus, this docking protein is likely to be 
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localized within caveolae. To corroborate this hypothesis, Ovcar-3 cells were used to 
prepare caveolin-enriched membrane fractions by detergent-free density-gradient ultra 
centrifugations in presence of sucrose as described in Methods. Totally 13 fractions 
were obtained and analysed by SDS-PAGE followed by immunoblot with anti-FRS2 
antibody. As shown in Figure 16, FRS2 was readily detected in fractions 5 to 8. Due to 
the high concentration of sucrose, proper separation of fractions 9-13 by SDS-PAGE 
was not possible (fractions 10-13 not shown). However, since the signal of FRS2 
peaked in fractions 6 and 7, then declined substantially in fraction 8, it was not likely to 
be detected in the last fractions. Reblotting of the same membrane with a specific anti-
caveolin-1 antibody revealed that this caveolae characteristic protein was present in the 
same fractions as FRS2. The EGFR was also found in these fractions (data not shown) 
which is in agreement with its reported caveolae localization (Engelman et al., 1998b). 
Together, these data suggest that FRS2 is very likely located within caveolae, and 
therefore might interact with other signaling molecules present in this organelle. Similar 
findings were also reported by other research groups later (Davy et al., 2000; Ridyard 
and Robbins, 2003).  
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3.6 FRS2 Mediates EGF-induced Signaling Pathway 
 
3.6.1 EGF Induces Tyrosine Phosphorylation of FRS2 
 
In the previous experiments attempting to identify FRS2 interaction partners, a 
phosphorylated protein of 170 kDa which might correspond to EGFR, was detected in 
different cell lines through different approaches. To investigate whether FRS2 is indeed 
involved in EGF-induced signaling pathway, the human epidermoid carcinoma line A-
431 and NIH3T3 cells stably expressing EGFR (NIH3T3/EGFR) were treated with 
either EGF or acidic FGF (aFGF). Cell lysates were analysed by anti-FRS2 
immunoprecipitation followed by immunoblotting. As expected, FRS2 became strongly 
tyrosine phosphorylated upon FGF stimulation in both cell lines (Figure 17, upper panel 
lane 3, 6). Interestingly, EGF also induced tyrosine phosphorylation of a 90 kDa protein 
(Figure 17, upper panel lane 2, 4) that was recognized by the anti-FRS2 antibody 
(Figure 17, bottom panel). Thus, EGF is able to induce a relatively moderate FRS2 
tyrosine phosphorylation in addition to NGF, BDNF, FGF, GDNF and VEGF (Xu et al., 
1998; Easton et al., 1999; Meakin et al., 1999; Kurokawa et al., 2001; Melillo et al., 
2001; Stoletov et al., 2002).  
 
 
3.6.2 FRS2 Complexes with SHP2, Grb2 and Activated EGFR 
 
Tyrosine phosphorylated FRS2 is able to bind the tyrosine phosphatase SHP2 
and the adaptor protein Grb2 upon stimulation with FGF or NGF (Figure 12) (Kouhara 
et al., 1997; Ong et al., 1997; Hadari et al., 1998; Meakin et al., 1999). Therfore, in 
response to EGF stimulation, the tyrosine phosphorylated FRS2 is likely to complex 
with these two molecules as well. The reblot with anti-SHP2 antibody clearly 
demonstrates that SHP2 coprecipitated with FRS2 in a ligand-stimulation-dependent 
manner (Figure 17, upper middle panels). Grb2 was also associated with tyrosine 
phosphorylated FRS2 (data not shown and see below).  
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Figure 17:The activated EGFR induces FRS2 tyrosine phosphorylation.  
(A) A-431 and (B) NIH3T3/EGFR cells were serum starved overnight and stimulated with 25 
ng/ml EGF or aFGF for 5 min. The lysates were subjected to immunoprecipitations with anti-
FRS2 antibody. The immunoprecipitates were resolved by SDS-PAGE followed by 
immunoblotting with indicated antibodies. Molecular weights are indicated on the left in 
kilodaltons. *Unspecific band due to an antibody cross-reaction with an unidentified protein. 
 
In addition to FRS2, EGF induced tyrosine phosphorylation of several other 
proteins that coprecipitated with FRS2. The predominant 170 kDa tyrosine 
phosphorylated protein detected solely after EGF stimulation was readily recognized by 
an antibody against EGFR (Figure 17, lower middle panels). The amount of EGFR 
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coprecipitated with FRS2 increased substantially upon EGF stimulation, which 
indicates that tyrosine phosphorylation of the receptor is essential for the association of 
EGFR with FRS2. The minor tyrosine phosphorylated bands of 116 kDa and 54 kDa 
that were experimentally detected only in EGF stimulated NIH3T3/EGFR cells 
represent most likely adaptor proteins Gab1 and Shc, respectively, which are known to 
be tyrosine phosphorylated upon EGF stimulation and to coprecipitate with the 
activated EGFR (Ruff-Jamison et al., 1993; Holgado-Madruga et al., 1996).  
In the FRS2 immunoprecipitates from FGF treated cells small amounts of 
coprecipitated EGFR were detected as in the unstimulated NIH3T3/EGFR control. In 
contrast to EGF stimulation there was no evidence for FGFR coprecipitation in either 
FGF treated A-431 or NIH3T3/EGFR cells, suggesting a lower affinity of the 
interaction of FRS2 with FGFR relative to that with the EGFR, since cDNA microarray 
analysis revealed that the receptors are expressed at comparable levels in the A-431 
cells (data not shown). Interestingly, in addition to the inverse extent of association and 
tyrosine phosphorylation of EGFR and FGFR with FRS2, the amount of associated 
SHP2 in the anti-FRS2 immunoprecipitate was only moderately enhanced in FGF 
versus EGF stimulated cells. These observations suggested a clear and distinct 
involvement of FRS2 in EGFR and FGFR signal transduction.  
Together, these results demonstrate for the first time that FRS2 undergoes EGF 
induced tyrosine phophorylation, and coprecipitates with the activated EGFR. 
Moreover, the tyrosine phosphorylated FRS2 is able to recruit the tyrosine phosphatase 
SHP2 and the adaptor protein Grb2. These results suggesting a role of FRS2 in EGF-
induced signal transduction pathway. 
 
 
3.6.3 FRS2 Associates with Activated EGFR through its PTB Domain 
 
As shown in the last experiment, the activated EGFR associates with the tyrosine 
phosphorylated FRS2 upon EGF stimulation. To map the EGFR binding site of FRS2, 
bacterially expressed GST-FRS2 fusion proteins (Figure 9) representing the full-length 
FRS2 (GST-FRS2-WT), the N-terminal PTB domain (GST-FRS2-PTB), the truncation 
mutant lacking the PTB domain (GST-FRS2-∆PTB), the N-terminal mutant (GST-
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FRS2-NT), and the C-terminal mutant (GST-FRS2-CT) were compared for their ability 
to bind EGF. When these proteins were employed as affinity reagents for in vitro 
binding assays using A-431 cell lysates, GST-FRS2-WT, GST-FRS2-PTB and GST-
FRS2-NT specifically bound to the ligand activated EGFR (Figure 18, lane 5, 8, 17), 
whereas GST alone or the fusion proteins lacking the PTB domain failed to associate 
with the receptor. It thus appeared that the PTB domain is responsible for the interaction 
of FRS2 with the activated EGFR, which is in agreement with the observation from the 
before described experiment in Ovcar-3 cells (Figure 15). This is also a result in 
accordance with findings reported for the association of FRS2 with receptor tyrosine 
kinases FGFR1 and TrkA (Xu et al., 1998; Meakin et al., 1999). In addition, the GST-
FRS2 fusion proteins failed to "pull-down" FGFR, despite the reported constitutive 
association (Lin et al., 1998; Xu et al., 1998; Ong et al., 2000) (data not shown). 
 
 
 
 
 
Figure 18: FRS2 binds to the activated EGFR through its PTB domain.  
A-431 cells were serum starved overnight and stimulated with 25 ng/ml EGF or aFGF. The 
lysates were subjected to in vitro binding assays with 1µg glutathione sepharose bound GST or 
GST-FRS2 fusion proteins as indicated, resolved by SDS-PAGE and followed by 
immunoblotting. Molecular weight is indicated on the left in kilodalton. 
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3.6.4 FRS2 Enhances the MAP Kinase Activity in EGFR Signaling 
 
It is well established the that tyrosine phosphorylated FRS2 links the FGF and 
NGF receptor activations to the Ras/MAPK signaling cascade. To examine the function 
of FRS2 in EGFR signaling, an in vitro MAP kinase assay was carried out after 
cotransfecting equal amounts of expression vectors for HA-tagged ERK2 along with 
increasing amounts of FRS2-FLAG vectors into Cos-7 cells which express detectable 
levels of endogenous EGFR. After stimulation with EGF or FGF, ERK2 was 
immunoprecipitated by anti-HA antibody. The precipitates were divided and either 
subjected to in vitro MAP kinase assay using myelin basic protein (MBP) as substrate, 
or resolved by SDS-PAGE to monitor the amount of expressed ERK2 (Figure 19A, 
upper and middle panels). Crude lysates were additionally immunoblotted with anti-
Flag antibody (Figure 19A, bottom panels). As shown in Figure 19A, while the amount 
of transfected FRS2 increased, the MAP kinase activities elevated proportionally in 
response to both EGF and FGF stimulation. The results from two separate experiments 
summarized in Figure 19B demonstrate that FRS2 enhances both EGF and FGF induced 
ERK2 activation in a dose-dependent manner, indicating a positive role of FRS2 in 
relaying signals from the activated EGFR to the MAP kinase cascade. The moderate 
induction of ERK2 catalytic activity by FGF when compared to EGF is possibly due to 
the relatively low FGFR expression level in Cos-7 cells. Thus, FRS2 provides an 
alternative route in linking EGFR to the Ras/MAPK signaling cascade.  
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Figure 19: FRS2 enhances EGF- and FGF-induced MAP kinase activity. 
(A) Cos-7 cells in 6-well plates were cotransfected with 0.2 µg HA-ERK2 and 0.2-0.8 µg FRS2-
Flag, stimulated with 25 ng/ml EGF or aFGF. The cells were lysed and the lysates subjected to 
immunoprecipitation with anti-HA antibody followed by MAP kinase assays using MBP as 
substrate (upper panel). Equal amounts of lysates were also subjected to immunoprecipitation 
with anti-HA antibody followed by immunoblotting with anti-ERK antibodies (middle panel). 
Total crude lysates were resolved by SDS-PAGE followed by immunoblotting with anti-Flag 
antibody (bottom panel). (B) Quantification of in vitro MAP kinase assays. 
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3.7 FRS2 is Serine/Threonine Phosphorylated 
 
3.7.1 Different Growth Factors Induce FRS2 Migration Shift  
 
Upon EGF and FGF stimulation, a significant alteration of FRS2 electrophoretic 
mobility in SDS-PAGE was observed in Figure 17 (bottom panel). In untreated cells, 
FRS2 has an apparent molecular weight of 70 to 75 kDa, which significantly shifted to 
92-95 kDa in EGF or FGF treated cells. This migration shift of FRS2 was mediated by 
the RTK activation of the respective growth factors, since it was completely abolished 
by pre-incubation of cells with the specific RTK inhibitors AG1478 against EGFR and 
SU5402 against FGFR (data not shown).  
 
 
 
 
 
Figure 20: Induction of FRS2 migration shift by multiple growth factors.  
DAL and MDA-MB-361 cells were serum starved overnight and stimulated with different 
ligands for 5 min at 37°C. The lysates were subjected to immunoprecipitations with anti-FRS2 
antibody. The immunoprecipitates were resolved by SDS-PAGE followed by immunoblotting 
with anti-FRS2 antibody. Lane 1 and 7, untreated; lane 2 and 8, 25 ng/ml EGF; lane 3 and 9, 25 
ng/ml aFGF; lane 4 and 10, 50 ng/ml PDGF; lane 5 and 11, 50 ng/ml IGF-I; lane 6 and 12, 100 
nM insulin. Molecular weights are indicated on the left in kilodaltons.  
 
To explore the effects of other growth factors on FRS2 migration shift, two 
human mammary carcinoma cell lines, DAL and MDA-MB-361, that express FRS2 at 
relatively high level (Figure 13B), were stimulated with EGF, heregulin, FGF, PDGF, 
IGF-I or insulin. As shown in Figure 20, FRS2 had an apparent molecular weight of 72-
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75 kDa in untreated DAL cells, while it migrated as an 80-85 kDa protein in untreated 
MDA-MB-361 cells. This observation of various electrophoretic mobilities of FRS2 in 
different cell lines suggests that FRS2 is differentially modified in a cell line-dependent 
manner. While EGF and FGF induced FRS2 migration shift in both cell lines, IGF-1 
and insulin were only able to alter FRS2 migration in DAL cells (Figure 20, lanes 5 and 
6), but not in MDA-MB-361 cells (lanes 11 and 12). PDGF had no significant effect on 
FRS2 in either cell line (lanes 4 and 10), which may be due to a low or even lack of the 
PDGFR expression. In contrast, PDGF was able to induce FRS2 migration shift in U-
1242 cells (data not shown), a human glioblastoma lineage known to express the 
PDGFR (Farooqui et al., 1999). Moreover, IGF-I and insulin induced FRS2 migration 
shift was also observed in A-431 and Ovcar-3 cells (data not shown). FRS2 thus is 
involved in considerably more signal transduction pathways than previously thought. 
 
 
 
3.7.2 FRS2 Associates with a Kinase that Phosphorylates MBP 
 
The observation of the FRS2 migration shift upon stimulation with multiple 
growth factors further emphasized the need to identify the underlying modification. 
Although abolished by RTK inhibitors, the extent of this shift is so drastic that it is 
unlikely to be caused solely by tyrosine phosphorylation. Immunoblot with specific 
anti-ubiquitin antibody showed that the low FRS2 gel mobility was not due to 
ubiquitination (data not shown). Additionally, deglycosylation treatment of the FRS2 
immunocomplexes with endoglycosidase had no effect on the shift (data not shown). 
Another plausible explanation of this ligand-induced post-translational modification of 
FRS2 is phosphorylation on serine and threonine residues.  
According to computational analysis of the protein sequence with Scansite 
(Yaffe et al., 2001) and Prosite (Sibbald et al., 1991), FRS2 contains more than 30 
potential serine/threonine phosphorylation sites for PKA, PKG, PKC, PKB, and 
CaMKII throughout the protein (see Figure 25). Thus, the remarkable shift in 
electrophoretic mobility after growth factor stimulation shown in Figure 17 and 20 is 
possibly caused by serine/threonine in addition to tyrosine phosphorylation.  
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This hypothesis was first examined by determining whether FRS2 complexes 
with a serine/threonine kinase in immunoprecipitation. An in vitro kinase assay was 
performed with lysates from Ovcar-3 cells stimulated with either EGF or FGF. After 
immunoprecipitation with the anti-FRS2 antibody or pre-immunserum, the 
immunoprecipitates were subjected to in vitro kinase assay with myelin basic protein 
(MBP) as substrate. It is known that MBP serves as a substrate for many 
serine/threonine kinases including PKC, PKA, and MAPK (Vartanian et al., 1989; 
Rossomando et al., 1991; Eyster et al., 1993). Indeed, the autoradiography in Figure 21 
revealed that MBP became significantly phosphorylated when incubated together with 
anti-FRS2 immunoprecipitates. Moreover, specific immunocomplexes of EGF or FGF 
stimulated samples showed an elevated MBP phosphorylation as compared to FRS2-
precipitates of untreated cells. These data thus demonstrate that a serine/threonine 
kinase might be constitutively associated with FRS2 and become activated upon ligand 
stimulation, suggesting that it might phosphorylate FRS2 on serine/threonine residues.  
 
 
 
 
 
 
Figure 21: FRS2 complexes with a kinase that phosphorylates MBP. 
Ovcar-3 cells were serum starved overnight and stimulated with 25 ng/ml EGF or aFGF. The 
lysates were subjected to immunoprecipitations with pre-immunserum or anti-FRS2 antibody. 
The immunoprecipitates were then subjected to an in vitro kinase assay with MBP as substrate. 
After SDS-PAGE, the gel was dried and phosphorylated MBP was detected by autoradiography. 
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3.7.3 EGF and FGF Induce Serine/Threonine and Tyrosine Phosphorylation of 
FRS2 
 
In addition to the above described results and computational prediction of 
phosphorylation sites, another two lines of evidence support the hypothesis of FRS2 
serine/threonine phosphorylation. First, it is known that inhibition of serine/threonine 
phosphatases by okadaic acid or calyculin A leads to activation of a number of 
serine/threonine kinases, and subsequent phosphorylation of their substrates (Ishihara et 
al., 1989; Gopalakrishna et al., 1992; Song and Lavin, 1993). Incubation of 
unstimulated cells with calyculin A resulted in retarded FRS2 electrophoretic mobility, 
implying that FRS2 might be a substrate of serine/threonine kinases (data not shown). 
Second, treatment of immunoprecipitated FRS2 with alkaline phosphatase abolished the 
ligand-induced migration shift (data not shown), confirming that this shift might be due 
to serine/threonine phosphorylation.  
To corroborate this hypothesis, phosphoamino acid analysis of FRS2 was carried 
out with A-431 cells that were metabolically labelled with 32P-orthophosphate and 
treated with EGF or FGF. The lysates were subjected to immunoprecipitation with anti-
FRS2 antibody and resolved by SDS-PAGE followed by transfer to polyvinylidene 
difluoride (PVDF) membrane. After autoradiography, the band of interest was cut out 
and subjected to acid hydrolysis as described in Methods. The phosphoamino acids 
were then separated by 2-D thin-layer electrophoresis and detected by autoradiography. 
As shown in Figure 22A, FRS2 appeared as a diffuse band on SDS-PAGE with an 
apparent molecular weight of 70-75 kDa in untreated cells, and shifted to 90-95 kDa 
after EGF or FGF stimulation. The subsequent phosphoamino acid analysis revealed 
that in untreated cells FRS2 was constitutively phosphorylated on serine as well as 
threonine residues, but not on tyrosine residues. Upon stimulation with either EGF or 
FGF, extensive phosphorylation of FRS2 on serine and threonine residues and relatively 
low levels of tyrosine phosphorylation were observed (Figure 22B).  
Thus, analysis of FRS2 phosphorylation in vivo further supports the hypothesis 
that the migration shift of FRS2 is largely the result of enhanced phosphorylation on 
serine and threonine residues.  
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Figure 22: FRS2 is phosphorylated on both serine/threonine and tyrosine residues. 
A-431 cells were serum starved overnight and metabolically labeled with 150 µCi/ml 32P-
orthophosphate in phosphate and serum free medium for 4 hours and stimulated with 25 ng/ml 
EGF or aFGF for 5 min or left untreated. The lysates were subjected to immunoprecipitations 
with anti-FRS2 antibody. (A) The immunoprecipitates were resolved by SDS-PAGE, 
transferred to PVDF membrane and deteced by autoradiography. Molecular weights are 
indicated on the left in kilodaltons. (B) The specific bands were excised and subjected to 
phosphoamino acid analysis by two-dimensional thin layer eletrophoresis as described in 
Method. 
 
 
 
 
 
 
3. RESULTS  
 
 
81 
3.7.4 Pharmacological Inhibition of FRS2 Migration Shift  
 
In order to identify regulator of FRS2 serine/threonine phosphorylation, a set of 
enzyme inhibitors were utilized in pharmacological interference experiments 
(summarized in Table 1). Briefly, as outlined in Figure 23, Ovcar-3 cells were 
stimulated in the presence of the inhibitors and the FRS2 migration shift was analysed 
by immunoprecipitation followed by immunoblotting with the FRS2-specific antibody.  
 
 
 
 
 
Figure 23: Pharmacological interference experiments.  
Ovcar-3 cells were serum starved overnight and incubated with inhibitors for 20 min at 37°C 
before stimulation with 25 ng/ml EGF or aFGF for 5 min. The lysates were subjected to 
immunoprecipitations with anti-FRS2 antibody. The immunoprecipitates were resolved by 
SDS-PAGE followed by immunoblotting with anti-FRS2 antibody. (A) Treatment with broad 
sprectrum serine/threonine kinase inhibitor staurosporine (ST) at different concentrations. (B) 
Treatment with 5 µM MEK1/2 inhibitor U0126. Molecular weights are indicated on the left in 
kilodaltons. *Unspecific band due to an antibody cross-reaction with an unidentified protein. 
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As mentioned before, RTK inhibitors abolished FRS2 shift in response to their 
specific ligands, EGF (AG1478), aFGF (SU5402), and PDGF (AG1295). Inhibition of 
other enzymes, such as Src kinase and PLCγ which might be indirectly  involved in 
FRS2 serine/threonine phosphorylation, gave negative results (data not shown). The 
broad spectrum serine/threonine kinase inhibitor staurosporine was able to abolish the 
migration shift of FRS2. However, while for FGF stimulation a concentration of 70 nM 
was sufficient, 8 µM was required in EGF stimulation (Figure 23A). This different 
concentration requirement implies that either different kinases are responsible for the 
serine/threonine phosphorylation of FRS2, or some upstream kinase is inhibited in the 
FGF-induced signaling pathway. Serine/threonine kinase inhibitors specific for PKA, 
PKC, PKG, CaMK II, MLCK and cdc2 were not able to affect FRS2 serine/threonine 
phosphorylation (data not shown). The PI3K inhibitor wortmannin, which prevents 
activation of PKB, was also ineffective (data not shown).  
 
Table 1: Kinase Inhibitors Tested on FRS2 Mobility Change. 
Name Specificity Concentration Effect a 
AG1478 EGFR 250 nM + (EGF) 
SU5402 FGFR 20 µM + (aFGF) 
AG1295 PDGFR 10 µM + (PDGF) 
PP1 Src  20 µM -b 
U73122 PLC γ 10 µM - 
Staurosporine PKC, PKA, PKG, MLCK, CaMK-II 
8 µM (EGF) 
70 nM (aFGF) + 
H-89 PKA 5 µM - 
GÖ6976 PKC 5 µM - 
PKG inhibitor PKG 5 µM - 
KN-93 CaMK II 5 µM - 
ML-7 MLCK 5 µM - 
Roscovitine Cdc2 50 µM - 
Wortmannin PI-3K 200 nM - 
SB202190 p38 kinase 10 µM - 
SB600125 JNK 10 µM - 
U0126 MEK1/2 5 µM + 
 
a Effect on FRS2 migration shift: +, inhibition of the ligand-induced shift; -, no inhibition of the 
shift in presence of ligand and inhibitor. b FGFR kinase activity was inhibited at 10 µM.  
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It has been reported that docking protein Gab1 is associated with activated 
ERK2 and acts as a substrate for the kinase (Roshan et al., 1999; Yu et al., 2001; Yu et 
al., 2002), and IRS-1 is a substrate of JNK (Aguirre et al., 2000; Aguirre et al., 2002) . 
To examine the possible role of MAP kinases in EGF- or FGF-induced FRS2 
serine/threonine phosphorylation, inhibitors against the MAP kinase family members 
were tested. While the specific inhibitors against JNK (SB600125) and p38 kinase 
(SB202190) did not abrogate serine/threonine phosphorylation of FRS2 (data not 
shown), the specific MEK1/2 inhibitor U0126, which prevents activation of ERK1 and 
ERK2 (Favata et al., 1998), completely abolished the FRS2 gel migration shift upon 
both EGF and FGF stimulation (Figure 23B). These results demonstrate that ERK1/2 
are responsible for FRS2 serine/threonine phosphorylation.  
 
 
 
3.7.5 GPCR Agonists Induce FRS2 Serine/Threonine Phosphorylation 
 
Besides the growth factors, G-coupled protein receptor (GPCR) agonists were 
tested for their ability to induce the FRS2 serine/threonine phosphorylation. Ovcar-3 
cells were stimulated with GPCR agonists, carbachol, LPA and thrombin (Figure 24A, 
lanes 4, 6 and 8). The result demonstrated that the GPCR agonists are indeed able to 
induce the same migration shift of FRS2 as EGF (lane 2). It is well established that 
GPCR agonists can induce transactivation of the EGFR for cellular signal transduction 
(Daub et al., 1996; Daub et al., 1997; Prenzel et al., 1999). To examine whether the 
GPCR agonists induced migration shift of FRS2 is mediated by transactivation of 
EGFR, the EGFR specific inhibitor AG1478 was utilized. When AG1478 was present, 
the migration shift of FRS2 was significantly reduced in GPCR agonist stimulation 
(Figure 24A, lane 5, 7 and 9), whereas it was completely abrogated in EGF stimulation 
(lane 3). This result implies that the FRS2 mobility change by GPCR stimulation is 
partially caused by transactivation of EGFR.  
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Figure 24: FRS2 is also involved in GPCR signaling.  
Ovcar-3 cells were serum starved overnight and incubated with or without (A) 200 nM AG1478 
or (B) 5µM U0126 for 20 min at 37°C before stimulation with GPCR agonists for 5 min at 
37°C. Lane 1, untreated; lanes 2 and 3, 25 ng/ml EGF; lanes 4 and 5, 1 mM carbachol; lanes 6 
and 7, 10 µM LPA; lanes 8 and 9, 2U/ml thrombin. The lysates were subjected to 
immunoprecipitations with anti-FRS2 antibody. The immunoprecipitates were resolved by 
SDS-PAGE followed by immunoblotting with anti-FRS2 antibody. Molecular weights are 
indicated on the left in kilodaltons. *Unspecific band due to an antibody cross reaction with an 
unidentified protein. 
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GPCRs are able to activate ERK through Src or PKC independent of the EGFR 
(Gutkind, 2000; Marinissen and Gutkind, 2001). To determine whether the GPCR 
induced FRS2 migration shift is also mediated by ERK activation, U0126 was tested on 
Ovcar-3 cells. As shown in Figure 24B, the pre-incubation with U0126 completely 
abrogated the carbachol, LPA and thrombin induced FRS2 migration shift as well as in 
the setting of EGF. Thus, it is clear that GPCR activation is also able to induce ERK 
mediated FRS2 serine/threonine phosphorylation, implicating that FRS2 is also 
involved in regulation of GPCR signaling.  
Thus, the serine/threonine phosphorylation of FRS2 is induced in different cell 
lines by activation of different growth factor receptors as well as by GPCR agonists 
stimulations. The latter is partially mediated by transactivation through EGFR. The fact 
that this migration shift phenomenon occurs upon stimulations of a broad range of 
growth factors and GPCR agonists, implies that FRS2 is likely to be involved in 
multiple signal transduction pathways, and might play a role of central importance in 
the cellular signaling networks.  
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3.8 MAP Kinase and FRS2 form a Feedback Loop 
 
3.8.1 ERK Phosphorylates FRS2 in vitro 
 
The previous experiments demonstrated that FRS2 not only activates ERK 
(Figure 19 and 21), but also is a substrate of this serine/threonine kinase in vivo (Figure 
22, 23 and 24). The minimal consensus sequence for phosphorylation by ERK consist of 
a serine or threonine followed by a proline (S/TP). In addition, a proline at position –2 
is favourable, whereas a proline at position –1 is unfavourable (the phosphoacceptor S/T 
is position 0). The consensus ERK phosphorylation site is thus PXS/TP (Clark-Lewis et 
al., 1991; Gonzalez et al., 1991). Examination of the FRS2 primary sequence revealed 8 
threonine residues as putative ERK phosphorylation sites, including 130PRTP, 133PRTP, 
136PTTP, 374PKTP, 450PQTP, 453PKTP, 456PTTP and 461PQTP in different regions of the 
protein (Figure 25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: FRS2 phosphorylation and binding sites of ERK.  
The minimal consensus of ERK phosphorylation S/TP are marked in bold blue and the putative 
ERK phosphorylation sites (PXS/T) are in addition underlined. The putative ERK docking sites 
are marked in red boxes. The FxF motif is marked in red bold box. Computer program predicted 
putative phosphorylation sites of other serine/threonine kinases are marked in boxes. The 
tyrosine phosphorylation sites are marked in underlined bold.  
 
 
MGSCCSCPDK DTVPDNHRNK FKVINVDDDG NELGSGIMEL TDTELILYTR  50 
KRDSVKWHYL CLRRYGYDSN LFSFESGRRC QTGQGIFAFK CARAEELFNM  100 
LQEIMQNNSI NVVEEPVVER NNHQTELEVP RTPRTPTTPG FAAQNLPNGY  150 
PRYPSFGDAS SHPSSRHPSV GSARLPSVGE ESTHPLLVAE EQVHTYVNTT  200 
GVQEERKNRT SVHVPLEARV SNAESSTPKE EPSSIEDRDP QILLEPEGVK  250 
FVLGPTPVQK QLMEKEKLEQ LGRDQVSGSG ANNTEWDTGY DSDERRDAPS  300 
VNKLVYENIN GLSIPSASGV RRGRLTSTST SDTQNINNSA QRRTALLNYE  350 
NLPSLPPVWE ARKLSRDEDD NLGPKTPSLN GYHNNLDPMH NYVNTENVTV  400 
PASAHKIEYS RRRDCTPTVF NFDIRRPSLE HRQLNYIQVD LEGGSDSDNP  450 
QTPKTPTTPL PQTPTRRTEL YAVIDIERTA AMSNLQKALP RDDGTSRKTR  500 
HNSTDLPM 
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Figure 26: FRS2 is a substrate of ERK.  
(A) Cos-7 cells were transiently transfected with HA-ERK2, and serum starved overnight before 
stimulation with either 25 ng/ml EGF or aFGF at 37°C for 5 minutes. The lysates were 
subjected to immunoprecipitations with anti-HA antibody, followed by in vitro MAP kinase 
assay using GST or GST-FRS2 fusion proteins as substrates. After gel electrophoresis, the gel 
was dried and exposed to film for autoradiography. (B) In vitro kinase saay with purified ERK2 
and MEK1 and GST or GST-FRS2 fusion proteins as substrates. I: inactive (unphosphorylated). 
A: active (phosphorylated). Molecular weights are indicated on the left in kilodaltons. 
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To test whether FRS2 is a direct substrate for ERK2 phosphorylation, in vitro 
MAP kinase assays were performed by incubating different GST-FRS2 fusion proteins 
(see Figure 9) with immunoprecipitated HA-tagged ERK2 from EGF or FGF treated 
and untreated Cos-7 cells in the presence of 32P-γATP. SDS-PAGE followed by 
autoradiography revealed marked phosphorylation of GST-FRS2-∆PTB, GST-FRS2-CT 
and GST-FRS2-WT, i.e. all carboxyl-terminus containing GST-fusion proteins (Figure 
26A). In contrast, the amino-terminal portion of FRS2 including the PTB domain, GST-
FRS2-NT, was not phosphorylated, despite of the three predicted ERK phosphorylation 
sites within this part of protein (Figure 25).  
To exclude the possibility that FRS2 might be phosphorylated by another kinase 
that coprecipitates with ERK2, purified ERK2 and MEK1 were employed in in vitro 
kinase assays with the same set of GST-FRS2 fusion proteins as substrates. The result 
shown in Figure 26B corroborated the findings in Figure 26A and demonstrated that 
MEK1 is not able to phosphorylate FRS2. The activity of the purified kinases were 
controlled using MBP and unphosphorylated ERK2 as substrates (data not shown). The 
fact that phosphorylated GST-FRS2-WT migrates as a double band in Figure 26A, 
indicating that there is more than one ERK2 phosphorylation site and that differentially 
phosphorylated FRS2 molecules have different electrophoretic migration properties. 
These data establish that FRS2 is a substrate of ERK1/2 in vitro, and that the ERK 
phosphorylation site(s) appear(s) to be located in the C-terminal region of the molecule.  
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3.8.2 FRS2 Central Region Interacts Directly with ERK  
 
The pharmacological interference experiments (Figure 23 and 24) and the in 
vitro MAP kinase assay described above demonstrated an involvement of ERK1/2 in 
serine/threonine phosphorylation of FRS2, however, it remained unclear whether a 
direct interaction between FRS2 and ERK1/2 exists. To address this issue, in vitro 
binding assays were performed with lysates of A-431 cells stimulated with EGF or FGF 
using different GST-FRS2 fusion proteins as affinity reagents. As shown in Figure 27A, 
ERK1/2 of 44 kDa and 42 kDa from stimulated and unstimulated cells coprecipitated 
with GST-FRS2-WT and GST-FRS2-∆PTB. The phosphotyrosine and, to a lesser 
extent, the ERK1/2 signals were augmented upon ligand treatment of the cells. GST-
FRS2-CT was in weak association only with the p42 ERK2 from the EGF stimulated 
cells as it was observed before (Figure 15). The GST-FRS2 fusions containing only the 
N-terminus of FRS2, GST-FRS2-PTB and GST-FRS2-NT, were not able to bind 
ERK1/2 (Figure 27A, upper panel). The association of GST-FRS2-WT and GST-FRS2-
∆PTB fusion proteins with ERK1/2 from untreated as well as stimulated cells suggests a 
constitutive association between specific parts of FRS2 and these kinases.  
Comparison of the previous in vitro MAP kinase assay (Figure 26) and this 
binding assay reveals that the GST-FRS2 fusions that bind to ERK1/2 are identical with 
those that serve as ERK2 substrates (Figure 27C). The fusion proteins GST-FRS2-WT 
and GST-FRS2-∆PTB associate with ERK and are substrates for ERK phosphorylation, 
while GST-FRS2-PTB and GST-FRS2-NT do not bind to ERK nor become 
phosphorylated. Thus, it seems that docking of ERK with FRS2 is a prerequisite for 
phosphorylation of the latter.  
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Figure 27: FRS2 central region binds to ERK1/2 in vitro.  
(A), (B) A-431 cells were serum starved overnight and stimulated with 25 ng/ml EGF or aFGF. 
The lysates were subjected to in vitro binding assay with glutathione sepharose bound GST or 
GST-FRS2 fusion proteins as indicated, and resolved by SDS-PAGE followed by 
immunoblotting with the indicated antibodies. Molecular weights are indicated on the left in 
kilodaltons. *Unspecific bands due to antibody cross-reaction with GST-fusion proteins. (C) 
The association of GST-FRS2 fusion proteins with ERK1/2 are indicted as an estimation of 
anti-ERK1/2 reactive bands shown in (A). Whether these fusion proteins serve as ERK substrate 
is concluded from Figure 26. 
GST-FRS2 Fusion Proteins Association with ERK Substrate of ERK 
GST-FRS2-WT (1-508) +++ + 
GST-FRS2-PTB (1-163) - - 
GST-FRS2-∆PTB (156-508) +++ + 
GST-FRS2-CT (326-508) + + 
GST-FRS2-NT (1-240) - - 
GST-FRS2-∆CR (∆240-351) - N.D. 
GST-FRS2-CR (238-345) ++ N.D. 
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The relatively weak interaction between the C-terminus-containing mutant, 
GST-FRS2-CT, and ERK1/2 when compared to GST-FRS2-WT and GST-FRS2-∆PTB, 
together with the lack of interaction between GST-FRS2-NT and ERK1/2 suggest that 
the putative ERK binding site of FRS2 is likely located in the central region between the 
NT and CT truncation mutants plus the first residues from the C-terminus mutant. To 
examine this hypothesis, two additional fusion protein constructs CR (aa 238-345, 
Figure 9) encompassing the central region of FRS2, and its complimentary counterpart 
GST-FRS2-∆CR (∆240-352) were designed and employed. As shown in Figure 27B, 
the central-region-containing GST-FRS2-CR was able to bind ERK1/2, while GST-
FRS2-∆CR was not. Therfore, the central part of FRS2 contained the major docking 
region for ERK1/2.  
In addition, an association of FRS2 and ERK1/2 was further confirmed by in-gel 
kinase assays performed with immunoprecipitated FRS2 (data not shown). This method 
was chosen to visualize the coprecipitated kinase that would otherwise be masked by 
the antibody light chain.  
These experiments confirmed that the MAP kinases ERK1/2 constitutively 
associate with FRS2 through the ERK docking site in the central region of FRS2. 
Together with the fact that FRS2 is an upstream signaling mediator of ERKs, these data 
suggest a feedback loop between FRS2 and ERK1/2. 
 
 
 
3.8.3 ERK Activation Reduces EGF- and FGF-Induced FRS2 Tyrosine 
Phosphorylation  
 
The experiments so far have demonstrated a feedback mechanism where EGF- 
or FGF-induced tyrosine phosphorylation of FRS2 first leads to activation of ERK1/2 
that is constitutively associated with the central region of FRS2 and in turn 
phosphorylates FRS2 on threonine residues. However, it is still unclear whether this 
feedback mechanism plays a positive or a negative regulatory role, i.e. whether the 
FRS2 threonine phosphorylation affects its tyrosine phosphorylation positively or 
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negatively. As mentioned before, phosphorylation on threonine residues by ERK1/2 
resulted in a significant migration shift of FRS2 from ligand stimulated Ovcar-3 cells on 
SDS-PAGE, which was completely abolished by the presence of MEK1/2 inhibitor 
U0126 (Figure 23B). 
The same effect on FRS2 migration shift was observed when A-431 cells were 
treated with this inhibitor prior to stimulation with EGF or FGF (Figure 28, upper 
panel). Remarkably, reprobing of the same membrane with the antibody against 
phosphotyrosine revealed that while inhibition of ERK activity abrogated FRS2 
threonine phosphorylation, it significantly enhanced tyrosine phosphorylation of FRS2 
in response to both EGF and FGF stimulation (Figure 28, upper middle panel, lane 3, 5). 
Thus, under normal physiological condition, FRS2 threonine phosphorylation down-
regulates its tyrosine phosphorylation, demonstrating a negative feedback loop between 
ERK and FRS2 in the EGFR and FGFR signaling pathways.  
To find out whether this increase of tyrosine phosphorylation has any effect on 
proteins known to interact with FRS2, the membrane was reprobed with specific 
antibodies against SHP2 and Grb2 (Figure 28, middle panels). Indeed, augmented 
tyrosine phosphorylation of FRS2 after blocking its threonine phosphorylation by ERK 
resulted in an elevated recruitment of SHP2 in EGF as well as FGF stimulated A431 
cells . In contrast, FRS2-Grb2 complex formation increased only in response to FGF but 
not EGF stimulation. In correlation with this unchanged FRS2-Grb2 association, the 
amount of coprecipitated EGFR was not affected irrespective of the altered FRS2 
phosphotyrosine content (Figure 28), which implicates that FRS2-Grb2 association is 
likely indirect through Grb2 interaction with the EGFR. It thus seems that FRS2 links 
EGFR activation with MAP kinase primarily through SHP2.  
These results support a negative regulatory mechanism in which stimulation of 
MAPK activity via FRS2 leads to a reduction of FRS2 tyrosine phosphorylation. The 
resulting release of SH2 domain containing proteins from the RTK-FRS2 signaling 
complex might thereby down-regulate FRS2-mediated signaling pathways. 
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Figure 28: The FRS2 migration shift is abolished while tyrosine phosphorylation is 
enhanced upon inhibition of ERK activation.  
A-431 cells were serum starved overnight and incubated with 5 µM U0126 for 20 min at 37°C 
before stimulation with 25 ng/ml EGF or aFGF for 5 minutes. The lysates were subjected to 
immunoprecipitations with anti-FRS2 antibody. The immunoprecipitates were resolved by 
SDS-PAGE followed by immunoblotting with the indicated antibodies. Crude lysates resolved 
by SDS-PAGE and immunoblotted with anti-ERK1/2 antibodies served as control. Molecular 
weights are indicated on the left in kilodaltons. *Unspecific band due to an antibody cross 
reaction with an unidentified protein.  
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3.8.4 Differential Regulation of FRS2 Tyrosine Phosphorylation 
 
The FRS2 migration shift as a result of ERK-mediated threonine 
phosphorylation has been observed in responese to various stimuli in multiple cell lines, 
including EGF-treated Ovcar-3 (Figure 23 and 24), and PC12 cells (data not shown). 
However, only FGF but not EGF was able to induce FRS2 tyrosine phosphorylation in 
these cells, despite the relatively high expression levels of EGFR family members. 
Moreover, after pre-incubation with EGF, the FGF-induced FRS2 tyrosine 
phosphorylation was diminished in Ovcar-3 cells, but enhanced in PC12 cells (Figure 
29). These results indicate that, tyrosine phosphorylation is not a prerequisite for 
threonine phosphorylation of FRS2 and may be positively (PC12 cells) or negatively 
(Ovcar-3 cells) regulated by co-presence of EGF and FGF depending on the cellular 
context. Thus, feedback loop of FRS2 and ERK represents a part of a complex 
regulatory mechanism involving additional cell type-dependent factors.  
 
 
 
 
 
Figure 29: Differential regulation of FRS2 tyrosine phosphorylation by co-
stimulation with EGF and FGF.  
Ovcar-3 or PC12 cells were serum starved overnight and pre-incubated with 25 ng/ml EGF 
before stimulation with 25 ng/ml aFGF. The lysates were subjected to immunoprecipitations 
with anti-FRS2 antibody, resolved by SDS-PAGE and immunoblotted with anti-PY antibody.  
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3.9 Is FRS2 a Substrate of SHP2? 
 
In the FRS2 and ERK1/2 mediated negative feedback loop, the activated EGFR 
or FGFR induce FRS2 tyrosine phosphorylation thereby activates ERK1/2, which in 
turn phosphorylates threonine residues on the docking protein and results in reduction 
of phosphorylation on tyrosine residues of FRS2. The dephosphorylation of 
phosphotyrosine may be archieved by the recruitment and activation of a tyrosine 
phosphatase. In this case, the tyrosine phosphatase SHP2 has been identified as 
interaction partner of FRS2 in response to both EGF and FGF stimulations. It has been 
reported that in FGFR signaling, SHP2 acts as a docking protein downstream of FRS2, 
nevertheless its catalytical activity is essential for sustained MAPK activity and for 
potentiation of FGF-induced PC12 cell differentiation (Hadari et al., 1998).  
To survey whether FRS2 is a substrate of SHP2, wild-type as well as 
catalytically inactive CA mutant of SHP2 along with FRS2 were transiently transfected 
into NIH3T3/EGFR cells and immunoprecipitations were performed with the anti-FRS2 
antibody. Figure 30 shows that tyrosine phosphorylation of FRS2 somewhat increased 
in cells overexpressing SHP2 wild-type as compared to mock transfected cells in 
response to both EGF and FGF stimulation (Figure 30, upper panel), which correlates 
with enhanced association of FRS2 with SHP2 (Figure 30, upper middle panel). On one 
hand these results suggest that FRS2 is not a substrate of SHP2, on the other hand the 
expression of an enzymatically inactive SHP2-CA significantly increased FRS2 tyrosine 
phosphorylation, suggesting either a dominant negative effect or protection of 
phosphorylated tyrosine residues from the activity of another so far unidentified 
phosphatase. Thus, SHP2 seems to function as a downstream docking protein of FRS2 
in both EGF and FGF induced signaling pathways, where it has been demonstrated to 
play a positive role in propagating signals from the respective RTK to the ERK MAP 
kinase (Hadari et al., 1998; Feng, 1999; Qu et al., 1999). Further experiments such as 
phosphatase assay are necessary to determine whether FRS2 is indeed a substrate of 
SHP2. 
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Figure 30: Effects of tyrosine phosphatase SHP2 on FRS2 phosphorylation. 
Wild-type (wt) and catalytically inactive CA mutant SHP2 along with FRS2 were 
transiently transfected into NIH3T3/EGFR cells. Cells were serum starved overnight 
before stimulation with either 25 ng/ml EGF (E) or aFGF (F) at 37°C for 5 minutes. 
Immunoprecipitations were performed with anti-FRS2 antibody followed by 
immunoblotting with the indicated antibodies. Molecular weights are indicated on the 
left in kilodaltons. *Unspecific band due to an antibody cross reaction with an 
unidentified protein. 
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4. DISCUSSION 
 
4.1 FRS2 in RTK-Mediated Oncogenic Signaling  
 
Although the docking proteins lack intrinsic catalytic activity, it has been 
established that they function as platforms for the recruitment of signaling proteins in 
response to receptor tyrosine kinase (RTK) activation (Pawson and Scott, 1997; Hunter, 
2000; Guy et al., 2002). The docking protein FRS2 plays an important role in the 
signaling pathways induced by several growth factors including FGF, nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic 
factor (GDNF) and vascular endothelial growth factor (VEGF). FRS2 becomes tyrosine 
phosphorylated upon activation of the respective receptors, FGFR, TrkA, TrkB, Ret and 
VEGFR2, thereby creating docking sites for the phosphotyrosine binding adaptor 
protein Grb2 and tyrosine phosphatase SHP2 (Kouhara et al., 1997; Hadari et al., 1998; 
Xu et al., 1998; Easton et al., 1999; Meakin et al., 1999; Kurokawa et al., 2001; Melillo 
et al., 2001; Stoletov et al., 2002). FRS2 has also been suggested as a signal mediator 
downstream of IGF-IR and insulin receptor (Delahaye et al., 2000; Kimpinski and 
Mearow, 2001). In this study, FRS2 was found to be ubiquitously expressed in a variety 
of cell lines of different tissue origin, including fibroblasts, mammary carcinoma, 
ovarian adenocarcinoma, epidermoid carcinoma, glioblastoma, lung carcinoma, as well 
as hematopoietic cells. Immunoprecipitations and in vitro binding assays demonstrated 
that upon tyrosine phosphorylation FRS2 associates with multiple phosphoproteins, 
among which the EGFR, SHP2, and ERK1/2 were identified (Figures 7, 12, 14, 15, 17, 
18, 27 and 30).  
It is well established that perturbations of RTK signaling are closely related with 
cancer (Blume-Jensen and Hunter, 2001). There are evidences showing that the EGFR 
family RTKs are involved in mammary and ovarian carcinoma, non-small-cell lung 
cancer, and colon cancer; FGFR in mammary and ovarian carcinoma, leukemia and 
gastric carcinoma; TrkA in neuroblastoma and thyroid carcinoma; IGF-IR in cervical 
cancer; Ret in medullary thyroid carcinoma, pheochromocytoma; insulin receptor in 
insulinoma; and VEGFR in tumor angiogenesis (Blume-Jensen and Hunter, 2001). 
Hence, the ubiquitous expression of FRS2 and its involvement in different RTK 
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signaling pathways imply that FRS2 may function as a mediator in oncogenic RTK 
signaling.  
Several reports have indicated FRS2 involvement in human salivary 
adenocarcinoma, prostate tumor, as well as thyroid carcinogenesis triggered by Trk 
oncogenes (Zhang et al., 2001; Wang, 2002; Ranzi et al., 2003). FRS2 has also been 
found to be involved in parathyroid adenoma expressing an alternatively spliced variant 
of FGFR2 (Sakaguchi et al., 1999). Increased FRS2 tyrosine phosphorylation was 
observed in correlation with ligand-independent up-regulation of transforming activity 
in transfectants expressing the variant FGFR2. The higher transforming activity was not 
accompanied by increased dimerization or overall autophosphorylation of the receptor. 
Moreover, FRS2 couples RET with the MAP kinase signaling cascade under both 
normal biological and pathological conditions, such as in papillary thyroid carcinomas 
(Melillo et al., 2001). In human pancreatic cancer cells, FRS2 promotes mitogenic 
signaling generated by FGFR1/IIIc, which has the potential to enhance pancreatic ductal 
cell transformation (Kornmann et al., 2002). Thus, there is an emerging role of FRS2 in 
RTK-mediated oncogenic signaling. 
 
 
 
4.2 FRS2 in EGF- and FGF-Induced Signal Transduction 
 
FRS2 directly binds to RTKs through its PTB domain. The association is 
constitutive for FGFR and VEGFR2, but dependent on receptor activation for TrkA, 
TrkB and Ret. The binding site on FGFR1 has been mapped to the juxtamembrane 
region lacking phosphotyrosine residues, whereas the binding site on VEGFR2 is still 
unknown (Xu et al., 1998; Stoletov et al., 2002). TrkA, TrkB and Ret associate with the 
FRS2 PTB domain through the known phosphorylation-dependent binding site of Shc 
(NPXpY) (Meakin et al., 1999; Melillo et al., 2001). Therefore it has been suggested 
that a dynamic balance of Shc or FRS2 binding may affect the RTK-mediated 
intracellular signaling for cell proliferation, differentiation and survival (Meakin et al., 
1999; Califano et al., 2000; Kurokawa et al., 2001; Melillo et al., 2001).  
This study demonstrated that, upon EGF stimulation of A-431 and NIH3T3 cells 
stably expressing EGFR (NIH3T3/EGFR), FRS2 becomes tyrosine phosphorylated and 
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binds directly to the activated EGFR through its PTB domain (Figure 17 and 18). Thus, 
as in the case of TrkA, TrkB and Ret, activation of the EGFR is necessary for its 
interaction with FRS2. Therefore, it is tempting to assume that FRS2 might also share 
the binding site on EGFR with Shc. The docking protein Shc contains a PTB domain as 
well as a SH2 domain, which enables Shc to bind EGFR at two phosphotyrosine 
residues (Batzer et al., 1994; Batzer et al., 1995). It is thus possible that the FRS2 PTB 
domain competes with the Shc PTB domain for the binding site pY1148 of EGFR, while 
the Shc SH2 domain binding site pY1173 is not challenged. The observation that Shc 
coprecipitates with FRS2 and EGFR supports this hypothesis (Figure 17B).  
The failure to detect the EGF-induced FRS2 tyrosine phosphorylation in earlier 
studies might be explained by diverse cellular context, since the composition as well as 
the regulation of signaling molecules might vary in different cell lines. For example, in 
the cell lines PC12 and Ovcar-3, FRS2 tyrosine phosphorylation remained refractory to 
EGF stimulation. Moreover, FRS2 displayed a weaker tyrosine phosphorylation upon 
EGF stimulation in PC12 cells stably overexpressing the EGFR (PC12/EGFR) as 
compared to NIH3T3/EGFR cells (data not shown).  
In contrast to FRS2 and EGFR association, the previously reported direct 
interaction of FRS2 with the FGFR could not be confirmed by immunoprecipitation 
with anti-FRS2 antibody or in vitro association experiments with purified GST-FRS2 
fusion proteins (Figure 17 and data not shown). Nevertheless, FGF stimulation resulted 
in FRS2 tyrosine phosphorylation indicating that the FGFR transduced signal to FRS2 
in the cell lines used. This demonstrates a significant difference in the interaction of 
FRS2 with the EGFR versus the FGFR. The functional consequence of this distinctive 
feature for FRS2 signal transmission in EGF and FGF treated cells is subject to further 
investigation. The ability of FRS2 to interact with nonphosphorylated FGFR raises the 
possibility that FRS2 is sequestered by FGFR in unstimulated cells and is only available 
for activation by FGF. Alternatively, the constitutive association of FRS2 PTB domain 
with the juxtamembrane domain of FGFR might be required to maintain the membrane-
anchorage of FRS2. Since protein myristylation alone is usually insufficient for stable 
membrane association, an additional targeting signal might be necessary to generate a 
stable anchor to the cell membrane (Resh, 1994).  
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FRS2 is known to link growth factor-induced signal transduction pathways to 
the MAP kinase cascade, thus the effect of FRS2 on MAP kinase activity in EGFR 
signaling was examined. When increasing amounts of FRS2 were overexpressed in 
ERK2 transfected Cos-7 cells, a dose-dependent enhancement of MAPK activity after 
EGF stimulation was observed (Figure 19). This result suggests FRS2 as a positive 
regulator in EGF-induced signal transduction, hence providing an additional route, 
parallel to those via Grb2 and Shc, for signal transmission from the activated EGFR to 
the MAP kinase cascade. By this mechanism, FRS2 might contribute to the prolonged 
ERK activation that was reported to be necessary for EGF-induced differentiation of 
PC12/EGFR cells (Traverse et al., 1994).  
The exact mechanism underlying the EGF-induced and FRS2-promoted MAPK 
signal enhancement is still to be elucidated. Upon FGF stimulation, the enhancement of 
FRS2 tyrosine phosphorylation induced by ERK inactivation is accompanied by an 
increase of coprecipitated Grb2 and SHP2 (Figure 28). This is consistent with earlier 
reports demonstrating that the recruitment of both Grb2 and SHP2 by FRS2 is essential 
in mediating MAPK activation by FGF (Hadari et al., 1998; Hadari et al., 2001). In 
response to EGF stimulation, both Grb2 and SHP2 coprecipitated with FRS2. However, 
when the ERK activity was blocked, only the amount of SHP2, but not Grb2, in the 
multiprotein complex was elevated in correlation with enhanced FRS2 tyrosine 
phosphorylation. Concomitant with the unchanged amount of Grb2, the active EGFR 
coprecipitated was also not altered (Figure 28). The latter is due to independency of 
FRS2 tyrosine phosphorylation in the FRS2-EGFR interaction. Thus, the FRS2-Grb2 
association observed upon EGF stimulation might be an indirect one, which is mediated 
through the direct interaction of Grb2 with the activated EGFR. This leads to the 
hypothesis that FRS2 might link the activated EGFR with MAPK signaling cascade 
primarily through SHP2, which has been shown to be positively engaged in the EGFR-
ERK signaling cascade (Deb et al., 1998; Stein-Gerlach et al., 1998; Qu et al., 1999). 
Shi et al. reported that upon EGF stimulation SHP2 is recruited into a multiprotein 
complex assembled on Gab1 and promotes Ras-Raf-MEK-ERK cascade activation by 
specifically dephosphorylating an unidentified phosphoprotein p90 in the complex (Shi 
et al., 2000). As shown in this study, a tyrosine phosphorylated protein of 116 kDa very 
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likely corresponding to Gab1 coprecipitated with FRS2 and SHP2 in EGF stimulated 
cells, suggesting that the 90 kDa protein reported by Shi et al. might represent FRS2.  
The fact that coexpression of a catalytically inactive SHP2-CA mutant and FRS2 
results in a dramatic enhancement of FRS2 tyrosine phosphorylation, supports the 
hypothesis that FRS2 might be a substrate of SHP2 (Figure 30). Although the 
overexpression of wild-type SHP2 showed no dephosphorylation effect on tyrosine 
phosphorylated FRS2, the possibility cannot be excluded that under certain 
circumstances phosphorylated FRS2 serves as a substrate for SHP2. Alternatively, it is 
also possible that the inactive phosphatase mutant binds to FRS2 and thereby protects 
its phosphotyrosine sites from dephosphorylation by another so far unidentified 
phosphatase. One candidate might be the receptor-like PTP LAR, which inhibits FGF-
induced MAPK activation partially through interfering with phosphorylation and Grb2 
interaction of FRS2 in a human osteosarcoma cell line stably overexpressing the PTP 
(Wang et al., 2000).  
 
 
 
4.3 Serine/Threonine Phosphorylation of FRS2  
 
Previous studies of FRS2 have been concentrated on its tyrosine 
phosphorylation, though FRS2 has more than 30 putative serine/threonine 
phosphorylation sites as predicted by computer programs such as Scansite and Prosite 
(Sibbald et al., 1991; Yaffe et al., 2001). In this study, a significant migration shift of 
FRS2 on SDS-PAGE upon EGF and FGF stimulation was observed. This shift 
resembles the decrease of gel mobility described for IRS-1 as a result of 
serine/threonine phosphorylation (Tanti et al., 1994). In vitro kinase assays with FRS2 
immunocomplexes revealed the presence of a kinase that was able to phosphorylate 
MBP (Figure 21). In addition, incubation of FRS2 with a serine/threonine phosphatase 
inhibitor resulted in retarded gel migration, while treatment with alkaline phosphatase 
abolished the migration shift. Together, all these observations suggested that the 
migration shift of FRS2 is due to phosphorylation on serine/threonine residues. Indeed, 
phosphoamino acid analysis confirmed that, in response to EGF or FGF stimulation the 
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phosphoserine and phosphothreonine contents of FRS2 was elevated significantly as 
compared to the basal level.  
FRS2 is phosphorylated on serine as well as threonine residues in untreated 
cells. The function of this basal phosphorylation remains to be investigated. 
Interestingly, the basal serine/threonine phosphorylation of IRS-1 has been reported to 
play a positive role in its tyrosine phosphorylation by insulin and IGF-I receptors, 
whereas the same phosphorylation of IRS-2 has divergent effects on its interaction with 
these RTKs in a ligand-dependent manner (Greene and Garofalo, 2002). Hence, it is 
possible that, the effects of FRS2 basal serine/threonine phosphorylation on its tyrosine 
phosphorylation might differ in response to EGF or FGF stimulation. This might 
explain why EGF only induces relatively moderate tyrosine phosphorylation of FRS2 in 
A-431 cells when compared to FGF. This phenomenon is not likely to be caused by 
different amounts of the respective RTKs in the cells, since similar expression levels of 
EGFR and FGFR3 were detected by cDNA microarray analysis (data not shown). Thus, 
the different extents of FRS2 tyrosine phosphorylation upon EGF or FGF stimulation 
implicate distinct stimulus-dependent regulatory mechanisms for FRS2.  
It is known that docking proteins such as Gab1, Gab2 and IRS-1 are 
phosphorylated on serine/threonine as well as on tyrosine residues. The serine/threonine 
phosphorylation of Gab1 is catalyzed by PKCα, PKCβ1 and ERK, Gab2 by PKB, IRS-1 
by PKCζ, PKB and JNK1 (Paz et al., 1999; Roshan et al., 1999; Aguirre et al., 2000; 
Gual et al., 2001; Liu et al., 2001; Aguirre et al., 2002; Greene and Garofalo, 2002; 
Lynch and Daly, 2002). To identify the upstream kinase of FRS2, specific inhibitors 
against these serine/threonine kinases were tested for their ability to affect the FRS2 
migration shift. The PKC inhibitor had no effect, which is consistent with earlier report 
that, though FRS2 associates with atypical PKCs, PKCλ and PKCζ, it is not a substrate 
of these kinases. In this case, the likely role of FRS2 is to serve as an anchoring protein 
to target the activated PKCs to the plasma membrane (Lim et al., 1999).  
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4.4 FRS2-ERK Feedback Loop 
 
The MEK1/2 inhibitor U0126 that prevents activation of ERK1/2 was the only 
specific inhibitor that completely abolished the FRS2 gel migration shift, indicating that 
ERK1/2 are the responsible kinases for FRS2 phosphorylation. FRS2 has 11 putative 
ERK threonine phosphorylation sites, when S/TP is considered the minimal consensus 
sequence for ERK phosphorylation (Clark-Lewis et al., 1991; Gonzalez et al., 1991; 
Davis, 1993; Songyang et al., 1996). However, taken into account that a proline at 
position -2 is favorable, whereas a proline at position -1 is unfavorable, FRS2 has 8 
putative threonine phosphorylation sites. The in vitro MAP kinase assay indicated that 
the phosphorylation sites are located at the C-terminus of FRS2, despite the three 
predicted phosphorylation sites at the N-terminus (Figure 25 and 26).  
It is known that many MAP kinases form tight complexes with their substrates 
through docking sites within the substrate. These docking actions promote not only the 
specificity of substrate recognition, but also the efficiency and accuracy of substrate 
phosphorylation by MAP kinases (Gavin and Nebreda, 1999; Smith et al., 1999; 
Whitmarsh and Davis, 1999; Sharrocks et al., 2000; Chen et al., 2001). A direct 
interaction between FRS2 and ERK1/2 was observed in in vitro binding assays with 
GST fusion proteins containing the central region of FRS2. This constitutive association 
of FRS2 and ERK1/2 enables a rapid and solid feedback regulation, as the FRS2 
migration shift occurs almost simultaneously with the tyrosine phosphorylation (data 
not shown).  
Analysis of the primary sequence of the FRS2 central region revealed two amino 
acid stretches, 321RRGRL325 and 342RRTALL347, that resemble the previously identified 
MAPK binding consensus KIM (kinase interaction motif, L-X-X-K/R-K/R-X1-5-L/I-X-
L) (Pulido et al., 1998; Zuniga et al., 1999; Sharrocks et al., 2000). Another known 
motif FxF, (419FNF421) that provides enhanced binding to the MAP kinase is found C-
terminal to these putative docking site(s). Thus, FRS2 possesses all three determinants 
of MAP kinase-recognition modules mentioned in Introduction (Sharrocks et al., 2000). 
Nevertheless, experimental evidence is still required to determine whether they are all 
necessary for complex formation.  
In addition, subcellular distribution of ERKs to membrane (Kim and Kim, 1997; 
Liu et al., 1997; Menice et al., 1997; Chen et al., 2001) as well as detection of ERKs in 
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isolated caveolae upon PDGF and EGF stimulation has been reported (Liu et al., 1997; 
Engelman et al., 1998a; Furuchi and Anderson, 1998; Kim et al., 2000; Park et al., 
2000). FRS2 is membrane-anchored through its N-terminal myristylation site, and was 
found in caveolae (Figure 16) (Davy et al., 2000; Ridyard and Robbins, 2003). Hence, it 
is fully possible that FRS2 and ERKs colocalize within caveolae, thereby fulfilling the 
spatial prerequisite for a direct association.  
A comparison of the in vitro MAP kinase (Figure 26) and binding assays (Figure 
27) reveals that the ERK-binding GST-FRS2 fusions are identical with those serving as 
substrates. This indicates that docking of ERK to FRS2 is a prerequisite for 
phosphorylation of the latter. ERK neither binds nor phosphorylates the N-terminus of 
FRS2, in spite of the three predicted ERK phosphorylation sites within this region. 
However, the possibility cannot be excluded that when brought into association with 
ERK, such as in the full-length protein, the N-terminus of FRS2 might serve as 
substrate of the kinase. The fact that the truncation mutant lacking the PTB domain 
(GST-FRS2-∆PTB) became phosphorylated to a lesser extent in in vitro MAP kinase 
assay, might indicate a reduction of the three phosphorylation sites. Lax et al. recently 
reported that only replacement of all these 8 threonine residues by valine prevented the 
FGF-induced FRS2 migration shift, suggesting that there are 8 phosphorylation sites in 
the molecule (Lax et al., 2002). Additionally, the central region of FRS2 is only 
partially presented by the C-terminus GST-FRS2 fusion construct which nevertheless, 
in vitro serves as substrate for MAP kinases. These experiments were performed in 
excess of the kinase, which might account for substrate recognition even in the absence 
of a perfect docking site. 
The MAPKs ERK1/2 are downstream effectors as well as upstream regulators of 
FRS2, thus there is a feedback loop between these two proteins. Feedback regulation is 
known for docking proteins. For example, Gab1 and PI3K form a positive feedback 
loop in EGFR signaling (Rodrigues et al., 2000). Upon EGFR activation, Gab1 is 
recruited to and subsequently phosphorylated by the receptor, which facilitates its 
association with downstream effectors such as the p85 subunit of PI3K. The activation 
of PI3K then leads to production of PtdIns(3,4,5)P3 (phosphatidylinositol 3,4,5-
triphosphate), which further promotes membrane recruitment of Gab1 via its PH 
domain and additional enhancement of PI3K signaling. The termination of this positive 
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feedback loop is mediated by the tyrosine phosphatase SHP2 that dephosphorylates the 
p85 binding site of Gab1 (Zhang et al., 2002). Another example is the self-attenuated 
mechanism between IRS-1 and PKCζ. In the insulin-induced signaling pathway, 
tyrosine-phosphorylated IRS-1 associates with the p85 subunit of PI3K that mediates 
the activation of PKCζ. This serine/threonine kinase subsequently phosphorylates IRS-
1, thereby diminishing its tyrosine phosphorylation and reducing complex formation of 
IRS-1 and PI3K, finally inhibiting further activation of PKCζ itself (Liu et al., 2001).  
 
 
 
4.5 Regulation of the FRS2-ERK Negative Feedback Loop 
 
As mentioned above, docking proteins such as Gab1, Gab2 and IRS-1 are known 
to be phosphorylated on tyrosine as well as serine/threonine residues in response to 
stimulation with growth factors, where serine/threonine phosphorylation indirectly 
influences protein function by potentiating or diminishing tyrosine phosphorylation (Paz 
et al., 1997; Paz et al., 1999; Roshan et al., 1999; Aguirre et al., 2000; Gual et al., 2001; 
Liu et al., 2001; Aguirre et al., 2002; Greene and Garofalo, 2002; Lynch and Daly, 
2002). Hence, tyrosine phosphorylation of such a protein is like an on-off switch of its 
activity, while the phosphorylation on serine/threonine residues are more like fine-
tuning for the magnitude and duration of its function.  
Moreover, even for one docking protein, serine/threonine phosphorylation 
induced by different growth factors could lead to divergent regulations of its tyrosine 
phosphorylation state. One such example comes from the studies of Gab1. Yu et al. 
have recently demonstrated that EGF-mediated ERK activation in mouse IMCD-3 cells 
results in diminished tyrosine phosphorylation of Gab1 and consequently reduced 
binding to PI3K (Yu et al., 2002). Conversely, the same group had reported earlier that 
HGF stimulation of the same cells leads to ERK activation, which enhances Gab1-PI3K 
interaction without affecting Gab1 tyrosine phosphorylation (Yu et al., 2001). In 
addition, the ERK phosphorylation sites on Gab1 are different in EGF- and HGF-
induced signaling (Yu et al., 2001; Yu et al., 2002). Hence, the relay of signals to 
downstream effectors by docking proteins is quite versatile and likely to depend on the 
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nature of the stimulus as well as the cell physiological context. Similarly, the FRS2-
ERK feedback loop may be differentially regulated in response to various stimuli. For 
example, tyrosine phosphorylation of FRS2 in NIH3T3/EGFR and A-431 cells occurs 
to a lesser extent in response to EGF as compared to FGF (Figure 17). Therefore, the 
balance between serine/threonine and tyrosine phosphorylation of FRS2 is differentially 
controlled in a stimulus-dependent manner, which might be achieved by, for instance, 
ERK-mediated phosphorylation of different residues on the docking protein. 
Another important result of the present study is that prevention of FRS2 
threonine phosphorylation by inhibition of ERK1/2 activation correlates with enhanced 
FRS2 tyrosine phosphorylation in response to EGF as well as FGF stimulation. This 
result indicates that in vivo, after activation and phosphorylation of ERK1/2, FRS2 
tyrosine phosphorylation should be reduced and thereby its signal transmission potential 
would be curtailed. Since tyrosine phosphorylation is crucial for FRS2-mediated 
signaling, it is not surprising that tyrosine phosphorylation of the docking protein is 
under tight control. Growth factor-induced threonine phosphorylation of FRS2 by ERKs 
provides a molecular fine-tuning approach that adjusts the degree to which FRS2 is 
tyrosine phosphorylated and associated with downstream effector proteins.  
The mechanism underlying this negative feedback fine-tuning remains to be 
elucidated. One possibility is that FRS2 becomes dephosporylated on tyrosine residues 
in response to its threonine phosphorylation by ERK. The FRS2 associated protein 
tyrosine phosphatase SHP2 is therefore the foremost candidate. However, as discussed 
before (see section 4.1), the attempts to examine the effects of SHP2 on FRS2 
phosphorylation gave no clear answer. Alternatively, threonine phosphorylation might 
induce a structural change in FRS2 resulting in a poorer tyrosine kinase substrate, as 
exemplified by IRS-1 and Gab2. Phosphorylation of IRS-1 at a serine residue proximal 
to the PTB domain by JNK1 diminishes the interaction between the insulin receptor and 
IRS-1, resulting in inhibition of IRS-1 mediated signal transduction (Aguirre et al., 
2002). Gab2 constitutively associates with PKB, which phosphorylates the docking 
protein on a single serine residue leading to inhibition of its tyrosine phosphorylation 
(Lynch and Daly, 2002). A similar scenario may be deduced for the interaction between 
the Xenopus Src family kinase Laloo and FRS2 (Hama et al., 2001; Kusakabe et al., 
2001; Hama et al., 2002). A part of FRS2 PTB domain excluding the PXXP binding 
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motif for SH3 domain has been shown to bind to the SH4 domain of Laloo (Kusakabe 
et al., 2001), but an additional requirement of the SH3 domain of Laloo has also been 
described (Hama et al., 2001). Since the three predicted ERK phosphorylation sites 
within the N-terminal PTB domain of FRS2 colocalize with the SH3 binding PXXP 
motif, phosphorylation of these residues might lead to a local structural change and 
subsequent impairment of the FRS2-Laloo interaction. In addition, FRS2 threonine 
phosphorylation might trigger its association with phosphoserine/phosphothreonine-
binding proteins (Tzivion et al., 2001; Yaffe and Elia, 2001; Yaffe and Smerdon, 2001; 
Tzivion and Avruch, 2002). The complex formation may interfere with the interaction 
between the tyrosine kinase and FRS2. Alternatively, if the bound protein is a protein 
tyrosine phosphatase, it may reduce tyrosine phosphorylation of FRS2 in a 
phosphothreonine-dependent manner.  
 
 
 
4.6 Intracellular Negative Feedback Regulation  
 
As mentioned before, growth factor signaling by RTKs regulates important 
cellular responses, such as proliferation and differentiation (Hunter, 1998). 
Inappropriate signaling by RTKs has been implicated in cancer and disorders of 
developmental processes, implying that the strength and the duration of the signaling 
must be strictly regulated (Hunter, 2000). A negative feedback loop is one of the 
fundamental mechanisms that provide an effective way to modulate, limit or terminate 
RTK signaling (Perrimon and McMahon, 1999; Freeman, 2000). Perhaps the most 
obvious use of negative feedback is to limit the duration of a signal. In its simplest 
form, a signal induces its own negative regulator so that when a threshold has been 
reached, the signal ceases.  
The FRS2-ERK feedback loop is not the only negative regulation in which these 
two proteins are involved. It has been shown that ERKs induce negative feedback on 
their activation by phosphorylation of upstream components of the kinase cascade 
including SOS, Raf, and MEK (Waters et al., 1995; Corbalan-Garcia et al., 1996; Lewis 
et al., 1998; Chen et al., 2001). A recent study suggests that ERK1/2 also cause 
negative feedback of heterotrimeric G protein signaling (Ogier-Denis et al., 2000). 
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FRS2 has been found to mediate attenuation of FGFR signaling by forming a complex 
with Cbl via Grb2, where Cbl functions as an ubiquitin ligase that promotes 
ubiquitination and consequently degradation of the FGFR and FRS2 (Wong et al., 
2002).  
A novel negative regulatory pathway for FRS2 mediated signaling has been 
described recently. Sprouty (Spry) was identified as a negative regulator of FGFR 
signaling, but was also found to inhibit EGFR signaling (Hacohen et al., 1998; Kramer 
et al., 1999; Egan et al., 2002). Upon growth factor stimulation, Spry1 and Spry2 
translocate to the plasma membrane and become phosphorylated on a conserved 
tyrosine residue, through which they bind to Grb2. By this means, Spry1-2 impair the 
recruitment of the Grb2-SOS complex either to FRS2 or to SHP2, and consequently 
inhibit the FRS2 mediated signaling (Hanafusa et al., 2002).  
 
 
 
4.7 FRS2 Involvement in Multiple Signaling Pathways  
 
Docking proteins provide several important features for receptor signaling. Due 
to their ability of recruiting diverse signaling molecules, docking proteins expand the 
repertoire of the signaling pathways activated by a single receptor. Moreover, a single 
docking protein can integrate signals from various receptors by serving as a common 
substrate to integrate multiple inputs (White, 1998; Hunter, 2000). The fact that most 
RTKs activate broadly overlapping sets of signaling pathways raised the question of 
how different RTKs instruct cells to adopt specific fates. Since variations in strength 
and duration of a given signal are means to convey different instructions to a cell, 
mechanisms have evolved to ensure that appropriate thresholds of signal are achieved 
and maintained for the right time (Fiorini et al., 2001).  
In this study, it is shown that FRS2 becomes phosphorylated on serine/threonine 
residues in response to various stimuli, including EGF, FGF, NGF, PDGF, heregulin, 
IGF-I, insulin as well as GPCR agonists such as carbachol, LPA and thrombin. The 
major findings of the present study are summarized in Figure 31.  
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Figure 31: Schematic presentation of FRS2 mediated signaling. 
FRS2 undergoes tyrosine as well as serine/threonine phosphorylation upon EGF and FGF 
stimulation. FRS2 directly associates with the RTKs via its PTB domain and positively regulate 
the ligand-induced ERK activity. This is mediated by association of FRS2 with SHP2 in EGF-
induced signaling, or by direct recruitment of Grb2 or indirectly via SHP2. FRS2 and ERK form 
a negative regulatory feedback loop in EGF and FGF induced signal transduction pathway, in 
which ERK phosphorylates FRS2 on threonine residues thereby inhibits the tyrosine 
phosphorylation of FRS2. The GPCR-induced FRS2 serine/threonine phosphorylation is 
presumably achieved to some extent through transactivation of the EGFR and partially through 
other ERK activation pathways. 
 
FRS2 undergoes tyrosine as well as serine/threonine phosphorylation upon EGF 
and FGF stimulation. Upon EGF stimulation, FRS2 associates directly with the 
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activated EGFR via its PTB domain and promotes the signal primarily through SHP2 to 
the MAP kinase, whereas FRS2 propagates the FGF-induced signal both directly 
through Grb2 and indirectly via SHP2 to the same kinase cascade. FRS2 and ERK form 
a negative regulatory feedback loop in EGF- and FGF-induced signal transduction 
pathways, in which ERK phosphorylates FRS2 on threonine residues thereby inhibits 
the tyrosine phosphorylation of the docking protein.  
The GPCR-induced FRS2 serine/threonine phosphorylation is achieved to some 
extent through transactivation of the EGFR (Daub et al., 1996; Daub et al., 1997) and 
partially through other ERK activation pathways (Marinissen and Gutkind, 2001). Since 
FRS2 appears to be targeted in response to activation of a broad range of cell surface 
receptors, it seems to play a broader role as a central regulatory switch point in 
intracellular signaling than anticipated so far.  
 
 
 
4.8 Outlook 
 
In addition to tyrosine phosphorylation, threonine phosphorylation of FRS2 was 
established as a result of stimulation with multiple RTK and GPCR ligands. However, 
further details of FRS2’s role in signal transduction downstream the multiple surface 
receptors remains to be elucidated. As indicated by the variable modification of FRS2 in 
response to EGF stimulation, it is necessary to analyse FRS2 in individual receptor 
pathways in different cellular systems, including hematopoietic cells where the FRS2 
interaction partner SHP2 seems to play a critical role in modulation of signaling events 
(Tauchi et al., 1994; Fuhrer et al., 1995; Tauchi et al., 1995). Based on the differential 
and combinatory effects of EGF and FGF on FRS2 phosphorylation observed in this 
study, competition and cooperation among RTK and GPCR pathways should also be 
considered in both physiological and pathophysiological processes.  
As suggested by the FRS2-ERK feedback loop, regulation of FRS2 
phosphorylation itself might be a main key to address these issues. FRS2 tyrosine 
phosphorylation was shown to be regulated by the activity of RTKs as well as ERK, 
which simultaneously regulated the interaction of FRS2 with SHP2 and Grb2 in a 
stimulus-dependent manner. Thus, the mechanism underlying the ligand- and cell type-
4. DISCUSSION  
 
 
111 
specific differences in tyrosine phosphorylation and protein recruitment of FRS2 is still 
to be examined. Also the function of basal phosphorylation and induced serine 
phosphorylation of FRS2 remain to be investigated. 
FRS2 was found to be expressed not only in normal tissues (Kouhara et al., 
1997), but also in the vast majority of carcinoma cell lines analysed. Although the 
expression levels in these tumor cells were highly variable, the attempts to generate 
stable cell lines overexpressing FRS2 failed. This may be due to the toxicity of the 
overdose of this protein, as injection of high dose xFRS2 mRNA alone caused Xenopus 
embryonic death (Kusakabe et al., 2001). Together with the embryonic lethal phenotype 
of FRS2 knock out mice (Hadari et al., 2001), these data argue for a strict regulation of 
FRS2 at the expression level. However, the expression pattern and its potential 
regulatory function of FRS2 during development, differentiation and proliferation 
remain to be determined. In this context, the proposed identity of FRS2 with SNT and 
its potential impact on cell cycle regulation via p34 cdc2 are of specific interest.  
Cell fate decision in response to specific stimuli may also be mediated by the 
FRS2-ERK feedback loop. In PC12 cells, a transient ERK activation by EGF correlates 
with cell proliferation and a sustained ERK response to FGF or NGF stimulation leads 
to differentiation (Traverse et al., 1994; Marshall, 1995). FRS2 becomes tyrosine 
phosphorylated and promotes differentiation upon FGF treatment of PC12 cells 
(Kouhara et al., 1997). In this study, FRS2 was tyrosine phosphorylated in PC12 cells in 
response to FGF but not upon stimulation with EGF. Thus, FRS2 is either not in 
association with the EGFR in these cells or EGF-induced ERK activity abrogates FRS2 
tyrosine phosphorylation and SHP2 recruitment. Further experiments will have to 
elucidate whether FRS2 regulates or is regulated by the strength and duration of ERK 
activation in FGF- or EGF-stimulated PC12 cells and thus conveys the instructions for 
differentiation and proliferation, respectively.  
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This study provides evidence that the docking protein FRS2 also promotes an 
EGF signal to the MAP kinase cascade via Grb2 and SHP2, in addition to its known 
function in FGF, NGF, GDNF, BDNF and VEGF signaling. Upon EGF stimulation, 
FRS2 undergoes phosphorylation on tyrosine as well as serine/threonine residues. This 
involves direct interaction of the FRS2 PTB domain with the EGFR and results in a 
significantly altered mobility of FRS2 in SDS-PAGE that is also observed in FGF 
stimulated cells. This migration shift of FRS2 is completely abrogated by U0126, a 
specific MAPK kinase 1 (MEK1) inhibitor, suggesting that ERK1/2 is the 
serine/threonine kinase upstream of FRS2. Indeed, as the in vitro kinase and binding 
assays demonstrated, the central region of FRS2 constitutively associates with ERK1/2 
whereas the FRS2 carboxyl-terminal region serves as substrate for ERK2 
phosphorylation in response to both EGF and FGF stimulation. Notably, tyrosine 
phosphorylation of FRS2 is enhanced when ERK1/2 activation is inhibited after both 
EGF and FGF stimulation. These results indicate a ligand-stimulated negative 
regulatory feedback loop in which activated ERK1/2 phosphorylates FRS2 on 
serine/threonine residues thereby down-regulating its tyrosine phosphorylation. These 
findings support a broader role of FRS2 in EGFR controlled signaling pathways and 
provide insight into a molecular mechanism for ligand-stimulated feedback regulation.  
Moreover, analysis of a variety of cell lines by immunoprecipitation and 
Northern analysis revealed that FRS2 is ubiquitously expressed. Caveolae localization 
of FRS2 implicates possible interactions with other signaling molecules present in this 
compartment. Immunoprecipitations and in vitro binding assays demonstrate that 
tyrosine phosphorylated FRS2 associates with multiple phosphoproteins, among which 
the EGFR, SHP2, and ERK1/2 were identified. Furthermore, the serine/threonine 
phosphorylation of FRS2 is induced in different cell lines by activation of different 
RTKs as well as by GPCR agonist stimulation. The latter is at least partially mediated 
by transactivation through the EGFR. The fact that this migration shift phenomenon 
occurs upon stimulation with a broad range of growth factors and GPCR agonists, 
implies that FRS2 might be a central regulatory switch point in the cellular signal 
transduction network.  
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ABBREVIATIONS 
α Anti 
aa amino acid 
ATCC American Tissue Culture Catalogue 
ATP Adenosine triphosphate 
BCA Bicinchonic acid  
BDNF Brain-derived neurotrophic factor 
BLAST Basic Local Alignment Search Tool 
bp Base pair 
BSA Bovine serum albumin 
CaM kinase II Calmodulin kinase II 
cDNA Complementary DNA 
CMV Cytomegalovirus 
DAPI 4',6-diamidino-2-phenylindole 
DNA Deoxyribonucleic acid 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethyl sulfoxid 
DTT Dithiothreitol 
E Embryonic day 
ECL Enhanced Chemiluminiscence 
EDTA Ethylenediaminetetraacetic acid  
EGF Epidermal growth factor  
EGFP Enhanced green fluorescence protein 
EGFR Epidermal growth factor receptor 
EGTA Ethylene glycol-bis(2-aminoethylether)-
N,N,N',N'-tetraacetic acid 
ERK Extracellular regulated kinase 
FCS Fetal calf serum 
FGF Fibroblast growth factor  
FGFR Fibroblast growth factor receptor 
FRS2 Fibroblast growth factor receptor substrate 2 
Gab1 Grb2-associated binder-1 
GDNF Glial cell-derived neurotrophic factor 
GDP Guanosindiphosphat 
GPCR G protein-coupled receptor 
Grb2 Growth factor receptor binding protein 2 
GST Glutathion-S-Transferase 
GTP Guanosintriphosphat 
HA Hemagglutinin 
HB-EGF Heparin-binding epidermal growth factor  
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic 
acid 
HER Human EGFR 
HRP Horseradish peroxidase 
Ig Immunglobulin 
IGF-I Insulin-like growth factor I 
IPTG Isopropyl-β-thiogalactopyranoside  
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IP Immunoprecipitation 
JNK c-Jun amino (N)-terminal kinase 
Kb Kilobase 
kDa Kilodalton 
LPA Lysophosphatidic acid 
M Molar (mole per liter) 
MAP kinase Mitogen activated protein kinase 
MBP Myelin basic protein 
MEK MAP kinase kinase 
min Minute 
ml Milliliter 
mRNA Messenger RNA 
NDF Neu differentiation factor 
NCBI  National Center for Biotechnology Information 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase Chain Reaction 
PDGF Platelet-derived growth factor 
PH Pleckstrin Homology domain 
PI3K Phosphatidylinositol 3 kinase 
PLC Phospholipase C 
PKA Protein kinase A 
PKC Protein kinase C 
PMSF Phenylmethanesulfonyl fluoride 
PoV Sodium pervanadate 
PP Protein phosphatase 
PTB Phosphotyrosine-binding  
PTP Protein tyrosine phosphatase 
PTK Protein tyrosine kinase 
PVDF Polyvinyldifluorid 
RNA Ribonucleic acid 
RS/TK Receptor serine/threonine kinase 
RT Room temperature 
RTK Receptor tyrosine kinase 
SDS Sodium dodecyl sulphate 
SDS-PAGE SDS polyacrylamid gel electrophoresis 
sec Second 
SH2, 3, 4 Src homolgy domain 2, 3, 4 
Shc SH2 and collagen domain-containing protein 
SNT Suc1-associated neurotrophic factor target 
SOS Son of Sevenless 
TEMED N, N, N', N'-Tetramethylethylendiamine  
TGF-α Transforming growth factor alpha 
VEGF Vascular Endothelial Growth Factor 
WT Wild type 
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